11:\fit\Intrwovn\NRPortbl\DCC\FMT\10103426_l.docx-6 05/2016
                                                            ABSTRACT
An antisense molecule capable of binding to a selected target site to induce exon skipping in
the dystrophin gene, as set forth in SEQ ID NO: 1 to 59.

                                                    -1
                  Antisense Molecules and Methods for Treating Pathologies
   This is a divisional of Australian Patent Application No. <removed-apn>, which is a divisional
   of Australian Patent Application No. 2010317599, the entire contents of which are
   incorporated herein by reference.
 5 Field of the Invention
   The present invention relates to novel antisense compounds and compositions suitable for
   facilitating exon skipping. It also provides methods for inducing exon skipping using the
   novel antisense compounds as well as therapeutic compositions adapted for use in the
   methods of the invention.
10 Background Art
   The following discussion of the background art is intended to facilitate an understanding of
   the present invention only. The discussion is not an acknowledgement or admission that
   any of the material referred to is or was part of the common general knowledge as at the
   priority date of the application.
15 Significant effort is currently being expended into researching methods for suppressing or
   compensating for disease-causing mutations in genes. Antisense technologies are being
   developed using a range of chemistries to affect gene expression at a variety of different
   levels (transcription, splicing, stability, translation). Much of that research has focused on
   the use of antisense compounds to correct or compensate for abnormal or disease
20 associated genes in a myriad of different conditions.
   Antisense molecules are able to inhibit gene expression with exquisite specificity and
   because of this many research efforts concerning oligonucleotides as modulators of gene
   expression have focused on inhibiting the expression of targeted genes such as
   oncogenes or viral genes. The antisense oligonucleotides are directed either against RNA
25 (sense strand) or against DNA where they form triplex structures inhibiting transcription by
   RNA polymerase 1l.
   To achieve a desired effect in specific gene down-regulation, the oligonucleotides must
   either promote the decay of the targeted mRNA or block translation of that

                                           -2
   mRNA, thereby effectively preventing de novo synthesis of the undesirable target
   protein.
   Such techniques are not useful where the object is to up-regulate production of
   the native protein or compensate for mutations which induce premature
 5 termination of translation such as nonsense or frame-shifting mutations.
   Furthermore, in cases where a normally functional protein is prematurely
   terminated because of mutations therein, a means for restoring some functional
   protein production through antisense technology has been shown to be possible
   through intervention during the splicing processes (Sierakowska H, et al., (1996)
10 Proc Nati Acad Sci USA 93,12840-12844; Wilton SD, et al., (1999) Neuromusc
   Disorders 9,330-338; van Deutekom JC et al., (2001) Human Mol Genet 10, 1547
    1554). In these cases, the defective gene transcript should not be subjected to
   targeted degradation so the antisense oligonucleotide chemistry should not
   promote target mRNA decay.
15 In a variety of genetic diseases, the effects of mutations on the eventual
   expression of a gene can be modulated through'a process of targeted exon
   skipping during the splicing process. The splicing process is directed by complex
   multi-particle machinery that brings adjacent exon-intron junctions in pre-mRNA
   into close proximity and performs cleavage of phosphodiester bonds at the ends
20 of the introns with their subsequent reformation between exons that are to be
   spliced together. This complex and highly precise process is mediated by
   sequence motifs in the pre-mRNA that are relatively short semi-conserved RNA
   segments to which bind the various nuclear splicing factors that are then involved
   in the splicing reactions. By changing the way the splicing machinery reads or
25 recognises the motifs involved in pre-mRNA processing, it is possible to create
   differentially spliced mRNA molecules. It has now been recognised that the
    majority of human genes are alternatively spliced during normal gene expression,
   although the mechanisms invoked have not been identified. Using antisense
    oligonucleotides, it has been shown that errors and deficiencies in a coded mRNA
30  could be bypassed or removed from the mature gene transcripts.

                                             -3
   In nature, the -extent of genetic deletion or exon skipping in the splicing process is
   not fully understood, although many instances have been documented to. occur,
   generally at very low levels (Sherrat TG, et al., (1993) Am J Hum Genet 53, 1007
   1015). However, it is recognised that if exons associated with disease- causing
 5 mutations can be specifically deleted from some genes, a shortened protein
   product can sometimes be produced that has similar biological properties of the
   native protein or has sufficient biological activity to ameliorate the disease caused
   by mutations associated with the target exon (Lu QL, et al., (2003) Nature
   Medicine 9,1009-1014; Aartsma-Rus A et al., (2004) Am J Hum Genet 74: 83-92).
10 This process of targeted exon skipping is likely to be particularly useful in long
   genes where there are many exons and introns, where there is redundancy in the
   genetic constitution of the exons or where a protein is able to function without one
   or more particular exons (e.g. with the dystrophin gene, which consists of 79
   exons; or possibly some collagen genes which encode for repeated blocks of
15 sequence or the huge nebulin or titin genes which are comprised of -80 and over
   370 exons, respectively).
   Efforts to redirect gene processing for the treatment of genetic diseases
   associated with truncations caused by mutations in various genes have focused
   on the use of antisense oligonucleotides that, either: (1 ). fully or partially overlap
20 with the elements involved in the splicing process; or (2) bind to the pre-mRNA at
   a position sufficiently close to the element to disrupt the binding and function of
   the splicing factors that would normally mediate a particular splicing reaction
   which occurs at that element (e.g., binds to the pre-mRNA at a position within 3,
   6, or 9 nucleotides of the element to be blocked).
25 For example, modulation of mutant dystrophin pre-mRNA splicing with antisense
   oligoribonucleotides has been reported both in vitro and in vivo. In one type of
   dystrophin mutation reported in Japan, a 52-base pair deletion mutation causes
   exon 19 to be removed with the flanking introns during the splicing process
   (Matsuo et al., (1991) J Clin Invest. 87:2127-2131). An in vitro minigene splicing
30 system has been used to show that a 31-mer 2'-O-methyl oligoribonucleotide
   complementary to the 5' half of the deleted sequence in dystrophin Kobe exon 19

                                             -4
   inhibited splicing of wild-type pre-mRNA (Takeshima et al. (1995), J. Clin. Invest.
   95:515-520). The same oligonucleotide was used to induce exon skipping from
   the native dystrophin gene transcript in human cultured lymphoblastoid cells.
   Dunckley et al. (1997) Nucleosides & Nucleotides, 16,1665-1668 described in
 5 vitro constructs for analysis of splicing around exon 23 of mutated dystrophin in
   the mdx mouse mutant, a model for muscular dystrophy. Plans to analyse these
   constructs in vitro using 2' modified oligonucleotides targeted to splice sites within
   and adjacent to mouse dystrophin exon 23 were discussed, though no target sites
   or sequences were given.
10 2'-O-methyl oligoribonucleotides were subsequently reported to correct dystrophin
   deficiency in myoblasts from the mdx mouse from this group. An antisense
   oligonucleotide targeted to the 3' splice site of murine dystrophin intron 22 was
   reported to cause skipping of the mutant exon as well as several flanking exons
   and created a novel in-frame dystrophin transcript with a novel internal deletion.
15 This mutated dystrophin was expressed in 1-2% of antisense treated mdx
   myotubes. Use of other oligonucleotide modifications such as 2'-0- methoxyethyl
   phosphodiesters are described (Dunckley et al. (1998) Human Mol. Genetics,
   5:1083-90).
   Thus, antisense molecules may provide a tool in the treatment of genetic
20 disorders such as Duchenne Muscular Dystrophy (DMD). However, attempts to
   induce exon skipping using antisense molecules have had mixed success.
   Studies on dystrophin exon 19, where successful skipping of that exon from the
   dystrophin pre-mRNA was achieved using a variety of antisense molecules
   directed at the flanking splice sites or motifs within the exon involved in exon
25 definition as described by Errington et al. (2003) J Gen Med 5: 518-527).
   In contrast to the apparent ease of exon 19 skipping, the first report of exon 23
   skipping in the mdx mouse by Dunckley et al., (1998) is now considered to be
   reporting only a naturally occurring revertant transcript or artefact rather than any
   true antisense activity. In addition to not consistently generating transcripts
30 missing exon 23, Dunckley et al, (1998) did not show any time course of induced

   exon skipping, or even titration of antisense oligonucleotides, to demonstrate dose
   dependent effects where the levels of exon skipping corresponded with increasing
   or decreasing amounts of antisense oligonucleotide. Furthermore, this work could
   not be replicated by other researchers.
 5 The first example of specific and reproducible exon skipping in the mdx mouse
   model was reported by Wilton et al., (1999) Neuromuscular Disorders 9,330- 338.
   By directing an antisense molecule to the donor splice site, consistent and
   efficient exon 23 skipping was induced in the dystrophin mRNA within 6 hours of
   treatment of the cultured cells. Wilton et al., (1999), also describe targeting the
10 acceptor region of the mouse dystrophin pre-mRNA with longer antisense
   oligonucleotides and being unable to repeat the published results of Dunckley et
   al. (1998). No exon skipping, either 23 alone or multiple removal of several
   flanking exons, could be reproducibly detected using a selection of antisense
   oligonucleotides directed at the acceptor splice site of intron 22.
15 While the first antisense oligonucleotide directed at the intron 23 donor splice site
   induced consistent exon skipping in primary cultured myoblasts, this compound
   was found to be much less efficient in immortalized cell cultures expressing higher
   levels of dystrophin. However, with refined targeting and antisense oligonucleotide
   design, the efficiency of specific exon removal was increased by almost an order
20 of magnitude (see Mann CJ et al., (2002) J Gen Med 4,644-654).
   Thus, there remains a need to provide antisense oligonucleotides capable of
   binding to and modifying the splicing of a target nucleotide sequence. Simply
   directing the antisense oligonucleotides to motifs presumed to be crucial for
   splicing is no guarantee of the efficacy of that compound in a therapeutic setting.
25 The preceding discussion of the background to the invention is intended only to
   facilitate an understanding of the present invention. It should be appreciated that
   the discussion is not an acknowledgment or admission that any of the material
   referred to was part of the common general knowledge as at the priority date of
   the application.
30

                                            -6
    Summary of the Invention
    The present invention provides antisense molecule compounds and compositions
    suitable for binding to RNA motifs involved in the splicing of pre-mRNA that are
    able to induce specific and efficient exon skipping and a method for their use
 5  thereof.
   The choice of target selection plays a crucial role in the efficiency of exon skipping
   and hence its subsequent application of a potential therapy.         Simply designing
   antisense molecules to target regions of pre-mRNA presumed to be involved in
   splicing is no guarantee of inducing efficient and specific exon skipping. The most
10 obvious or readily defined targets for splicing intervention are the donor and
   acceptor splice sites although there are less defined or conserved motifs including
   exonic splicing enhancers, silencing elements and branch points. The acceptor
   and donor splice sites have consensus sequences of about 16 and 8 bases
   respectively (see Figure 1 for schematic representation of motifs and domains
15 involved in exon recognition, intron removal and the splicing process).
   According to a first aspect, the invention provides antisense molecules capable of
   binding to a selected target to induce exon skipping.
   For example, to induce exon skipping in exons 5, 12, 17, 21, 22, 24, 43-47, 49, 50,
   54-64, 66, 67, 70 and 72 in the Dystrophin gene transcript the antisense molecules
20 are preferably selected from the group listed in Table 1A.
   In a further example, it is possible to combine two or more antisense
   oligonucleotides of the present invention together to induce more efficient exon
   skipping in exons 3, 4, 8, 10, 26, 36, 48, 60, 66 and 68.           A combination or
   "cocktail" of antisense oligonucleotides are directed at exons to induce efficient
25 exon skipping.
    According to a second aspect, the present invention provides antisense molecules
    selected and or adapted to aid in the prophylactic or therapeutic treatment of a
    genetic disorder comprising at least an antisense molecule in a form suitable for
    delivery to a patient.

                                             -7
   According to a third aspect, the invention provides a method for treating a patient
   suffering from a genetic disease wherein there is a mutation in a gene encoding a
   particular protein and the affect of the mutation can be abrogated by exon
   skipping, comprising the steps of: (a) selecting an antisense molecule in
 5 accordance with the methods described herein; and (b) administering the
   molecule to a patient in need of such treatment.
   The invention also addresses the use of purified and isolated antisense
   oligonucleotides of the invention, for the manufacture of a medicament for treatment
   of a genetic disease.
10 The invention further provides a method of treating a condition characterised by
   Duchenne muscular dystrophy, which method comprises administering to a
   patient in need of treatment an effective amount of an appropriately designed
   antisense oligonucleotide of the invention, relevant to the particular genetic lesion
   in that patient.    Further, the invention provides a method for prophylactically
15 treating a patient to prevent or at least minimise Duchene muscular dystrophy,
   comprising the step of: administering to the patient an effective amount of an
   antisense oligonucleotide or a pharmaceutical composition comprising one or
   more of these biological molecules.
   The invention also provides kits for treating a genetic disease, which kits comprise
20 at least a antisense oligonucleotide of the present invention, packaged in a
   suitable container and instructions for its use.
   Other aspects and advantages of the invention will become apparent to those skilled
   in the art from a review of the ensuing description, which proceeds with reference to
   the following figures.
25
    Brief Description of the Drawings
    Figure 1       Schematic representation of motifs and domains involved in exon
                   recognition, intron removal and the splicing process.

   Figure 2.  Diagrammatic     representation   of  the   concept    of   antisense
              oligonucleotide induced exon skipping to by-pass disease-causing
              mutations (not drawn to scale).    The hatched box represents an
              exon carrying a mutation that prevents the translation of the rest of
 5            the mRNA into a protein.        The solid black bar represents an
              antisense oligonucleotide that prevents inclusion of that exon in the
              mature mRNA.
   Figure 3. Gel electrophoresis showing a "cocktail" of antisense molecules
             directed at exon 3 which induce strong and consistent exon skipping
10           at a transfection concentration of 10 nanomolar in cultured normal
             human muscle cells.
   Figure 4. Gel electrophoresis showing a "cocktail" of antisense molecules
             directed at exon 4 which induce strong and consistent exon skipping
             at a transfection concentration of 25 nanomolar in cultured normal
15           human muscle cells.
   Figure 5  Gel electrophoresis showing strong and efficient human exon 5
             skipping using an antisense molecules [H5A(+35+65)] directed at an
             exon 5 internal domain, presumably an exon splicing enhancer. This
             preferred   compound    induces consistent exon       skipping at a
20           transfection concentration of 25 nanomolar in cultured human
             muscle cells.
   Figure 6. Gel electrophoresis showing a "cocktail" of antisense molecules
             directed at exon 8 which induce strong and consistent exon skipping
             of both exon -8 and exon8/9 at a transfection concentration of 10
25           nanomolar in cultured normal human muscle cells.
   Figure 7. Gel electrophoresis showing various cocktails and single antisense
             molecules wich induce skipping of exon 10 and surrounding exons.
             A combination of [H1OA(-05+16)] and [H1OA(+98+119)] or [H1OA(
             05+16)] and [H1OA(+130+149)] induces skipping of exon 10 and
30           exons 9-12, whilst [H1OA(-05+16)] alone induces skipping of exons
             9-14.

   Figure 8.  Gel electrophoresis showing exon 14 skipping using antisense
              molecule H14A(+31+61) directed at exon 14.
   Figure 9.  Gel electrophoresis showing exon 17 skipping using antisense
              molecule H17A(+10+35) directed at exon 17.
 5 Figure 10. Gel electrophoresis showing two cocktails of antisense molecules
              directed at exon 26. The double cocktail of [H26A(-07+19)] and
              [H26A(+24+50)] induces good skipping of exon 26, and the addition
              of a further antisense molecule to the cocktail does not affect the
              efficiency of skipping.
10 Figure 11. Gel electrophoresis showing a "cocktail" of antisense molecules
              directed at exon 36 which induce strong and consistent exon
              skipping at a transfection concentration of 25 nanomolar in cultured
              normal human muscle cells.
   Figure 12. Gel electrophoresis showing strong and consistent exon 43 skipping
15            to 25 nanomolar in cultured normal human muscle cells using
              antisense molecule H43A(+92+117).
   Figure 13. Gel electrophoresis showing dose dependant exon 55 skipping using
              antisense molecule, H44A(+65+90).
   Figure 14. Gel electrophoresis showing strong and consistent exon 45 skipping
20            using antisense molecule H45A(-09+25).
   Figure 15. Gel electrophoresis showing strong and consistent exon 46 skipping
              using antisense molecule H46A(+81+109).
   Figure 16. Gel electrophoresis showing strong and consistent exon 47 skipping
              using antisense molecule H47A(+01+29).
25 Figure 17. Gel electrophoresis showing a "cocktail" of antisense molecules
              directed at exon 47 which induce strong and consistent exon
              skipping.
   Figure 18. Gel electrophoresis showing strong and consistent exon 49 skipping
              using antisense molecule H49A(+45+70).

                                        -10
   Figure 19. Gel electrophoresis showing strong and consistent exon 50 skipping
              using antisense molecule H50A(+48+74).
   Figure 20. Gel electrophoresis showing strong and consistent exon 51 skipping
              using antisense molecule H51A(+66+95).
 5 Figure 21. Gel electrophoresis showing strong and consistent exon 54 skipping
              using antisense molecule H54A(+67+97).
   Figure 22. Gel electrophoresis showing antisense molecule H55A(-10+20)
              induced dose dependant exon 55 skipping.
   Figure 23. Gel electrophoresis showing strong and consistent exon 56 skipping
10            using antisense molecule H56A(+92+121).
   Figure 24. Gel electrophoresis showing antisense molecule H57A(-10+20)
              induced dose dependant exon 57 skipping.
   Figure 25. Gel electrophoresis showing exon 59 and exon 58/59 skipping using
              antisense molecule H59A(+96+120) directed at exon 59.
15 Figure 26. Gel electrophoresis showing two different cocktails which induce
              exon skipping of exon 60.
   Figure 27. Gel electrophoresis showing exon 63 skipping using antisense
              molecule H63A(+20+49).
   Figure 28. Gel electrophoresis showing exon 64 skipping using antisense
20            molecule H64A(+34+62).
   Figure 29. Gel electrophoresis showing a "cocktail" of antisense molecules
              directed at exon 66 which induce dose dependant exon skipping.
   Figure 30. Gel electrophoresis showing exon 67 skipping using antisense
              molecule H67A(+17+47).
25 Figure 31. Gel electrophoresis showing a "cocktail" of antisense molecules
              directed at exon 68 which induce dose dependant exon skipping.
   Figure 32. Gel electrophoresis showing a "cocktail" of antisense molecules
              which induce strong and consistent exon skipping of exons 69/70 at
              a transfection concentration of 25 nanomolar.

                                        - 11
   Figure 33. Gel electrophoresis     showing various     "cocktails" of antisense
              molecules which induce various levels of skipping in exon 50.
   Figure 34. Gel electrophoresis showing a cocktail of three antisense molecules
              which induce efficient skipping of exons 50/51.
 5 Figure 35. Graph of densitometry results showing various efficiencies of exon
              skipping.    The antisense       molecules    tested   were   Exon  3
              [H3A(+30+60)     &    H3A(+61+85)];     Exon    4    [H4D(+14-11)   &
              H4A(+11+40)]; Exon 14 [H14A(+32+61)]; Exon 17 [H17A(+10+35)];
              Exon 26 [H26A(-07+19), H26A(+24+50) & H26A(+68+92)]; Exon 36
10            [H36A(-16+09) & H36A(+22+51)].
   Figure 36. Graph of densitometry results showing various efficiencies of exon
              skipping.    The antisense      molecules    tested   were   Exon  46
              [H46A(+81+109)];       Exon    47     [H47A(+01+29)];       Exon   48
              [H48A(+01+28) & H48A(+40+67)]; Exon 49 [H49A(+45+70)].
15 Figure 37. Gel electrophoresis showing exon 11 skipping using antisense
              molecule HI IA(+50+79).
   Figure 38. Gel electrophoresis showing exon 12 skipping using antisense
              molecule H12A(+30+57).
   Figure 39. Gel electrophoresis showing exon 44 skipping using antisense
20            molecule H44A(+59+85).
   Figure 40. Gel electrophoresis showing exon 45 skipping using antisense
              molecule H45A(-03+25).
   Figure 41. Gel electrophoresis showing exon 51 skipping using antisense
              molecule H51A(+71+100).
25 Figure 42. Gel electrophoresis showing exon 52 skipping using antisense
              molecule H52A(+09+38).
   Figure 43. Gel electrophoresis showing exon 53 skipping using antisense
              molecule H53A(+33+65).

                                        - 12
  Figure 44.    Gel electrophoresis showing exon 46 skipping using antisense
                molecule H46A(+93+122).
  Figure 45. Gel electrophoresis showing exon 73 skipping using antisense
                molecule H73A(+02+26).
5 Figure 46.    Sequences of antisense molecules.
  Detailed Description
  BRIEF DESCRIPTION OF THE SEQUENCE LISTINGS
  Table 1A: Single antisense molecules
    SEQ ID   Exon                Sequence
             Exon 5
      I      H5A(+35+65)         AAA CCA AGA GUC AGU UUA UGA UUU CCA UCU A
             Exon 11
      52     H11A(+50+79)        CUG UUC CAA UCA GCU UAC UUC CCA AUU GUA
             Exon 12
      2      H12A(+52+75)        UCU UCU GUU UUU GUU AGC CAG UCA
      53     H12A(+30+57)        CAG UCA UUC AAC UCU UUC AGU UUC UGA U
             Exon 17
      3      H17A(-07+23)        GUG GUG GUG ACA GCC UGU GAA AUC UGU GAG
      4      H17A(+61+86)        UGU UCC CUU GUG GUC ACC GUA GUU AC
             Exon 21
      5      H21A(+86+114)       CAC AAA GUC UGC AUC CAG GAA CAU GGG UC
      6      H21A(+90+119)       AAG GCC ACA AAG UCU GCA UCC AGG AAC AUG
             Exon 22
      7      H22A(+125+146)      CUG CAA UUC CCC GAG UCU CUG C
             Exon 24
      8      H24A(+51+73)        CAA GGG CAG GCC AUU CCU CCU UC
             Exon 43
      9      H43A(+92 +117)      GAG AGG UUC CUG UAG CUU CAC CCU UU
             Exon 44
      10     H44A(+65+90)        UGU UGA GCU UCU GUU AGC CAC UGA
      54     H44A(+59+85)        CUG UUC AGC UUC UGU UAG CCA CUG AUU
             Exon 45
      11     H45A (-09+25)       GCU GCC CAA UGC CAU CCU GGA GUU CCU GUA AGA U
      55     H45A(-03+25)        GCU GCC CAA UGC CAU CCU GGA GUU CCU G
      61     H45A(-06+25)        GCU GCC CAA UGC CAU CCU GGA GUU CCU GUA A
      62     H45A(-12+19)        CAA UGC CAU CCU GGA GUU CCU GUA AGA UAC C
             Exon 46
      12     H46A(+81+109)       UCC AGG UUC AAG UGG GAU ACU AGC AAU GU
      56     H46A(+93+122)       GUU GCU GCU CUU UUC CAG GUU CAA GUG GGA
             Exon 47
      13     H47A(+01+29)        UGG CGC AGG GGC AAC UCU UCC ACC AGU AA
             Exon 49
      14     H49A(+45+70)        ACA AAU GCU GCC CUU UAG ACA AAA UC
             Exon 50

                                        -13
   15      H50A(+48+74)          GGC UGC UUU GCC CUC AGC UCU UGA AGU
           Exon 51
   57      H51A(+71+100)          GGU ACC UCC AAC AUC AAG GAA GAU GGC AUU
           Exon 52
   58      H52A(+09+38)          UCC AAC UGG GGA CGC CUC UGU UCC AAA UCC UGC
           Exon 53
   59      H53A(+33+65)          UUC AAC UGU UGC CUC CGG UUC UGA AGG UGU UCU
           Exon 54
   16      H54A(+67+97)          UGG UCU CAU CUG CAG AAU AAU CCC GGA GAA G
           Exon 55
   17      H55A(-10 +20)         CAG CCU CUC GCU CAC UCA CCC UGC AAA GGA
           Exon 56
   18      H56A(+92+121)         CCA AAC GUC UUU GUA ACA GGA CUG CAU
   19      H56A(+1 12+141)       CCA CUU GAA GUU CAU GUU AUC CAA ACG UCU
           Exon 57
   20      H57A(-10+20)          AAC UGG CUU CCA AAU GGG ACC UGA AAA AGA
           Exon 58
   21      H58A(+34+64)          UUC GUA CAG UCU CAA GAG UAC UCA UGA UUA C
   22      H58D(+17-07)          CAA UUA CCU CUG GGC UCC UGG UAG
           Exon 59
   23      H59A(+96 +120)        CUA UUU UUC UCU GCC AGU CAG CGG A
           Exon 60
   24      H60A(+33+62)          CGA GCA AGG UCA UUG ACG UGG CUC ACG UUC
           Exon 61
   25      H61A(+10+40)          GGG CUU CAU GCA GCU GCC UGA CUC GGU CCU C
           Exon 62
   26      H62A(23+52)           UAG GGC ACU UUG UUU GGC GAG AUG GCU CUC
           Exon 63
   27      H63A(+20+49)          GAG CUC UGU CAU UUU GGG AUG GUC CCA GCA
           Exon 64
   28      H64A(+34+62)          CUG CAG UCU UCG GAG UUU CAU GGC AGU CC
           Exon 66
  .29      H66A(-8+19)           GAU CCU CCC UGU UCG UCC CCU AUU AUG
           Exon 67
   30      H67A(+1 7+47)         GCG CUG GUC ACA AAA UCC UGU UGA ACU UGC
           Exon 73
   60      H73A(+02+26)          CAU UGC UGU UUU CCA UUU CUG GUA G
Table I B: Cocktails of antisense molecules
 SEQ ID    Exon                  Sequence
           Exon 3 cocktails
   31      H3A(+30+60)           UAG GAG GCG CCU CCC AUC CUG UAG GUC ACU G
   32      H3A(+61+85)           G CCC UGU CAG GCC UUC GAG GAG GUC
           Exon 4 cocktails
   33      H4A(+1 1+40)          UGU UCA GGG CAU GAA CUC UUG UGG AUC CUU
   34      H4D(+14-11)           GUA CUA CUU ACA UUA UUG UUC UGC A
           Exon 8 cocktails
   35      H8A(-06+24)           UAU CUG GAU AGG UGG UAU CAA CAU CUG UAA
   36      H8A(+134+158)         AUG UAA CUG AAA AUG UUC UUC UUU A
           Exon 10 cocktails
   37      H1OA(-05+16)          CAG GAG CUU CCA AAU GCU GCA
   38      H1OA(+98+119)         UCC UCA GCA GAA AGA AGC CAC G
           Exon 26 cocktails
   39      H26A(-07+19)          CCU CCU UUC UGG CAU AGA CCU UCC AC
   40      H26A(+24+50)          CUU ACA GUU UUC UCC AAA CCU CCC UUC

                                            -14
       41      H26A(+68+92)          UGU GUC AUC CAU UCG UGC AUC UCU G
               Exon 36 cocktails
       42      H36A(-16+09)          CUG GUA UUC CUU AAU UGU ACA GAG A
       43      H36A(+22+51)          UGU GAU GUG GUC CAC AUU CUG GUC AAA AGU
               Exon 48 cocktails
       44      H48A(+01+28)          CUU GUU UCU CAG GUA AAG CUC UGG AAA C
       45      H48A(+40+67)          CAA GCU GCC CAA GGU CUU UUA UUU GAG C
               Exon 60 cocktails
       46      H60A(+87+116)         UCC AGA GUG CUG AGG UUA UAC GGU GAG AGC
       47      H60A(+37+66)          CUG GCG AGC AAG GUC CUU GAC GUG GCU CAC
               Exon 66 cocktails
       48      H66A(-02+28)          CAG GAC ACG GAU CCU CCC UGU UCG UCC CCU
       49      H66D(+13-17)          UAA UAU ACA CGA CUU ACA UCU GUA CUU GUC
               Exon 68 cocktails
       50      H68A(+48+72).         CAC CAU GGA CUG GGG UUC CAG UCU C
       51      H68D(+23-03)          UAC CUG AAU CCA AUG AUU GGA CAC UC
   GENERAL
   Those skilled in the art will appreciate that the invention described herein is
   susceptible to variations and modifications other than those specifically described.
 5 It is to be understood that the invention includes all such variations and
   modifications. The invention also includes all of the steps, features, compositions
   and compounds referred to or indicated in the specification, individually or
   collectively and any and all combinations or any two or more of the steps or
   features.
10 The present invention is not to be limited in scope by the specific embodiments
   described herein, which are intended for the purpose of exemplification only.
   Functionally equivalent products, compositions and methods are clearly within the
   scope of the invention as described herein.
   Sequence identity numbers (SEQ ID NO:) containing nucleotide and amino acid
15 sequence information included in this specification are collected at the end of the
   description and have been prepared using the programme Patentin Version 3.0.
   Each nucleotide or amino acid sequence is identified in the sequence listing by
   the numeric indicator <210> followed by the sequence identifier (e.g. <210>1,
   <210>2, etc.).      The length, type of sequence and source organism for each
20 nucleotide or amino acid sequence are indicated by information provided in the
   numeric indicator fields <211>, <212> and <213>, respectively. Nucleotide and

                                               -15
   amino acid sequences referred to in the specification are defined by the
   information provided in numeric indicator field <400> followed by the sequence
   identifier (e.g. <400>1, <400>2, etc.).
   An antisense molecule nomenclature system was proposed and published to
 5 distinguish between the different antisense molecules (see Mann et al., (2002) J
   Gen Med 4, 644-654).           This nomenclature became especially relevant when
   testing several slightly different antisense molecules, all directed at the same
   target region, as shown below:
                                         H # A/D (x: y).
10 The first letter designates the species       (e.g. H: human, M: murine, C: canine)
   "#" designates target dystrophin exon number.
   "A/D" indicates acceptor or donor splice site at the beginning and end of the exon,
   respectively.
   (x y) represents the annealing coordinates where           "-" or "+" indicate intronic or
15 exonic sequences respectively. As an example, A(-6+18) would indicate the last
   6 bases of the intron preceding the target exon and the first 18 bases of the target
   exon. The closest splice site would be the acceptor so these coordinates would
   be preceded with an "A". Describing annealing coordinates at the donor splice
   site could be D(+2-18) where the last 2 exonic bases and the first 18 intronic
20 bases correspond to the annealing site of the antisense molecule. Entirely exonic
   annealing coordinates that would be represented by A(+65+85), that is the site
   between the    6 5 th and 85th nucleotide from the start of that exon.
   The entire disclosures of all publications (including patents, patent applications,
   journal articles, laboratory manuals, books, or other documents) cited herein are
25 hereby incorporated by reference. ' No admission is made that any of the
   references constitute prior art or are part of the common general knowledge of
   those working in the field to which this invention relates.
   As used herein the term "derived" and "derived from" shall be taken to indicate
   that a specific integer may be obtained from a particular source albeit not
30 necessarily directly from that source.

                                            -16
   Throughout this specification, unless the context requires otherwise, the word
   "comprise", or variations such as "comprises" or "comprising", will be understood
   to imply the inclusion of a stated integer or group of integers but not the exclusion
   of any other integer or group of integers.
 5 Other definitions for selected terms used herein may be found within the detailed
   description of the invention and apply throughout. Unless otherwise defined, all
   other scientific and technical terms used herein have the same meaning as
   commonly understood .to one of ordinary skill in the art to which the invention
   belongs.
10 DESCRIPTION OF THE PREFERRED EMBODIMENT
   When antisense molecule(s) are targeted to nucleotide sequences involved in
   splicing in exons within pre-mRNA sequences, normal splicing of the exon may be
   inhibited, causing the splicing machinery to by-pass the entire mutated exon from
   the mature mRNA.        The concept of antisense oligonucleotide induced exon
15 skipping is shown in Figure 2.
   In many genes, deletion of an entire exon would lead to the production of'a non
   functional protein through the loss of important functional domains or the
   disruption of the reading frame.      However, in some proteins it is possible to
   shorten the protein by deleting one or more exons from within the protein, without
20 disrupting the reading frame and without seriously altering the biological activity of
   the protein. . Typically, such proteins have a structural role and or possess
   functional domains at their ends.       The present invention describes antisense
   molecules capable of binding to specified dystrophin pre-mRNA targets and re
   directing processing of that gene.
25 A preferred aim of a therapy based on antisense molecules is to get maximum
   exon skipping by providing the lowest possible concentration of the antisense
   molecule.    Generally, an antisense molecule may cause strong, robust exon
   skipping; weak, sporadic exon skipping or no exon skipping at all. It is preferable
   to develop antisense molecules (alone or in combination) which can deliver
30 strong, robust consistent exon skipping at a low therapeutic dose.

                                           -17
   Antisense Molecules
   According to a first aspect of the invention, there is provided antisense molecules
   capable of binding to a selected target to induce exon skipping. To induce exon
   skipping in exons of the Dystrophin gene transcript, the antisense molecules are
 5 preferably selected from the group of compounds shown in Table 1A.
   There is also provided a combination or "cocktail" of two or more antisense
   oligonucleotides capable of binding to a selected target to induce exon skipping.
   To induce exon skipping in exons of the Dystrophin gene transcript, the antisense
   molecules in a "cocktail" are preferably selected from the group of compounds
10 shown in Table 1B.
   Designing antisense molecules to completely mask consensus splice sites may
   not necessarily generate any skipping of the targeted exon.        Furthermore, the
   inventors have discovered that size or length of the antisense oligonucleotide
   itself is not always a primary factor when designing antisense molecules. With
15 some targets such as exon 19, antisense oligonucleotides as short as 12 bases
   were able to induce exon skipping, albeit not as efficiently as longer (20-31 bases)
   oligonucleotides.   In some other targets, such as murine dystrophin exon 23,
   antisense oligonucleotides only 17 residues long were able to induce more
   efficient skipping than another overlapping compound of 25 nucleotides.
20 However, in the present invention it has been generally found that longer
   antisense molecules are often more effective at inducing exon skipping than
   shorter molecules.     Thus preferably, the antisense molecules of the present
   invention are between 24 and 30 nucleic acids in length, preferably about 28
   nucleotides in length.     For example, it has previously been found that an
25 antisense oligonucleotide of 20 bases (H16A(-07+13)) was ineffective at inducing
   exon skipping of exon 16, but an oligonucleotide of 31 bases (H16A(-06+25)),
   which completely encompassed the shorter oligonucleotide, was effective at
   inducing skipping (Harding et al (2007) Mol Ther 15:157-166).
   The inventors have also discovered that there does not appear to be any
30 standard motif that can be blocked or masked by antisense molecules to redirect
   splicing. In some exons, such as mouse dystrophin exon 23, the donor splice

                                           - 18
   site was the most amenable to target to re-direct skipping of that exon. It should
   be noted that designing and testing a series of exon 23 specific antisense
   molecules to anneal to overlapping regions of the donor splice site showed
   considerable variation in the efficacy of induced exon skipping. As reported in
 5 Mann et al., (2002) there was a significant variation in the efficiency of bypassing
   the nonsense mutation depending upon antisense oligonucleotide annealing
   ("Improved antisense oligonucleotide induced exon skipping in the mdx mouse
   model of muscular dystrophy". J Gen Med 4: 644-654). Targeting the acceptor
   site of exon 23 or several internal domains was not found to induce any
10 consistent exon 23 skipping.
   In other exons targeted for removal, masking the donor splice site did not induce
   any exon skipping. However, by directing antisense molecules to the acceptor
   splice site (human exon 8 as discussed below), strong and sustained exon
   skipping was induced.     It should be noted that removal of human exon 8 was
15 tightly linked with the co-removal of exon 9.       There is no strong sequence
   homology between the exon 8 antisense oligonucleotides and corresponding
   regions of exon 9 so it does not appear to be a matter of cross reaction. Rather,
   the splicing of these two exons is generally linked.        This is not an isolated
   instance, as the same effect is observed in canine cells where targeting exon 8 for
20 removal also resulted in the skipping of exon 9. Targeting exon 23 for removal in
   the mouse dystrophin pre-mRNA also results in the frequent removal of exon 22
   as well. This effect occurs in a dose dependent manner and also indicates close
   coordinated processing of 2 adjacent exons.
   In other targeted exons, antisense molecules directed at the donor or acceptor
25 splice sites did not induce exon skipping or induce poor skipping, while annealing
   antisense molecules to intra-exonic regions (i.e. exon splicing enhancers within
   human dystrophin exon 4) was most efficient at inducing exon skipping. Some
   exons, both mouse and human exon 19 for example, are readily skipped by
   targeting antisense molecules to a variety of motifs. That is, targeted exon
30 skipping is induced after using antisense oligonucleotides to mask donor and
   acceptor splice sites or exon splicing enhancers.

                                            - 19
   It is also not possible to predict which cocktails of antisense molecules will induce
   exon skipping. For example, the combination of two antisense molecules which,
   on their own, are very good at inducing skipping of a given exon may not cause
   skipping of an exon when combined in a cocktail.              For example, each of
 5 H50A(+02+30) and H50A(+66+95) on their own induce good skipping of exon 50
   and 51. Hoowever, in combination as a cocktail, they only induced poor skipping
   of the two exons. Likewise, the combination of H50A(+02+30) and H51A(+66+90)
   or H50A(+02+30) and H51A(+61+90) did not cause efficient skipping of exons 50
   and 51, even though the individual antisense molecules were effective. Yet the
10 introduction of a third antisense molecule ([H51D(+16-07)] which by itself did not
   cause     skipping),   created    a   three   element     cocktail  ([H50A(+02+30)],
   H51A(+66+90) and [H51D(+16-07)]) that was able to cause skipping of exons 50
   and 51 down to 1 nM.
   Alternatively, the combination of two or three antisense molecules which are
15 ineffective or only moderately effective on their own may cause excellent skipping
   when combined.        For example, individually H26A(-07+19) [SEQ ID NO: 39],
   H26A(+24+50) [SEQ ID NO: 40] and H26A(+68+92) [SEQ ID NO: 41] cause
   inefficient skipping of exon 26, and also induce multiple exon skipping (26-29 or
   27-30).    However, when the three exons are combined as a cocktail, highly
20 efficient skipping of exon 26 occurs.
   From the above examples and discussion, it is clear that there is no way to
   accurately predict whether a combination will work or not.
   Antisense molecules may cause skipping of exons in a 'dose dependant' or 'non
   dose dependant' manner. By dose dependant, it is meant that a larger amount of
25 the antisense molecule induces better skipping of the exon, whereas non-dose
   dependant antisense molecules are able to induce skipping even at very low
   doses. For example, from Figure 15 it can be seen that H46A(+81+109) [SEQ ID
   NO: 12] gives equally good skipping of exon 46 regardless of the amount of
   antisense molecule present (from 600nM to 25nM).           In contrast, H57A(-10+20)
30 [SEQ ID NO: 20] (Figure 24) induces strong skipping of exon 57 at 100nM, but
   reduced skipping at 5OnM and an even greater reduction in skipping at 25nM.

                                            -20
   It is preferable to select antisense molecules that induce skipping in a dose
   independant manner, as these molecules may be administered at very low
   concentrations and still give a therapeutic effect. However, it is also acceptable to
   select as preferred molecules those antisense molecules that induce skipping in a
 5 dose dependant manner, particularly if those molecules induce good or excellent
   skipping at low concentrations.        Preferably, the antisense molecules of the
   present invention are able to induce good or excellent exon skipping at
   concentrations of less than 500nM, preferably less than 200nM and more
   preferably as low as 1OOnM, 50 nM or even 25 nM.               Most preferably, the
10 oligonucleotide molecules of the present invention are able to induce skipping at
   levels of greater that 30% at a concentration of 100 nM.
   To identify and select antisense oligonucleotides suitable for use in the
   modulation of exon skipping, a nucleic acid sequence whose function is to be
   modulated must first be identified. This may be, for example, a gene (or mRNA
15 transcribed form the gene) whose expression is associated with a particular
   disorder or disease state, or a nucleic acid molecule from an infectious agent.
   Within the context of the present invention, preferred target site(s) are those
   involved in mRNA splicing (i.e. splice donor sites, splice acceptor sites, or exonic
   splicing enhancer elements).        Splicing branch points and exon recognition
20 sequences or splice enhancers are also potential target sites for modulation of
   mRNA splicing.
   Preferably, the present invention aims to provide antisense molecules capable of
   binding to a selected target in the dystrophin pre-mRNA to induce efficient and
   consistent exon skipping. Duchenne muscular dystrophy arises from mutations
25 that preclude the synthesis of a functional dystrophin gene product.           These
   Duchenne muscular dystrophy gene defects are typically nonsense mutations or
   genomic rearrangements such as deletions, duplications or micro-deletions or
   insertions that disrupt the reading frame. As the human dystrophin gene is a large
   and complex gene (with 79 exons being spliced together to generate a mature
30 mRNA with an open reading frame of approximately 11,000 bases), there are
   many     positions where      these   mutations   can  occur.      Consequently,    a
   comprehensive antisense oligonucleotide based therapy to address many of the

                                             -21
   different disease-causing mutations in the dystrophin gene will require that many
   exons can be targeted for removal during the splicing process.
   Within the context of the present invention, preferred target site(s) are those
   involved in mRNA splicing (i.e. splice donor sites, splice acceptor sites or exonic
 5 splicing enhancer elements).         Splicing branch points and exon recognition
   sequences or splice enhancers are also potential target sites for modulation of
   mRNA splicing.
   The oligonucleotide and the DNA or RNA are complementary to each other when
   a sufficient number of corresponding positions in each molecule are occupied by
10 nucleotides which can hydrogen bond with each other.             Thus, "specifically
   hybridisable" and "complementary" are terms which are used to indicate a
   sufficient degree of complementarity or precise pairing such that stable and
   specific binding occurs between the oligonucleotide and the DNA or RNA target.
   It is understood in the art that the sequence of an antisense molecule need not be
15 100% complementary to that of its target sequence to be specifically hybridisable.
   An antisense molecule is specifically hybridisable when binding of the compound
   to the target DNA or RNA molecule interferes with the normal function of the
   target DNA or RNA to cause a loss of utility, and there is a sufficient degree of
   complementarity to avoid non-specific binding of the antisense compound to non
20 target sequences under conditions in which specific binding is desired, i.e., under
   physiological conditions in the case of in vivo assays or therapeutic treatment, and
   in the case of in vitro assays, under conditions in which the assays are performed.
   While the above method may be used to select antisense molecules capable of
   deleting any exon from within a protein that is capable of being shortened without
25 affecting its biological function, the exon deletion should not lead to a reading
   frame shift in the shortened transcribed mRNA. Thus, if in a linear sequence of
   three exons the end of the first exon encodes two of three nucleotides in a codon
   and the next exon is deleted then the third exon in the linear sequence must start
   with a single nucleotide that is capable of completing the nucleotide triplet for a
30 codon. If the third exon does not commence with a single nucleotide there will be

                                            -22
   a reading frame shift that would lead to the generation of a truncated or a non
   functional protein.
    It will be appreciated that the codon arrangements at the end of exons in
   structural proteins may not always break at the end of a codon. Consequently,
 5 there may be a need to delete more than one exon from the pre-mRNA to ensure
   in-frame reading of the mRNA. In such circumstances, a plurality of antisense
   oligonucleotides may need to be selected by the method of the invention, wherein
   each is directed to a different region responsible for inducing splicing in the exons
   that are to be deleted.
10 The length of an antisense molecule may vary so long as it is capable of binding
   selectively to the intended location within the pre-mRNA molecule. The length of
   such sequences can be determined in accordance with selection procedures
   described herein.      Generally, the antisense molecule will -be from about 10
   nucleotides in length up to about 50 nucleotides in length. However, it will be
15 appreciated that any length of nucleotides within this range may be used in the
   method. Preferably, the length of the antisense molecule is between 17 to 30
   nucleotides in length.     Surprisingly, it has been found that longer antisense
   molecules are often more effective at inducing exon skipping.            Thus, most
   preferably the antisense molecule is between 24 and 30 nucleotides in length.
20  In order to determine which exons can be connected in a dystrophin gene,
   reference should be made to an exon boundary map. Connection of one exon
   with another is based on the exons possessing the same number at the 3' border
   as is present at the 5' border of the exon to which it is being connected.
   Therefore, if exon 7 were deleted, exon 6 must connect to either exons 12 or 18 to
25 maintain the reading frame. Thus, antisense oligonucleotides would need to be
   selected which redirected splicing for exons 7 to 11 in the first instance or exons 7
   to 17 in the second instance. Another and somewhat simpler approach to restore
   the reading frame around an exon 7 deletion would be to remove the two flanking
   exons. Induction of exons 6 and 8 skipping should result in an in-frame transcript
30 with the splicing of exons 5 to 9.       In practise however, targeting exon 8 for
    removal from the pre-mRNA results in the co-removal of exon 9 so the resultant

                                           -23
   transcript would have exon 5 joined to exon 10. The inclusion or exclusion of
   exon 9 does not alter the reading frame.
   Once the antisense molecules to be tested have been identified, they are
   prepared according to standard techniques known in the art. The most common
 5 method for producing antisense molecules is the methylation of the 2'
   hydroxyribose position and the incorporation of a phosphorothioate backbone.
   This produces molecules that superficially resemble RNA but that are much more
   resistant to nuclease degradation.
   To avoid degradation of pre-mRNA during duplex formation with the antisense
10 molecules, the antisense molecules used in the method may be adapted to
   minimise or prevent cleavage by endogenous RNase H. This property is highly
   preferred, as the presence of unmethylated RNA oligonucleotides in an
   intracellularly environment or in contact with crude extracts that contain RNase H
   will lead to degradation of the pre-mRNA: antisense oligonucleotide duplexes.
15 Any form of modified antisense molecules that are capable of by-passing or not
   inducing such degradation may be used in the present method.          The nuclease
   resistance may be achieved by modifying the antisense molecules of the invention
   so that it comprises partially unsaturated aliphatic hydrocarbon chain and one or
   more polar or charged groups including carboxylic acid groups, ester groups, and
20 alcohol groups.
   An example of antisense molecules which, when duplexed with RNA, are not
   cleaved by cellular RNase H are 2'-O-methyl derivatives.                2'-O-methyl
   oligoribonucleotides are very stable in a cellular environment and in animal
   tissues, and their duplexes with RNA have higher Tm values than their ribo- or
25 deoxyribo- counterparts.       Alternatively,  the  nuclease resistant antisense
   molecules of the invention may have at least one of the last 3-terminus
   nucleotides fluoridated. Still alternatively, the nuclease resistant antisense
   molecules of the invention have phosphorothioate bonds linking between at least
   two of the last 3-terminus nucleotide bases, preferably having phosphorothioate
30 bonds linking between the last four 3'-terminal nucleotide bases.

                                           - 24
   Antisense molecules that do not activate RNase H can be made in accordance
   with known techniques (see, e.g., U.S. Pat. 5,149,797).             Such antisense
   molecules, which may be deoxyribonucleotide or ribonucleotide sequences,
   simply contain any structural modification which sterically hinders or prevents
 5 binding of RNase H to a duplex molecule containing the oligonucleotide as one
   member thereof, which structural modification does not substantially hinder or
   disrupt duplex formation. Because the portions of the oligonucleotide involved in
   duplex formation are substantially different from those portions- involved in RNase
   H binding thereto, numerous antisense molecules that do not activate RNase H
10 are available. For example, such antisense molecules may be oligonucleotides
   wherein at least one, or all, of the inter-nucleotide bridging phosphate residues
   are    modified     phosphates,     such    as   methyl    phosphonates,      methyl
   phosphorothioates,      phosphoromorpholidates,      phosphoropiperazidates     and
   phosphoramidates. For example, every other one of the internucleotide bridging
15 phosphate residues may be modified as described.            In another non-limiting
   example, such antisense molecules are molecules wherein at least one, or all, of
   the nucleotides contain a 2' lower alkyl moiety (e.g., Cr-C4 , linear or branched,
   saturated or unsaturated alkyl, such as methyl, ethyl, ethenyl, propyl, 1-propenyl,
   2-propenyl, and isopropyl). For example, every other one of the nucleotides may
20 be modified as described.
   While antisense oligonucleotides are a preferred form of the antisense molecules,
   the present invention comprehends other oligomeric antisense molecules,
   including but not limited to oligonucleotide mimetics such as are described below.
   Specific examples of preferred antisense compounds useful in this invention
25 include oligonucleotides containing modified backbones or non-natural inter
   nucleoside linkages.     As defined in this specification, oligonucleotides having
   modified backbones include those that retain a phosphorus atom in the backbone
   and those that do not have a phosphorus atom in the backbone.                For the
   purposes of this specification, and as sometimes referenced in the art, Modified
30 oligonucleotides that do not have a phosphorus atom in their inter-nucleoside
   backbone can also be considered to be oligonucleosides.

                                            -25
   In other preferred oligonucleotide mimetics, both the sugar and the inter
   nucleoside linkage, i.e., the backbone, of the nucleotide units are replaced with
   novel groups. The base units are maintained for hybridization with an appropriate
   nucleic    acid   target compound.         One such      oligomeric   compound,   an
 5 oligonucleotide mimetic that has been shown to have excellent hybridization
   properties, is referred to as a peptide nucleic acid (PNA). In PNA compounds, the
   sugar-backbone of an oligonucleotide is replaced with an amide containing
   backbone, in particular an aminoethylglycine backbone.' The nucleo-bases are
   retained and are bound directly or indirectly to aza nitrogen atoms of the amide
10 portion of the backbone.
   Modified oligonucleotides may also contain one or more substituted sugar
   moieties. Oligonucleotides may also include nucleobase (often referred to in the
   art simply as "base") modifications or substitutions.        Certain nucleobases are
   particularly useful for increasing the binding affinity of the oligomeric compounds
15 of the invention. These include 5-substituted pyrimidines, 6-azapyrimidines and
   N-2, N-6 and 0-6 substituted purines, including 2-aminopropyladenine, 5
   propynyluracil and 5-propynylcytosine. 5-methylcytosine substitutions have been
   shown to increase nucleic acid duplex stability by 0.6-1.2*C and are presently
   preferred base substitutions, even more particularly when combined with 2'-0
20 methoxyethyl sugar modifications.
   Another modification of the- oligonucleotides of the invention involves chemically
   linking to the oligonucleotide one or more moieties or conjugates that enhance the
   activity, cellular distribution or cellular uptake of the oligonucleotide.      Such
   moieties include but are not limited to lipid moieties such as a cholesterol moiety,
25 cholic acid, a thioether, e.g., hexyl-S-tritylthiol, a thiocholesterol, an aliphatic
   chain, e.g., dodecandiol or undecyl residues, a phospholipid, e.g., di-hexadecyl
   rac-glycerol       or     triethylammonium       1,2-di-0-hexadecyl-rac-glycero-3-H
   phosphonate, a polyamine or a polyethylene glycol chain, or adamantane acetic
   acid, a     palmityl   moiety,    or an  octadecylamine      or hexylamino-carbonyl
30 oxycholesterol moiety.

                                             -26
   It is not necessary for all positions in a given compound to be uniformly modified,
   and in fact more than one of the aforementioned modifications may be
   incorporated in a single compound or even at a single nucleoside within an
   oligonucleotide. The present invention also includes antisense compounds that
 5 are chimeric compounds. "Chimeric" antisense compounds or "chimeras," in the
   context of this invention, are antisense molecules, particularly oligonucleotides,
   which contain two or more chemically distinct regions, each made up of at least
   one monomer unit, i.e., a nucleotide in the case of an oligonucleotide compound.
   These oligonucleotides typically contain at least one region wherein the
10 oligonucleotide is modified so as to confer upon the increased resistance to
   nuclease degradation, increased cellular uptake, and an additional region for
   increased binding affinity for the target nucleic acid.
   Methods of Manufacturing Antisense Molecules
   The antisense molecules used in accordance with this invention may be
15 conveniently and routinely made through the well-known technique of solid phase
   synthesis. Equipment for such synthesis is sold by several vendors including, for
   example, Applied Biosystems (Foster City, Calif.). One method for synthesising
   oligonucleotides on a modified solid support is described in U.S. Pat. No.
   4,458,066.
20 Any other means for 'such synthesis known in the art may additionally or
   alternatively be employed. It is well known to use similar techniques to prepare
   oligonucleotides such as the phosphorothioates and alkylated derivatives. In one
   such automated embodiment, diethyl-phosphoramidites are used as starting
   materials and may be synthesized as described by Beaucage, et al., (1981)
25 Tetrahedron Letters, 22:1859-1862.
   The antisense molecules of the invention are synthesised in vitro and do not
   include antisense compositions of biological origin, or genetic vector constructs
   designed to direct the in vivo synthesis of antisense molecules. The molecules of
   the invention may also be mixed, encapsulated, conjugated or otherwise
30 associated with other molecules, molecule structures or mixtures of compounds,

                                            - 27
   as for example, liposomes, receptor targeted molecules, oral, rectal, topical or
   other formulations, for assisting in uptake, distribution and/or absorption.
   Therapeutic Agents
   The present invention also can be used as a prophylactic or therapeutic, which
 5 may be utilised for the purpose of treatment of a genetic disease.
   Accordingly, in one embodiment the present invention provides antisense
   molecules that bind to a selected target in the dystrophin pre-mRNA to induce
   efficient and consistent exon skipping described herein in a therapeutically
   effective amount admixed with a pharmaceutically acceptable carrier, diluent, or
10 excipient.
   The phrase "pharmaceutically acceptable" refers to molecular entities and
   compositions that are physiologically tolerable and do not typically produce an
   allergic or similarly untoward reaction, such as gastric upset and the like, when
   administered to a patient. The term "carrier' refers to a diluent, adjuvant, excipient,
15 or vehicle with which the compound is administered. Such pharmaceutical carriers
   can be sterile liquids, such as water and oils, including those of petroleum, animal,
   vegetable or synthetic origin, such as peanut oil, soybean oil, mineral oil, sesame oil
   and the like. Water or saline solutions and aqueous dextrose and glycerol solutions
   are preferably employed as carriers, particularly for injectable solutions. Suitable
20 pharmaceutical carriers are described in Martin, Remington's Pharmaceutical
   Sciences, 18th Ed., Mack Publishing Co., Easton, PA, (1990).
   In a more specific form of the invention there are provided pharmaceutical
   compositions comprising therapeutically effective amounts of an antisense molecule
   together with pharmaceutically acceptable diluents, preservatives, solubilizers,
25 emulsifiers, adjuvants and/or carriers. Such compositions include diluents of various
   buffer content (e.g., Tris-HCI, acetate, phosphate), pH and ionic strength and
   additives such as detergents and solubilizing agents (e.g., Tween 80, Polysorbate
   80), anti-oxidants (e.g., ascorbic acid, sodium metabisulfite), preservatives (e.g.,
   Thimersol, benzyl alcohol) and bulking substances (e.g., lactose, mannitol).       The
30 material may be incorporated into particulate preparations of polymeric compounds

                                             -28
   such as polylactic acid, polyglycolic acid, etc. or into liposomes. Hylauronic acid may
   also be used. Such compositions may influence the physical state, stability, rate of
   in vivo release, and rate of in vivo clearance of the present proteins and derivatives.
   See, e.g., Martin, Remington's Pharmaceutical Sciences, 18th Ed. (1990, Mack
 5 Publishing Co., Easton, PA 18042) pages 1435-1712 that are herein incorporated by
   reference. The compositions may be prepared in liquid form, or may be in dried
   powder, such as lyophilised form.
   It will be appreciated that pharmaceutical compositions provided according to the
   present invention may be administered by any means known in the art. Preferably,
10 the pharmaceutical compositions for administration are administered by injection,
   orally, or by the pulmonary, or nasal route. The antisense molecules are more
   preferably delivered by intravenous, intra-arterial, intraperitoneal, intramuscular, or
   subcutaneous routes of administration.
   Antisense molecule based therapy
15 Also addressed by the present invention is the use of antisense molecules of the
   present invention, for manufacture of a medicament for modulation of a genetic
   disease.
   The delivery of a therapeutically useful amount of antisense molecules may be
   achieved by methods previously published. For example, intracellular delivery of
20 the antisense molecule may be via a composition comprising an admixture of the
   antisense molecule and an effective amount of a block copolymer. An example of
   this method is described in US patent application US 20040248833.
   Other methods of delivery of antisense molecules to the nucleus are described in
   Mann CJ et al., (2001) ["Antisense-induced exon skipping and the synthesis of
25 dystrophin in the mdx mouse". Proc., NatI. Acad. Science, 98(1) 42-47] and in
   Gebski et al., (2003). Human Molecular Genetics, 12(15): 1801-1811.
   A method for introducing a nucleic acid molecule into a cell by way of an
   expression vector either as naked DNA or'complexed to lipid carriers, is described
   in US patent US 6,806,084.

                                           -29
   It may be desirable to deliver the antisense molecule in a colloidal dispersion
   system.      Colloidal dispersion systems include macromolecule complexes,
   nanocapsules, microspheres, beads, and lipid-based systems including oil-in
   water     emulsions, micelles,    mixed   micelles,  and liposomes     or liposome
 5 formulations.
   Liposomes are artificial membrane vesicles which are useful as delivery vehicles
   in vitro and in vivo. These formulations may have net cationic, anionic or neutral
   charge characteristics and are useful characteristics with in vitro, in vivo and ex
   vivo delivery methods. It has been shown that large unilamellar vesicles (LUV),
10 which range in size from 0.2-4.0 .PHI.m can encapsulate a substantial percentage
   of an aqueous buffer containing large macromolecules. RNA and DNA can be
   encapsulated within the aqueous interior and be delivered to cells in a biologically
   active form (Fraley, et al., Trends Biochem. Sci., 6:77, 1981).
   In order for a liposome to be an efficient gene transfer vehicle, the following
15 characteristics should be present: (1) encapsulation of the antisense molecule of
   interest at high efficiency while not compromising their biological activity; (2)
   preferential and substantial binding to a target cell in comparison to non-target
   cells;. (3) delivery of the aqueous contents of the vesicle to the target cell
   cytoplasm at high efficiency; and (4) accurate and effective expression of genetic
20 information (Mannino, et al., Biotechniques, 6:682, 1988).
   The composition of the liposome is usually a combination of phospholipids,
   particularly    high-phase-transition-temperature     phospholipids,    usually    in
   combination with steroids, especially cholesterol. Other phospholipids or other
   lipids may also be used. The physical characteristics of liposomes depend on pH,
25 ionic strength, and the presence of divalent cations.
   Alternatively,   the   antisense    construct   may    be   combined    with    other
   pharmaceutically acceptable carriers or diluents to produce a pharmaceutical
   composition. Suitable carriers and diluents include isotonic saline solutions, for
   example phosphate-buffered saline.        The composition may be formulated for

                                             -30
   parenteral, intramuscular,     intravenous,      subcutaneous,  intraocular,   oral or
   transdermal administration.
   The routes of administration described are intended only as a guide since a skilled
   practitioner will be able to determine readily the optimum route of administration
 5 and any dosage for any particular animal and condition.
   The antisense molecules of the invention encompass any pharmaceutically
   acceptable salts, esters, or salts of such esters, or any other compound which,
   upon administration to an animal including a human, is capable of providing
   (directly or indirectly) the biologically active metabolite or residue thereof.
10 Accordingly, for example, the disclosure is also drawn to prodrugs and
   pharmaceutically acceptable        salts   of   the  compounds    of the     invention,
   pharmaceutically acceptable salts of such pro-drugs, and other bioequivalents:
   The term "pharmaceutically acceptable salts" refers to physiologically and
   pharmaceutically acceptable salts of the compounds of the invention: i.e., salts
15 that retain the desired biological activity of the parent compound and do not impart
   undesired toxicological effects thereto.
   For oligonucleotides, preferred examples of pharmaceutically acceptable salts
   include but are not limited to (a) salts formed with cations such as sodium,
   potassium, ammonium, magnesium, calcium, polyamines such as spermine and
20 spermidine, etc.; (b) acid addition salts formed with inorganic acids, for example
   hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, nitric acid and
   the like; (c) salts formed with organic acids such as, for example, acetic acid,
   oxalic acid, tartaric acid, succinic acid, maleic acid, fumaric acid, gluconic acid,
   citric acid, malic acid, ascorbic acid, benzoic acid, tannic acid, palmitic acid,
25 alginic acid, polyglutamic acid, naphthalenesulfonic acid, methanesulfonic acid, p
   toluenesulfonic acid, naphthalenedisulfonic acid, polygalacturonic acid, and the
   like; and (d) salts formed from elemental anions such as chlorine, bromine, and
   iodine. The pharmaceutical compositions of the present invention may be
   administered in a number of ways depending upon whether local or systemic
30 treatment is desired and upon the area to be treated. Administration may be
   topical (including ophthalmic and to mucous membranes including rectal delivery),

                                             -31
   pulmonary, e.g., by inhalation or insufflation of powders or aerosols, (including by
   nebulizer, intratracheal, intranasal, epidermal and transdermal), oral or parenteral.
   Parenteral administration includes intravenous, intra-arterial, subcutaneous,
   intraperitoneal or intramuscular injection or infusion; or intracranial, e.g.,
 5 intrathecal or intraventricular, administration. Oligonucleotides with at least one
   2'-O-methoxyethyl modification are believed to be particularly useful for oral
   administration.
   The pharmaceutical formulations of the present invention, which may conveniently
   be presented in unit dosage form, may be prepared according to conventional
10 techniques well known in the pharmaceutical industry. Such techniques include
   the step of bringing into association the active ingredients with the pharmaceutical
   carrier(s) or excipient(s). In general the formulations are prepared by uniformly
   and intimately bringing into association the active ingredients with liquid carriers or
   finely divided solid carriers or both, and then, if necessary, shaping the product.
15 Kits of the Invention
   The invention also provides kits for treatment of a patient with a genetic disease
   which kit comprises at least an antisense molecule, packaged in a suitable
   container, together with instructions for its use,
   In a preferred embodiment, the kits will contain at least one antisense molecule as
20 shown in Table 1A, or a cocktail of antisense molecules as shown in Table 1B. The
   kits may also contain peripheral reagents such as buffers, stabilizers, etc.
   The contents of the kit can be lyophilized and the kit can additionally contain a
   suitable solvent for reconstitution of the lyophilized components. Individual
   components of the kit would be packaged in separate containers and, associated
25 with such containers, can be a notice in the form prescribed by a governmental
   agency regulating the manufacture, use or sale of pharmaceuticals or biological
   products, which notice reflects approval by the agency of manufacture, use or
   sale for human administration.
   When the components of the kit are provided in one or more liquid solutions, the
30  liquid solution can be an aqueous solution, for example a sterile aqueous solution.

                                            -32
   For in     vivo use, the     expression construct may         be formulated    into a
   pharmaceutically acceptable syringeable composition. In this case the container
   means may itself be an inhalant, syringe, pipette, eye dropper, or other such like
   apparatus, from which the formulation may be applied to an affected area of the
 5 animal, such as the lungs, injected into an animal, or even applied to and mixed
   with the other components of the kit.
   The components of the kit may also be provided in dried or lyophilized forms.
   When reagents or components are provided as a dried form, reconstitution
   generally is by the addition of a suitable solvent. It is envisioned that the solvent
10 also may be provided in another container means. Irrespective of the number or
   type of containers, the kits of the invention also may comprise, or be packaged
   with, an instrument for assisting with the injection/administration or placement of
   the ultimate complex composition within the body of an animal. Such an
   instrument may be an inhalant, syringe, pipette, forceps, measured spoon, eye
15 dropper or any such medically approved delivery vehicle.
   Those of ordinary skill in the field should appreciate that applications of the above
   method has wide application for identifying antisense molecules suitable for use in
   the treatment of 'many other diseases.
20 Examples
   The following Examples serve to more fully describe the manner of using the
   above-described invention, as well as to set forth the best modes contemplated
   for carrying out various aspects of the invention.       It is understood that these
    Examples in no way serve to limit the true scope of this invention, but rather are
25  presented for illustrative purposes. The references cited herein are expressly
    incorporated by reference.
    Methods of molecular cloning, immunology and protein chemistry, which are not
   explicitly described in the following examples, are reported in the literature and
   are known by those skilled in the art. General texts that described conventional
30  molecular biology, microbiology, and recombinant DNA techniques within the skill of

                                           - 33
   the art, included, for example: Sambrook et al., Molecular Cloning: A Laboratory
   Manual, Second Edition, Cold Spring Harbor Laboratory Press, Cold Spring Harbor,
   New York (1989); Glover ed., DNA Cloning: A Practical Approach, Volumes I and II,
   MRL Press, Ltd., Oxford, U.K. (1985); and Ausubel, F., Brent, R., Kingston, R.E.,
 5 Moore, D.D., Seidman, J.G., Smith, J.A., Struhl, K. Current Protocols in Molecular
   Biology. Greene Publishing Associates/Wiley Intersciences, New York (2002).
   Determining Induced Exon Skipping in Human Muscle Cells
   Attempts by the inventors to develop a rational approach in antisense molecules
   design were not completely successful as there did not appear to be a consistent
10 trend that could be applied to all exons. As such, the identification of the most
   effective and therefore most therapeutic antisense molecules compounds has
   been the result of empirical studies.
   These empirical studies involved the use of computer programs to identify motifs
   potentially involved in the splicing process. Other computer programs were also
15 used to identify regions of the pre-mRNA which may not have had extensive
   secondary structure and therefore potential sites for annealing of antisense
   molecules. Neither of these approaches proved completely reliable in designing
   antisense oligonucleotides for reliable and efficient induction of exon skipping.
   Annealing sites on the human dystrophin             pre-mRNA were selected for
20 examination, initially based upon known or predicted motifs or regions involved in
   splicing. 2OMe antisense oligonucleotides were designed to be complementary to
   the target sequences under investigation and were synthesised on an Expedite
   8909    Nucleic   Acid    Synthesiser.     Upon    completion    of   synthesis,   the
   oligonucleotides were cleaved from the support column and de-protected in
25 ammonium hydroxide before being desalted. The quality of the oligonucleotide
   synthesis was monitored by the intensity of the trityl signals upon each
   deprotection step during the synthesis as detected in the synthesis log.          The
   concentration of the antisense oligonucleotide was estimated by measuring the
   absorbance of a diluted aliquot at 260nm.
30 Specified amounts of the antisense molecules were then tested for their ability to
   induce exon skipping in an in vitro assay, as described below.

                                           - 34
   Briefly, normal primary myoblast cultures were prepared from human muscle
   biopsies obtained after informed consent. The cells were propagated and allowed
   to differentiate into myotubes using standard culturing techniques. The cells were
   then transfected with the antisense oligonucleotides by delivery of the
 5 oligonucleotides to the cells as cationic lipoplexes, mixtures of antisense
   molecules or cationic liposome preparations.
   The cells were then allowed to grow for another 24 hours, after which total RNA
   was extracted and molecular analysis commenced.             Reverse transcriptase
   amplification (RT-PCR) was undertaken to study the targeted regions of the
10 dystrophin pre-mRNA or induced exonic re-arrangements.
   For example, in the testing of an antisense molecule for inducing exon 19 skipping
   the RT-PCR test scanned several exons to detect involvement of any adjacent
   exons. For example, when inducing skipping of exon 19, RT-PCR was carried out
   with primers that amplified across exons 17 and 21. Amplifications of even larger
15 products in this area (i.e. exons 13-26) were also carried out to ensure that there
   was minimal amplification bias for the shorter induced skipped transcript. Shorter
   or exon skipped products tend to be amplified more efficiently and may bias the
   estimated of the normal and induced transcript.
   The sizes of the amplification reaction products were estimated on an agarose gel
20 and compared against appropriate size standards.          The final confirmation of
   identity of these products was carried out by direct DNA sequencing to establish
   that the correct or expected exon junctions have been maintained.
   Once efficient exon skipping had been induced with one antisense molecule,
   subsequent overlapping antisense molecules may be synthesized and then
25 evaluated in the assay as described above.           Our definition of an efficient
   antisense molecule is one that induces strong and sustained exon skipping at
   transfection concentrations in the order of 300 nM or less. Most preferably, the
   oligonucleotide molecules of the present invention are able to induce skipping at
    levels of greater that 30% at a concentration of 100 nM.
30  Densitometry Methods

                                          -35
   Densitometry analysis of the results of the exon skipping procedures was carried
   out, in order to determine which antisense molecules achieved the desired
   efficiency. Amplification products were fractionated on 2% agarose gels, stained
   with ethidium bromide and the images captured by a Chemi-Smart 3000 gel
 5 documentation system (Vilber Lourmat, Marne La Vallee).The bands were then
   analyzed using gel documentation system (Bio-Profil, Bio-1D version 11.9, Vilber
   Lourmat, Marne La Vallee), according to the manufacturer's instructions.
   Densitometry was carried out on the following antisense molecules:
   Figure 35
   Exon 3         H3A(+30+60) & H3A(+61+85)
   Exon 4         H4D(+14-11) & H4A(+11+40)
   Exon 14        H14A(+32+61)
   Exon 17        H17A(+10+35)
   Exon 26        H26A(-07+19), H26A(+24+50) & H26A(+68+92)
   Exon 36        H36A(-16+09) & H36A(+22+51)
   Figure 36
   Exon 46        H46A(+81+109)
   Exon 47        H47A(+01 +29)
   Exon 48        H48A(+01+28) & H48A(+40+67)
   Exon 49        H49A(+45+70)
10 Antisense Oliqonucleotides Directed at Exon 17
   Antisense oligonucleotides directed at exon 17 were prepared and tested for their
   ability to induce exon skipping in human muscle cells using similar methods as
   described above.
   From Table 2 below, it can be seen that the effect of antisense molecules directed
15 at the same site (the exon 17 acceptor splice site) can be very different, even
   though the binding location of the two antisense molecules are overlapping.
   H17A(-07+23) [SEQ ID NO:3], which anneals to the last 7 bases of intron 16 and
   the first 23 bases of exon 17, induces exon 17 skipping when delivered into the
   cell at a concentration of 25nM.     In contrast, the antisense molecule H17A(
20 12+18), which anneals to the last 12 bases of intron 16 and the first 18 bases of
   exon 17, and thus overlaps the location of binding of H17A(-07+23), was not able
   to induce exon skipping at all. Furthermore, H17A(-07+16), which anneals to the

                                               -36
   last 7 bases of intron 16 and the first 16 bases of exon 17 caused skipping of both
   exon 17 and 18 at 200nM. Antisense molecule H17A(+61+86) [SEQ ID NO:4],
   which binds in an intra-exonic splicing enhancer motif of exon 17, is also able to
   induce good skipping. It can be seen that the ability of antisense molecules to
 5 induce exon skipping cannot be predicted simply from their binding location and
   must be determined through rigourous testing.
   Table 2: Antisense molecule sequences tested to determine if they induce exon
   17 skipping
     Antisense         Sequence                                Ability to Induce skipping
     Ollgonucleotide
     name
     H17A(-12 +18)    GGU GAC AGC CUG UGA AAU CUG UGA GAA GUA No Skipping
     H17A(-07+23)     GUG GUG GUG ACA GCC UGU GAA AUC UGU GAG Skipping at 25nM
     H17A(-07+16)     UGA CAG CCU GUG AAA UCU GUG AG          Skipping ex 17 +18 at 200nM
     H17A(+10 +35)    AGU GAU GGC UGA GUG GUG GUG ACA GC       Skipping at 5OnM
     H17A(+31+50).    ACA GUU GUC UGU GUU AGU GA              inconsistent skipping
     H17A(+61 +86)    UGU UCC CUU GUG GUC ACC GUA GUU AC      Skipping at 50nM,
     H17A(+144+163)   CAG AAU CCA CAG UAA UCU GC              skipping at 300nM
10 This data shows that some particular antisense molecules induce efficient exon
   skipping while another antisense molecule, which targets a near-by or overlapping
   region, can be much less efficient. Titration studies show one molecule is able to
   induce targeted exon skipping at 20-25 nM while a less, efficient antisense
   molecule might only induced exon skipping at concentrations of 300 nM and
15 above. Therefore, we have shown that targeting of the antisense molecules to
   motifs involved in the splicing process plays a crucial role in the overall efficacy of
   that compound.
   Efficacy refers to the ability to induce consistent skipping of a target exon.
   However, sometimes skipping of the target exons is consistently associated with a
20 flanking exon. That is, we have found that the splicing of some exons is tightly
   linked.      For example, in targeting exon 23 in the mouse model of muscular
   dystrophy with antisense molecules directed at the donor site of that exon,
   dystrophin transcripts missing exons 22 and 23 are frequently detected.                As
   another example, when using an antisense molecule directed to exon 8 of the

                                              - 37
   human dystrophin gene, many induced transcripts are missing both exons 8 and
   9.
   Antisense Oligonucleotides Directed at Exon 2
   Antisense oligonucleotides directed at exon 2 were prepared and tested for their
 5 ability to induce exon skipping in human muscle cells using similar methods as
   described above.
   Table 3: Antisense molecule sequences tested to determine if they induce exon 2
   skipping
    Antisense             Sequence                                  Ability to induce
    Oligonucleotide name                                            skipping
    H2A(-14+10)          UCU CUU UCA UCU AAA AUG CAA AAU            No Skipping
    H2A(-1+23)           CUU UUG AAC AUC UUc UCU UUC AUC            No Skipping
    H2A(+7+38)           UUU UGU GAA UGU UUu CUU UUG AAC AUC UUC UC No Skipping
    H2A(+16+39)          AUU UUG UGA AUG UUU UCU UUU GAA            No Skipping
    H2A(+30+60)          UAG AAA AUU GUG CAU UUA CCC AUU UUG UGA A  No Skipping
    H2D(+19-11)          ACC AUU CUU ACC UUA GAA AAU UGU GCA UUU    No Skipping
    H2D(+03-21)          AAA GUA ACA AAC CAU UCU UAC CUU            No Skipping
10 Antisense Oliqonucleotides Directed at Exon 3
   Antisense oligonucleotides directed at exon 3 were prepared and tested for their
   ability to induce exon skipping in human muscle cells using similar methods as
   described above.
   Each used alone, antisense molecules H3A(+30+60) [SEQ ID NO: 31] and
15 H3A(+61+85) [SEQ ID NO: 32] induce exon 3 skipping. However, in combination,
   the two molecules are even more effective at inducing skipping (Figure 3), and are
   also able to induce skipping of exons 4 and 5 at 300nM and 600nM, a result not
   seen or predicted by the results of the use of each antisense molecule alone.
   Additional products above the induced transcript missing exon 3 arise from
20 amplification from carry-over outer primers from the RT-PCR as well as
   heteroduplex formation.
   Table 4: Antisense molecule sequences tested to determine if they induce exon 3
   skipping
    Antisense             Sequence                                   Ability to induce

                                                     - 38
    Oligonucleotide name                                                           skipping
    H3A(+14+38)              AGG UCA CUG AAG AGG UUC UCA AUA U                     Moderate skipping to
    H3A(+20+40)               GUA GGU CAC UGA AGA GGU UCU                          Strong skipping to 50nM
    H3A(+25+60)               AGG AGG CGU CUC CCA UCC UGU AGG UCA CUG AAG AG       weak skipping
    H3A(+45+65)               AGG UCU AGG AGG CGC CUC CCA                          No skipping
    H3A(+48+73)               CUU CGA GGA GGU CUA GGA GGC GCC UC                   No Skipping
    H3A(+61+85)               GCC CUG UCA GGC CUU CGA GGA GGU C                    Skipping to 300nM
    H3D(+17-08)               uca cau acA GUU UUU GCC CUG UCA G                    No skipping
    H3D(+19-02)               UAC AGU UUU UGC CCU GUC AGG                          No skipping
    H3D(+14-10)              AAG UCA CAU ACA GUU UUU GCC CUG                       No skipping
    H3D(+12-07)               UCA CAU ACA GUU UUU GCC C                            No skipping
    Cocktails for exon 3
                                                                                   Excellent skipping to
    H3A(+30+60)               UAG GAG GCG CCU CCC AUC CUG UAG GUC ACU G            1OnM, skipping to
    H3A(+61+85)               G CCC UGU CAG GCC UUC GAG GAG GUC                    Aso taking out 4&5 to
                                                                                   300nM
    H3A(+61+85)
    H3A(+30+54)               G CCC UGU CAG GCC UUC GAG GAG GUC                    Very strong skipping to
                              GCG CCU CCC AUC CUG UAG GUC ACU G                    50nM
    H3A(+61+85)               G CCC UGU CAG GCC UUC GAG GAG GUC                    Very strong skipping to
    H3A(+25+60)               AGG AGG CGU CUC CCA UCC UGU AGG UCA CUG AAG AG       5OnM
   Antisense Oligonucleotides Directed at Exon 4
   Antisense oligonucleotides directed at exon 4 were prepared and tested for their
   ability to induce exon skipping in human muscle cells using similar methods as
 5 described above.             Figure 4 shows skipping of exon 4 using a cocktail of
   H4A(+11+40) [SEQ ID NO: 33] and H4D(+14-11) [SEQ ID NO: 34].
   Table 5: Antisense molecule sequences tested to determine if they induce exon 4
   skipping
    Antisense             Sequence                                     Ability to Induce skipping
    Oligonucleotide
    name
    H4A(-08+17)          GAU CCU UUU UCU UUU GGC UGA GAA C            Weak skipping down to 10nM
    H4A(+36+60)          CCG CAG UGC CUU GUU GAC AUU GUU C            Good skipping to 1OnM
    H4D(+14-11)          GUA CUA CUU ACA UUA UUG UUC UGC A            Very poor skipping to 10nM
    Exon 4 Cocktails
    H4A(+1 1+40)         UGU UCA GGG CAU GAA CUC UUG UGG AUC CUU      Excellent skipping( 100% to 1OOnM)
    H4D(+14-11)          GUA CUA CUU ACA UUA UUG UUC UGC A            and good skipping down to 5nM
10 Antisense Oligonucleotides Directed at Exon 5
   Antisense oligonucleotides directed at exon 5 were prepared and tested for their
   ability to induce exon skipping in human muscle cells using similar methods as

                                             - 39
   described above. H5D(+26-05) would be regarded as a non-preferred antisense
   molecule as it failed to induce even low level skipping of exon 5.                However,
   H5A(+35+65) [SEQ ID NO: 1], which presumably targets an exonic splicing
   enhancer was evaluated, found to be highly efficient at inducing skipping of that
 5 target exon, as shown in Figure 5 and is regarded as the preferred compound for
   induced exon 5 skipping.
   Table 6: Antisense molecule sequences tested to determine if they induce exon 5
   skipping
    Antisense        Sequence                                 Ability to Induce skipping
    Oligonucleotide
    name
    H5A(+35+65)     AAA CCA AGA GUC AGU UUA UGA UUU CCA UCU A Great skipping to 1OnM
    H5D(+26-05)     CUU ACC UGC CAG UGG AGG AUU AUA UUC CAA A No skipping
10 Antisense Oliqonucleotides Directed at Exon 6
   Antisense oligonucleotides directed at exon 6 were prepared and tested for their
   ability to induce exon skipping in human muscle cells using similar methods as
   described above.
   Table 7: Antisense molecule sequences tested to determine if they induce exon 6
15 skipping
    Antisense        Sequence                                  Ability to induce skipping
    Oligonucleotide
    name
    H6A(-09+17)     UUC AUU ACA UUU UUG ACC UAC AUG UG        faint to 600nM
    H6A(+32+57)     CUU UUC ACU GUU GGU UUG UUG CAA UC        skipping at 25nM
    KH9 6A(+66+94)  AAU UAC GAG UUG AUU GUC GGA CCC AGC UC    skipping at 25nM
    H6A(+69+96)     AUA AUU ACG AGU UGA UUG UCG GAC CCA G     skipping to 100 nM
    H6A(+98+123)    GGU GAA GUU GAU UAC AUU AAC CUG UG        No  skipping
    H6D(+18-06)     UCU UAC CUA UGA CUA UGG AUG AGA           No  skipping
    H6D(+07-15)     CAG UAA UCU UCU UAC CUA UGA C             No  skipping
    H6D(+07-16)     UCA GUA AUC UUC UUA CCU AUG AC            No  skipping
    H6D(+04-20)     UGU CUC AGU MU CUU CUU ACC UAU            No  skipping
   Antisense Oliqonucleotides Directed at Exon 7

                                                 -40
   Antisense oligonucleotides directed at exon 7 were prepared and tested for their
   ability to induce exon skipping in human muscle cells using similar methods as
   described above.
   Table 8: Antisense molecule sequences tested to determine if they induce exon 7
 5 skipping
    Antisense           Sequence                                 Ability to induce skipping
    Oligonucleotide
    name
    H7A(-07+15)        UCA AAU AGG UCU GGC CUA AAA C            no skipping
    H7A(-03+18)        CCA GUC AAA UAG GUC UGG CCU A            no skipping
    H7A(+41+63)        UGU UCC AGU CGU UGU GUG GCU GA           skipping 50nM
    H7A(+41+67)        UGC AUG UUC CAG UCG UUG UGU GGC UGA      skipping 25nM
    H7A(+47+74)        UGU UGA AUG CAU GUU CCA GUC GUU GUG U    skippking 25nM but weak
    H7A(+49+71)        UGA AUG CAU GUU CCA GUC GUU GU           good skipping to 25 nM
   Antisense Oliqonucleotides Directed at Exon 8
   Antisense oligonucleotides directed at exon 8 were prepared and tested for their
   ability to induce exon skipping in human muscle cells using similar methods as
10 described above. See Figure 6.
   Table 9: Antisense molecule sequences tested to determine if they induce exon 8
   skipping
    Antisense           Sequence                                 Ability to Induce skipping
    Oligonucleotide
    name
    H8A(-10+20)        UGG AUA GGU GGU AUC AAC AUC UGU AAG CAC  Very weak skipping of 8+9 to 1OnM
    H8A(-07+15)        GAU AGG UGG UAU CAA CAU CUG U            Veryvery weak skipping of 8+9 to
                     ___________                                 OnM
    H8A(-06+24)        UAU CUG GAU AGG UGG UAU CAA CAU CUG UAA  Weak skipping of 8+9 to 1OnM
    H8A(-04+18)        GAU AGG UGG UAU CAA CAU CUG U            works strongly to 40nM
    H8A(+42+66)        AAA CUU GGA AGA GUG AUG UGA UGU A        good skipping of 8+9 to 10nM
    H8A(+57+83)        GCU CAC UUG UUG AGG CAA AAC UUG GAA      good skipping of 8+9 at high
                                                                conc,down to lOnM
    H8A(+96+120)       GCC UUG GCA ACA UUU CCA CUU CCU G        Weak skipping of 8+9 to 300nM
    H8A(+134+158)      AUG UAA CUG AAA AUG UUC UUC UUU A        Weak skipping of 8+9 to 1OOnM
    H8D(+13-12)         UAC ACA CUU UAC CUG UUG AGA AUA G       Weak skipping of 8+9 to 50nM
    Exon 8 Cocktails
    H8A(-06+24)         UAU CUG GAU AGG UGG UAU CAA CAU CUG UAA Good skipping to 1OnM (8+9) but
    H8A(+134+158)      AUG UAA CUG AAA AUG UUC UUC UUU A        also 8 on its own
    H8A(-06+24)         UAU CUG GAU AGG UGG UAU CAA CAU CUG UAA Good skipping to 1OnM (8+9) but
    H8D(+13-12)         UAC ACA CUU UAC CUG UUG AGA AUA G       also 8 on its own
    H8A(-06+24)         UAU CUG GAU AGG UGG UAU CAA CAU CUG UAA Good skipping to 1OnM (8+9) but
    H8A(+57+83)         GCU CAC UUG UUG AGG CAA AAC UUG GAA     also 8 on its own
    H8A(-06+24)         UAU CUG GAU AGG UGG UAU CAA CAU CUG UAA Good skipping to 1OnM (8+9) but
    H8A(+96+120)        GCC UUG GCA ACA UUU CCA CUU CCU G       also 8 on its own

                                             -41
   Antisense Oligonucleotides Directed at Exon 9
   Antisense oligonucleotides directed at exon 9 were prepared and tested for their
   ability to induce exon skipping in human muscle cells using similar methods as
 5 described above.
   Table 10: Antisense molecule sequences tested to determine if they induce exon
   9 skipping
    Antisense        Sequence                                   Ability to Induce skipping
    Oligonucleotide
    name
    H9A(+154+184)   AGC AGC CUG UGU GUA GGC AUA GCU CUU GAA U  working strongly to 1OOnM
    H9D(+26-04)     AGA CCU GUG AAG GAA AUG GGC UCC GUG UAG    working strongly to 200nM
   Antisense Oliqonucleotides Directed at Exon 10
10 Antisense oligonucleotides directed at exon 10 were prepared and tested for their
   ability to induce exon skipping in human muscle cells using similar methods as
   described above. See Figure 7 for examples of a single antisense oligonucleotide
   molecule and cocktails which induce skippig of exon 10 and surrounding exons.
   Single antisense oligonuceotide molecule H1OA(-05+16) [SEQ ID NO: 37] was
15 able to induce skipping of exons 9-14, whilst the combination with H1OA(+98+119)
   [SEQ ID NO: 38] was able to induce skipping of exon 10 alone and exons 9-12
   (and some skipping of exons 10-12).           The combination of H1OA(-05+16) and
   H1OA(+130+149) was able to induce skipping of exon 10 and exons 9-12.
   Table 11: Antisense molecule sequences tested to determine if they induce exon
20 10 skipping
    Antisense        Sequence                                   Ability to induce skipping.
    Oligonucleotide
    name
    H1OA(-09+16)    CAG GAG CUU CCA AAU GCU GCA CAA U          no skipping
    H1OA(+08+27)    UGA CUU GUC UUC AGG AGC UU                 no skipping
    H10A (+21 +42)  CAA UGA ACU GCC AAA UGA CUU G              Skipping at 1OOnM
    HIOA(+27+51)    ACU CUC CAU CAA UGA ACU GCC AAA U           No Skipping
    HIOA(+55+79)    CUG UUU GAU AAC GGU CCA GGU UUA C           No Skipping
    H1OA(+80+103)   GCC ACG AUA AUA CUU CUU CUA AAG             No Skipping
    H10D(+16-09)    UUA GUU UAC CUC AUG AGU AUG AAA C           No Skipping

                                                       -42
     Cocktails Exon 10
     H1OA(-05+16)         CAG GAG CUU CCA AAU  GCU GCA
     HIOA(+98+119)        UCC UCA GCA GAA AGA  AGC CAC G           Strong skipping at 200nM
     HIOA(-05+16)         CAG GAG CUU CCA AAU  GCU GCA
     H1OA(+130+149)       UUA GAA AUC UCU CCU  UGU GC              Skipping at 200nM
    Antisense Oligonucleotides Directed at Exon 11
    Antisense oligonucleotides directed at exon 11 were prepared and tested for their
    ability to induce exon skipping in human muscle cells using similar methods as
 5  described above. See Figure 37.
    Table 12: Antisense molecule sequences tested to determine if they induce exon
    11 skipping
     Antisense             Sequence                                 Ability to induce skipping
     Oligonucleotide
     name
     H11A(-07+13)         CCA UCA UGU ACC CCU GAC AA               Skipping at 300nM
     H11A+(+134+157)      CCC UGA GGC AUU CCC AUC UUG AAU          Skipping at 1OOnM
     H1 1A(+20+45)        AUU ACC AAC CCG GCC CUG AUG GGC UG       skipping to 25 nM
     Hi 1A(+46+75)        UCC AAU CAG CUU ACU UCC CAA UUG UAG AAU  Strong skipping to 25 nM hint at 2.5
                                                                   nM
     H11A(+50+75)         UCC AAU CAG CUU ACU UCC CAA UUG UA       Strong skipping to 10 nM faint at 2.5
                       _____                    _____nM
     H1IA(+50+79)         CUG UUC CAA UCA GCU UAC UUC CCA AUU GUA  Strong skipping to 5 nM faint at 2.5
                       ______                      _____nM
     H11A(+80+105)        AGU  UUC UUC AUC UUC UGA UAA UUU UC      Faint skipping to 25 nM
     Hi1A(+106+i135)      AUU UAG  GAG AUU CAU CUG CUC UUG UAC UUC Strong skipping to 25 nM (20%)
     HIIA(+110+135)       AUU UAG  GAG AUU CAU CUG CUC UUG UA      Strong skipping to 25 nM (20%)
     HiIA(+110+139)       UUG  AAU UUA GGA GAU UCA UCU GCU CUU GUA Strong skipping to 25 nM (20%)
   -Antisense Oligonucleotides Directed at Exon 12
    Antisense oligonucleotides directed at exon 12 were prepared and tested for their
10  ability to induce exon skipping in human muscle cells using similar methods as
    described above. See Figure 38.
    Table 13: Antisense molecule sequences tested to determine if they induce exon
    12 skipping
     Antisense             Sequence                                 Ability to induce skipping
     Oligonucleotide
     name
     H12D(+06-16)         CAU AAG AUA CAC CUA CCU UAU G            No Skipping
     H12A(+52+75)         UCU UCU GUU UUU GUU AGC CAG UCA.         Strong skipping
                                                                   Strong skipping to 10 nM faint at 2.5
     H12A(+30+57)         CAG UCA UUC AAC UCU UUC AGU UUC UGA U    nM
                                                                   Strong skipping to 25 nM faint at 5
     H12A(+60+87)         UUC CUU GUU CUU UCU UCU GUU UUU GUU A    nM
     H12A(+90+117)        AGA UCA GGU CCA AGA GGC UCU UCC UCC A    Strong skipping to 25 nM (30%)

                                             -43
    H12A(+120+147)  UGU UGU UGU ACU UGG CGU UUU AGG UCU U  Strong skipping to 25 nM (30%)
   Antisense Oligonucleotides Directed at Exon 13
   Antisense oligonucleotides directed at exon 13 were prepared and tested for their
   ability to induce exon skipping in human muscle cells using similar methods as
 5 described above.
   Table 14: Antisense molecule sequences tested to determine if they induce exon
   13 skipping
    Antisense       Sequence                               Ability to induce skipping
    Oligonucleotide
    name
    H13A(-12+12)    UUC UUG AAG CAC CUG AAA GAU AAA        No Skipping
   Antisense Oliqonucleotides Directed at Exon 14
10 Antisense oligonucleotides directed at exon 14 were prepared and tested for their
   ability to induce exon skipping in human muscle cells using similar methods as
   described above. See Figure 8.
   Table 15: Antisense molecule sequences tested to determine if they induce exon
   14 skipping
    Antisense       Sequence                               Ability to Induce skipping
    oligonucleotide
    name
    H14A(+45 +73)   GAA GGA UGU CUU GUA AAA GAA CCC AGC GG Skipping at-25nM
15
   Antisense Oliqonucleotides Directed at Exon 16
   Antisense oligonucleotides directed at exon 16 were prepared and tested for their
   ability to induce exon skipping in human muscle cells using similar methods as
   described above.
20 Table 16: Antisense molecule sequences tested to determine if they induce exon
   16 skipping

                                             -44
    Antisense       Sequence                                    Ability to Induce skipping
    Oligonucleotide
    name
    H16A(-07+19)    CUA GAU CCG CUU UUA AAA CCU GUU AA         No skipping
    H16A(+09+31)    GCU UUU UCU UUU CUA GAU CCG CU             No skipping
    H16D(+18-07)    CAC UAA CCU GUG CUG UAC UCU UUU C          No skipping
   Antisense Oligonucleotides Directed at Exon 17
   Antisense oligonucleotides directed at exon 17 were prepared and tested for their
   ability to induce exon skipping in human muscle cells using similar methods as
 5 described above.
   Table 64: Antisense molecule sequences tested to determine if they induce exon
   17 skipping
    Antisense        Sequence                                   Ability to induce skipping
    Oligonucleotlde
    name
    'i 7A(+48+78)    UGU GGU CAC CGU AGU UAC UGU UUC CAU UCA A  No skipping
    H17A(+55+85)     GUU CCC UUG UGG UCA CCG UAG UUA CUG UUU C  Skipping to 100 nM
   Antisense Oligonucleotides Directed at Exon 18
10 Antisense oligonucleotides directed at exon 18 were prepared and tested for their
   ability to induce exon skipping in human muscle cells using similar methods as
   described above. See Figure 9.
   Table 17: Antisense molecule sequences tested to determine if they induce exon
   18 skipping
    Antisense       Sequence                                    Ability to induce skipping
    Oligonucleotide
    name
    H18A(-09+11)    CAA CAU CCU UCC UAA GAC VG                 No skipping
                                                               Inconsistent skipping of both exon
     H18A(+24+43)   GCG AGU AAU CCA GCU GUG AA                 17 + 18
     H18A(+41 +70)  UUC AGG ACU CUG CAA CAG AGC UUC UGA GCG    Skipping exons 17+18 300nM
    H18A(+83+108)   UUG UCU GUG AAG UUG CCU UCC UUC CG         Skipping exons 17+18 300nM
    H18D(+04-16)    UUA AUG CAU AAC CUA CAU UG                 No skipping
15
   Antisense Oligonucleotides Directed at Exon 19

                                             -45
   Antisense oligonucleotides directed at exon 19 were prepared and tested for their
   ability to induce exon skipping in human muscle cells using similar methods as
   described above.
   Table 18: Antisense molecule sequences tested to determine if they induce exon
 5 19 skipping
    Antisense       Sequence                                   Ability to induce skipping
    Oligonucleotide
    name
    H19A(+19+48)    GGC AUC UUG CAG UUU UCU GAA CUU CUC AGC   skipping to 25 nM
    H19A(+27+54)    UCU GCU GGC AUC UUG CAG UUU UCU GAA C     skipping to 25 nM
    H19D(+3-17)     UCA ACU CGU GUA AUU ACC GU                skipping
   Antisense Oligonucleotides Directed at Exon 20
   Antisense oligonucleotides directed at exon 20 were prepared and tested for their
   ability to induce exon skipping in human muscle cells using similar methods as
10 described above.
   Table 19: Antisense molecule sequences tested to determine if they induce exon
   20 skipping
    Antisense       Sequence                                   Ability to induce skipping
    oligonucleotide
    name
    H20A(+23+47)    GUU CAG UUG UUC UGA GGC UUG UUU G         faint shadow at 600 nM
    H20A(+140+164)  AGU AGU UGU CAU CUG CUC CAA UUG U         no skipping
   Antisense Oligonucleotides Directed at Exon 23
15 Antisense oligonucleotides directed at exon 23 were prepared and tested for their
   ability to induce exon skipping in human muscle cells using similar methods as
   described above. Antisense oligonucleotides directed at exon 23 were prepared
   and tested for their ability to induce exon skipping in human muscle cells using
   similar methods as described above.            H23(+69+98)-SNP        contains a single
20 nucleotide polymorphism (SNP) that has been previously documented.

                                            -46
   Table 65: Antisense molecule sequences tested to determine if they induce exon
   23 skipping
    Antisense       Sequence                                 Ability to induce skipping
    Oligonucleotide
    name
    H23(+69+98)-SNP CGG CUA AUU UCA GAG GGC GCU UUC UUU GAC skipping to 25 nM
   Antisense Oliqonucleotides Directed at Exon 24
 5 Antisense oligonucleotides directed at exon 24 were prepared and tested for their
   ability to induce exon skipping in human muscle cells using similar methods as
   described above.
   Table 20: Antisense molecule sequences tested to determine if they induce exon
   24 skipping.
    Antisense       Sequence                                 Ability to induce skipping
    Otigonucleotide
    name
    H24A(+51+73)    CAA GGG CAG GCC AUU CCU CCU UC          Strong skipping to 25 nM
10
   Antisense Olicionucleotides Directed at Exon 25
   Antisense oligonucleotides directed at exon 25 were prepared and tested for their
   ability to induce exon skipping in human muscle cells using similar methods as
   described above.      Oligonucleotide H25A(+95+119)-DupA is a patient specific
15 antisense molecule.
   Table 21: Antisense molecule sequences tested to determine if they induce exon
   25 skipping.
    Antisense       Sequence                                 Ability to induce skipping
    Oligonucleotide
    name
    H25A(+10+33)    UGG GCU GAA UUG UCU GAA UAU CAC         strong at 25nM but did not reduce
                                                            the full length product
    H25D(+06-14)    GAG AUU GUC UAU ACC UGU UG              very strong at 25nM
    H25A(+10+38)    AGA CUG GGC UGA AUU GUC UGA AUA UCA CU  Strong skipping at 5 nM faint 2.5 nM
    H25A(+95+119)-  UUG AGU-UCU GUU CUc AAG UCU CGA AG      Strong skipping at 25 nM faint 5 nM
    DupA                                                    (patient specific)
    H25D(+13-14)    GAG AUU GUC UAU ACC UGU UGG CAC AUG     Strong skipping at 10 nM

                                               -47
   Antisense Oligonucleotides Directed at Exon 26
   Antisense oligonucleotides directed at exon 26 were prepared and tested for their
   ability to induce exon skipping in human muscle cells using similar methods as
   described above. See Figure 10.
 5 Table 22: Antisense molecule sequences tested to determine if they induce exon
   26 skipping.
    Antisense          Sequence                                Ability to induce skipping
    Ollgonucleotlde
    name
    H26A(-16+09)      GGC AUA GAC CUU CCA CAA AAC AAA C       Faint skipping 600 nM &300 nM
    H26A(-7+23)       AAG GCC UCC UUU CUG GCA UAG ACC UUC CAC Faint at 600, 300nM , multiple
                                                              exons 26-29 or 27-30
    H26A(-03+27)      CUU CAA GGC CUC CUU UCU GGC AUA GAC CUU Faint at 600, 300nM , multiple
                                                              exons 26-29 or 27-30
    H26A(+5+35)       AAC CUC CCU UCA AGG CCU CCU UUC UGG CAU No skipping
    H26A(+24+50)      CUU ACA GUU UUC UCC AAA CCU CCC UUC     Faint at 600, 300nM , multiple
                                                              exons 26-29 or 27-30
    H26D(+06-19)      UUU CUU UUU UUU UUU UUA CCU UCA U       Faint at 600, multiple exons 26-29
                                                              or 27-30
    H26D(+21-04)      UUA CCU UCA UCU CUU CAA CUG CUU U       multiple exons 26-29 or 27-30
    H26D(+10-10)      UUU UUU UUA CCU UCA UCU CU              Not skipping 26 other bands
    Exon 26 cocktails
    H26A(-07+19)      CCU CCU UUC UGG CAU AGA CCU UCC AC      strong skipping down to 25nM
    H26A(+24+50)      CUU ACA GUU UUC UCC AAA CCU CCC UUC
    H26A(+68+92)      UGU GUC AUC CAU UCG UGC AUC UCU G
   Antisense Oliqonucleotides Directed at Exon 31
   Antisense oligonucleotides directed at exon 31 were prepared and tested for their
10 ability to induce exon skipping in human muscle cells using similar methods as
   described above.
   Table 23: Antisense molecule sequences tested to determine if they induce exon
   31 skipping
    Antisense          Sequence                                Ability to induce skipping
    Oligonucleotide
    name
    H31D(+12-18)      UUC UGA AAU UUC AUA UAC CUG UGC AAC AUC skipping to 1OOnM
    H31 D(+08-22)     UAG UUU CUG AAA UAA CAU AUA CCU GUG CAA skipping to 1OOnM
    H31D(+06-24)      CUU AGU UUC UGA AAU AAC AUA UAC CUG UGC skipping to 1OOnM
    H31D(+02-22)      UAG UUU CUG AAA UAA CAU AUA CCU         skipping to 1OOnM
    H31D(+01-25)      CCU UAG UUU CUG AAA UAA CAU AUA CC      strong skipping at 300nM

                                             -48
   Antisense Oliqonucleotides Directed at Exon 32
   Antisense oligonucleotides directed at exon 32 were prepared and tested for their
   ability to induce exon skipping in human muscle cells using similar methods as
   described above.
 5 Table 24: Antisense molecule sequences tested to determine if they induce exon
   32 skipping
    Antisense        Sequence                                Ability to Induce skipping
    Oligonucleotlde
    name
    H32A(+49+78)    ACU UUC UUG UAG ACG CUG CUC AAA AUU GGC skipping to 1OOnM
   Antisense Oligonucleotides Directed at Exon 34
   Antisense oligonucleotides directed at exon 34 were prepared and tested for their
10 ability to induce exon skipping in human muscle cells using similar methods as
   described above.
   Table 25: Antisense molecule sequences tested to determine if they induce exon
   34 skipping
    Antisense        Sequence                                Ability to induce skipping
    oligonucleotide
    name
    H34A(+36+59)    UUU CGC AUC UUA CGG GAC AAU UUC         skipping to 200 nM
    H34A(+41+70)    CAU UCA UUU CCU UUC GCA UCU UAC GGG ACA skipping to 200 nM
    H34A(+43+72)    GAC AUU CAU UUC CUU UCG CAU CUU ACG GGA skipping to 100 nM
    H34A(+51+83)    UCU GUC AAG ACA UUC AUU UCC UUU CGC AUC skipping to 200 nM
    H34A(+91+120)   UGA UCU CUU UGU CAA UUC CAU AUC UGU AGC skipping to 100 nM
    H34A(+92+121)   CUG AUC UCU UUG UCA AUU CCA UAU CUG UGG skipping to 100 nM
    H34A(+95+120)   UGA UCU CUU UGU CAA UUC CAU AUC UG      Faint to 25nM
    H34A(+95+124)   CUG CUG AUC UCU UUG UCA AUU CCA UAU CUG skipping to 100 nM
15 Antisense Oliqonucleotides Directed at Exon 35
   Antisense oligonucleotides directed at exon 35 were prepared and tested for their
   ability to induce exon skipping in human muscle cells using similar methods as
   described above.

                                               -49
   Table 26: Antisense molecule sequences tested to determine if they induce exon
   35 skipping
    Antisense          Sequence                                 Ability to induce skipping
    Oligonucleotide
    name
    H35A(+14+43)      UCU UCA GGU GCA CCU UCU GUU UCU CAA UCU  skipping to 100 nM
    H35A(+24+53)      UCU GUG AUA CUC UUC AGG UGC ACC UUC UGU  skipping to 100 nM
   Antisense Oliqonucleotides Directed at Exon 36
 5 Antisense oligonucleotides directed at exon 36 were prepared and tested for their
   ability to induce exon skipping in human muscle cells using similar methods as
   described above. See Figure 11.
   Table 27: Antisense molecule sequences tested to determine if they induce exon
   36 skipping
    Antisense          Sequence                                 Ability to induce skipping
    Oligonucleotide
    name
    H36A(-16+09)      CUG GUA UUC CUU AAU UGU ACA GAG A        no skipping
    H36A(-01+19)      CCA UGU GUU UCU GGU AUU CC               very faint skipping 300 nM
    H36A(+10+39)      CAC AUU CUG GUC AAA AGU UUC CAU GUG UUU  Skipping to 25nM
    H36A(+22+51)      UGU GAU GUG GUC CAC AUU  CUG GUC AAA AGU Skipping at  1OOnM
    H36A(+27+51)      UGU GAU GUG GUC CAC AUU  CUG GUC A       Skipping at  1OOnM
    H36A(+27+56)      CAC UUU GUG AUG UGG UCC  ACA UUC UGG UCA Skipping at  300nM
    H36A(+32+61)      UGA UCC ACU UUG UGA UGU  GGU CCA CAU UCU Skipping to  25nM
    H36A(+59+78)      AAG UGU GUC AGC CUG AAU GA               very weak skipping
    H36A(+65+94)      UCU CUG AUU CAU CCA AAA GUG UGU CAG CCU  100% skipping at 600nM, skipoping
                                                               to 25nM
    H36A(+80+109)     GCU GGG GUU UCU UUU UCU CUG AUU CAU CCA  t1o0/   skipping at 600nM, skipping
    H36D(+15-10)      UAU UUG CUA CCU UAA GCA CGU CUU C        very weak skipping
    Exon 36 cocktails
    H36A(-16+09)      CUG GUA UUC CUU AAU UGU ACA GAG A
    H36A(+22+51)      UGU GAU GUG GUC CAC AUU CUG GUC AA AGU   good skipping down to 25nM
10
   Antisense Oligonucleotides Directed at Exon 38
   Antisense oligonucleotides directed at exon 38 were prepared and tested for their
   ability to induce exon skipping in human muscle cells using similar methods as
   described above.

                                              - 50
   Table 28: Antisense molecule sequences tested to determine if they induce exon
   38 skipping
    Antisense        Sequence                                 Ability to induce skipping
    Oligonucleotide
    name
    H38A(-21-01)    CUA AAA AAA AAG AUA GUG CUA              skipping to 25 nM
    H38A(-12+14)    AAA GGA AUG GAG GCC UAA AAA AAA AG       skipping to 25 nM
    H38D(+14-11)    AAC CAA UUU ACC AUA UCU UUA UUG A        skipping to 25 nM
   Antisense Oliqonucleotides Directed at Exon 39
 5 Antisense oligonucleotides directed at exon 39 were prepared and tested for their
   ability to induce exon skipping in human muscle cells using similar methods as
   described above.
   Table 29: Antisense molecule sequences tested to determine if they induce exon
   39 skipping
    Antisense        Sequence                                 Ability to induce skipping
    Oligonucleotide
    name
    H39A(-07+23)    ACA GUA CC6 UCA UUG UCU UCA UUC UGA UC   skipping to 600 nM
    H39A(-07+23)    ACA GUA CC. UCA UUG UCU UCA UUC UGA UC   skipping to  600 nM
    H39A(+58+87)    CUC  UCG CUU UCU CUC AUC UGU GAU UCU UUG skipping to  100 nM
    H39A(+60+89)    UCC  UCU CGC UUU CUC UCA UCU GUG AUU CUU skipping to  100 nM
    H39A(+102+126)  UAU  GUU UUG UCU GUA ACA GCU GCU G       skipping to  600 nM
10
   Antisense Oliqonucleotides Directed at Exon 41
   Antisense oligonucleotides directed at exon 41 were prepared and tested for their
   ability to induce exon skipping in human muscle cells using similar methods as
   described above.
15 Table 30: Antisense molecule sequences tested to determine if they induce exon
   41 skipping
    Antisense        Sequence                                 Ability to induce skipping
    Oligonucleotide
    name
    H41A(-15+5)     AUU  UCC UAU UGA GCA AAA CC              Skipping down to 200nM
    H41A(+66+90)    CAU  UGC GGC CCC AUC CUC AGA CAA G       Skipping down to 1OOnM
    H41A(+92+120)   GCU  GAG CUG GAU CUG AGU UGG CUC CAC UG  Skipping down to 1OnM
    H41A(+143+171)  GUU  GAG UCU UCG AAA CUG AGC AAA UUU GC  No visible skipping
    H41D(+5-15)     CCA  GUA ACA ACU CAC AAU UU              Skipping down to 200nM

                                             - 51
   Antisense Oligonucleotides Directed at Exon 42
   Antisense oligonucleotides directed at exon 42 were prepared and tested for their
   ability to induce exon skipping in human muscle cells using similar methods as
 5 described above.
   Table 31: Antisense molecule sequences tested to determine if they induce exon
   20 skipping
    Antisense       Sequence                                    Ability to induce skipping
    Oligonucleotide
    name
    Exon 42
    H42D(+18-02)    ACC UUC AGA GAC UCC UCU UGC               -strong skipping
   Antisense Oligonucleotides Directed at Exon 43
10 Antisense oligonucleotides directed at exon 43 were prepared and tested for their
   ability to induce exon skipping in human muscle cells using similar methods as
   described above. See Figure 12.
   Table 32: Antisense molecule sequences tested to determine if they induce exon
   20 skipping
    Antisense       Sequence                                    Ability to induce skipping
    Oligonucleotide
    name
    Exon 43
    H43A(+83+1 10)  UCC UGU AGO UUC ACC CUU UCC ACA GGC G      No skipping
    H43A(+92 +117)  GAG AGC UUC CUG UAG CUU CAC CCU UU         Skipping at 1OnM
    H43A(+101 +130) AAU CA GCU GGG AGA GAG CUU CCU GUA GCU     No skipping
    H43D(+08-12)    UGU GUU ACC UAC CCU UGU CG                 Skipping down to 200nM
    H43A(-09+18)    UAG ACU AUC UUU UAU AUU CUG UAA UAU        Faint skipping to 25 nM
    H43A(+89+117)   GAG AGC UUC CUG UAG CUU CAC CCU UUC CA     Strong skipping at 25 nM faint 2.5
    H43A(+81+111)   UUC CUG UAG CUU CAC CCU UUC CAC AGG CGU U      ong skipping at 50 nM faint 2.5
    H43A(+92+114)   AGC UUC CUG UAG CUU CAC CCU UU             Faint skipping to 2.5 nM
    H43A(+92+120)   GGA GAG AGC UUC CUG UAG CUU CAC CCU UU     Strong skipping at 10 nM faint 5 nM
    H43A(+95+117)   GAG AGC UUC CUG UAG CUU CAC CC             Strong skipping at 25 nM faint 10 nM
15
   Antisense Oligonucleotides Directed at Exon 44

                                              - 52
    Antisense oligonucleotides directed at exon 44 were prepared and tested for their
    ability to induce exon skipping in human muscle cells using similar methods as
    described above. See Figure 13 and Figure 39.
    Table 33: Antisense molecule sequences tested to determine if they induce exon
 5 '44 skipping
     Antisense       Sequence                                   Ability to induce skipping
     Oligonucleotide
     name
     Exon44
     H44A(-13+13)    UCU GUC AAA UCG CCU GCA GGU AAA AG
     H44A(-06+24)    UUC UCA ACA GAU CUG UCA AAU CGC CUG CAG   No skipping
     H44A(+44+68)    GCC ACU GAU UAA AUA UCU UUA UAU C         Skipping at 1OOnM
     H44A(+46+75)    UCU GUU AGC CAC UGA UUA AAU AUC UUU AUA   Skipping at 5OnM
     H44A(+61+84)    UGU UCA GCU UCU GUU AGC CAC UGA           Skipping at 100nM
     H44A(+61+91)    GAG AAA CUG UUC AGC UUC UGU UAG CCA CUG A Skipping at 25nM
     H44A(+65+90)    UGU UCA GCU UCU GUU AGC CAC UGA           Skipping at 10nM
     H44A(+68+98)    UCU UUC UGA GAA ACU GUU CAG CUU CUG UUA G weak at 50 nM
     H44A(-09+17)    CAG AUC UGU CAA AUC GCC UGC AGG UA        Faint skipping to 10 nM
     H44A(-06+20)    CAA CAG AUC UGU CAA AUC GCC UGC AG        Faint skipping to 2.5 nM
                     AAA CUG UUC AGC UUC UGU UAG CCA CUG AUU
     H44A(+56+88)    AAA                                       Strong skipping at 5 nM faint 2.5 nM
     H44A(+59+85)    CUG UUC AGC UUC UGU UAG CCA CUG AUU       Strong skipping at 5 nM
     H44A(+59+89)    GAA ACU GUU CAG CUU CUG UUA GCC ACU GAU U Faint skipping to 10 nM
     H44A(+61+88)    AAA CUG UUC AGC UUC UGU UAG CCA CUG A     Faint skipping to 25 nM
     H44A(+65+92)    UGA GAA ACU GUU CAG CUU CUG UUA GCC A     Faint skipping to 25 nM
     H44A(+64+95)    UUC UGA GAA ACU GUU CAG CUU CUG UUA GCCA
                     C                                         Faint skipping to 25 nM
     H44A(+70+95)    UUC UGA GAA ACU GUU CAG CUU CUG UU        Faint skipping to 50 nM
    Antisense Oligonucleotides Directed at Exon 45
    Antisense oligonucleotides directed at exon 45 were prepared and tested for their
    ability to induce exon skipping in human muscle cells using similar methods as
10  described above. See Figure 14 and Figure 40..
    Table 34: Antisense molecule sequences tested to determine if they induce exon
    45 skipping
     Antisense        Sequence                                  Ability to Induce skipping
     Oligonucleotide
     name
     Exon 45
     H45A(-14+25)    GCU GCC CAA UGC CAU CCU GGA GUU CCU GUA   Generates multiple bands
                     AG
     H45A(-10 +20)   CCA AUG CCA UCC UGG AGU UCC UGU AAG AUA   Skipping at 1OnM
     H45A(-09+30)    UUG CCG CUG CCC AAU GCC AUC CUG GAG UUC   No Skipping
                     CUG UAA GAU
     H45A (-09+25)   GCU GCC CAA UGC CAU CCU GGA GUU CCU GUA   Skipping at 1OnM (100% skipping at

                                             - 53
                   AGA U                                     25nM)
   H45A(-08 +19)   CAA UGC CAU CCU GGA GUU CCU GUA AGA       Skipping at 5OnM
   HM45A(-07+25)   GCU GCC CAA UGC CAU CCU GGA GUU CCU GUA   Skipping at 25nM
                   AG
   H45A(+09 +34)   CAG UUU GCC GCU  GCC CAA UGC CAU CC       No  Skipping
   H45A(+41 +64)   CUU CCC CAG UUG  CAU UCA AUG UUC          No  Skipping
   H45A(+76 +98)   CUG GCA UCU GUU  UUU GAG GAU UG           No  Skipping
   H45D(+02-18)    UUA GAU CUG UCG  CCC UAC CU               No  Skipping
   H45A(-14+25)    GCU GCC CAA UGC  CAU CCU GGA GUU CCU GUA
                   AGA UAC CAA
   H45A(-12+22)    GCC CAA UGC CAU CCU GGA GUU CCU GUA AGA   Strong skipping at 5 nM faint 2.5 nM
                   UAC C
   H45A(-12+13)    CAU CCU GGA GUU CCU GUA AGA UAC C         No skipping
   H45A(-12+16)    UGC CAU CCU GGA GUU CCU GUA AGA UAC C     Strong skipping at  25 nM faint 5 nM
   H45A(-09+16),   UGC CAU CCU GGA GUU CCU GUA AGA U         skipping to 10 nM
   H45A(-09+19)    CAA UGC CAU CCU GGA GUU CCU GUA AGA U     Strong skipping at  25 nM faint 2.5
                                                             nM
   H45A(-09+22)    GCC CAA UGC CAU CCU GGA GUU CCU GUA AGA U Strong skipping at  10 nM faint 5 nM
   H45A(-09+30)    UUG CCG CUG CCC AAU GCC AUC CUG GAG UUC   Strong skipping at  5 nM faint 2.5 nM
                   CUG UAA GAU
   HM45A(-07+25)   GCU GCC CAA UGC CAU CCU GGA GUU CCU GUA   Strong skipping at 2.5 nM
                   AG
   H45A(-06+22)    GCC CAA UGC CAU CCU GGA GUU CCU GUA A     Strong skipping at 5 nM faint 2.5 nM
   H45A(-06+28)    GCC GCU GCC CAA UGA CAU CCU GGA GUU CCU   Strong skipping at 2.5 nM
                   GUA A
   H45A(-03+19)    CAA UGC CAU CCU GGA GUU CCU G             Strong skipping at 5 nM faint 2.5 nM
   H45A(-03+22)    GCC CAA UGC CAU CCU GGA GUU CCU G         Strong skipping at 10 nM faint 2.5
                                                             nM
   H45A(-03+25)    GCU GCC CAA UGC CAU CCU GGA GUU CCU G     Strong skipping at 2.5 nM
   H45A(-03+28)    GCC GCU GCC CAA UGC CAU CCU GGA GUU CCU G Strong skipping at 10 nM faint 2.5
                                                             nM
   H45D(+10-19)    AUU AGA UCU GUC GCC CUA CCU CUU UUU UC    No skipping
   H45D(+16-11)    UGU CGC CCU ACC UCU UUU UUC UGU CUG       No skipping
   H45A(-06+25)    GCU GCC CAA UGC CAU CCU GGA GUU CCU GUA A strong skipping at 2.5 nM
   H45A(-12+19)    CAA UGC CAU CCU GGA GUU CCU GUA AGA UAC C strong skipping at 25 nM
  Antisense Oligonucleotides Directed at Exon 46
  Antisense oligonucleotides directed at exon 46 were prepared and tested for their
  ability to induce exon skipping in human muscle cells using similar methods as
  described above. See Figure 15 and Figure 44.
5 Table 35: Antisense molecule sequences tested to determine if they induce exon
  46 skipping
   Antisense        Sequence                                  Ability to induce skipping
   Oligonucleotide
   name
   Exon 46
   H46A(-05+19)    AUU CUU UUG UUC UUC UAG CCU GGA           No skipping
   H46A(+16+42)    UCU CUU UGA AAU UCU GAC AAG AUA UUC       skipping to 25 nM, other bands
   H46A(+27+44)    UUA AAU CUC UUU GAA AUU CU                No skipping
   H46A(+35+60)    AAA ACA AAU UCA UUU AAA UCU CUU UG        very faint skipping to 50 nM
   H46A(+56+77)    CUG CUU CCU CCA ACC AUA AAA C             No skipping
   H46A(+63+87)    GCA AUG UUA UCU GCU UCC UCC AAC C         No skipping
   H46A(+81+109)   UCC AGG UUC AAG UGG GAU ACU AGC AAU GU    strong skipping at 25nM
   H46A(+83+103)   UUC AAG UGG GAU ACU AGC AAU               skipping at 25nM

                                              - 54
    H46A(+90+109)    UCC AGG UUC AAG UGG GAU AC.               no skipping
    H46A(+91+118)    CUG CUC UUU UCC AGG UUC AAG UGG GAU A     strong skipping at 25nM
    H46A(+95+122)    GUU GCU GCU CUU UUC CAG GUU CAA GUG G     strong skipping at 25nM
    H46A(+101+128)   CUU UUA GUU GCU GCU CUU UUC CAG GUU C     strong skipping at 25nM
    H46A(+113+136)   AAG CUU UUC UUU UAG UUG CUG CUC           skipping at 100nM
    H46A(+115+134)   GCU  UUU CUU UUA GUU GCU GC               skipping at 100nM
    H46A(+116+145)   GAC UUG CUC AAG CUU UUC UUU UAG UUG CUG   strong skipping at 25nM
    H46D(+02-1 8)    UUC AGA AAA UAA AAU UAC CU                 no skipping
    H46A(+93+122)    GUU GCU GCU CUU UUC CAG GUU CAA GUG GGA     00% skipping at 25 nM strong at 5
    H46A(+95+124)    UAG UUG CUG CUC UUU UCC AGG UUC AAG UGG   100% skipping at 25 nM
   Antisense Oligonucleotide Cocktails Directed at Exons 44 to 46
   Antisense oligonucleotide cocktails directed at exons 44 to 46 were prepared and
   tested for their ability to induce exon skipping in human muscle cells using similar
 5 methods as described above.
   Table 36: Antisense molecule sequence cocktails that induce exon 44 to 45
   skipping
    Antisense        Sequence                                   Ability to induce skipping
    Oilgonucleotide
    name
    Cocktails for
    skipping 44 + 45
    H44A(+65 +90)    AGA AAC UGU UCA GCU UCU GUU AGC CA
    H45A(-10 +20)    CCA AUG CCA UCC UGG AGU UCC UGU AAG AUA   Skipping at 25nM
    Cocktails for
    skipping exons
    45 and 46
    H45A(-10 +20)    CCA AUG CCA UCC UGG AGU UCC UGU AAG AUA
    H46A(+91 +118)   CUG CUC UUU UCC AGG UUC AGG UGG GAU A     Skipping at 25nM
    H45A(-10 +20)    CCA AUG CCA UCC UGG AGU UCC UGU AAG AUA
    H46A(+107 +137)  CAA GCU UUU.CUU UUA GUU GCU GCU CUU UUC C Skipping at 25nM
    Cocktail for
    skipping exon 44
    145146
    H45A(-10 +20)    CCA AUG CCA UCC UGG AGU UCC UGU AAG AUA
    H44A(+65 +90)    AGA AAC UGU UCA GCU UCU GUU AGC CA
    H46A(+91 +118)   CUG CUC UUU UCC AGG UUC AGG UGG GAU A     Skipping at 25nM
   Antisense Oliqonucleotides Directed at Exon 47
10 Antisense oligonucleotides directed at exon 47 were prepared and tested for their
   ability to induce exon skipping in human muscle cells using similar methods as
   described above. See Figure 16.

                                             - 55
   Table 37: Antisense molecule sequences tested to determine if they induce exon
   47 skipping
    Antisense        Sequence                                  Ability to induce skipping
    Oligonucleotide
    name
    Exon 47
    H47A(-07+19)    GCA ACU CUU CCA CCA GUA ACU GAA AC        Skipping at 10nM
    H47A(+01 +29)   UGG CGC AGG GGC AAC UCU UCC ACC AGU AA    strong skipping at 25nM
    H47A(+44+70)    GCA CGG GUC CUC CAG UUU CAU UUA AUU       Skipping at 600nM
    H47A(+68+92)    GGG CUU AUG GGA GCA CUU ACA AGC A         No skipping
    H47A(+73+103)   CUU GCU CUU CUG GGC UUA UGG GAG CAC UUA C No skipping
                             CUU CUG GGC UUA UGG GAG CAC U    Faint skipping at 200nM, full length
    H47A(+76+1 03)  CUU GCU       U   G   U UGGGCCUroduct     p         not reduced
    H47D(+17-10)    AAU GUC UAA CCU UUA UCC ACU GGA GAU        No skipping
   Antisense Oligonucleotides Directed at Exon 48
 5 Antisense oligonucleotides directed at exon 48 were prepared and tested for their
   ability to induce exon skipping in human muscle cells using similar methods as
   described above. See Figure 17.
   Table 38: Antisense molecule sequences tested to determine if they induce exon
   48 skipping
    Antisense        Sequence                                  Ability to induce skipping
    Oligonucleotide
    name
    Exon 48
    H48A(-09+21)    CUC AGG UAA AGC UCU GGA AAC CUG AAA GGA   No skipping
    H48A(-08+19)    CAG GUA AAG CUC UGG AAA CCU GAA AGG       No skipping
    H48A(-07+23)    UUC UCA GGU AAA GCU CUG GAA ACC UGA AAG   Skipping at 600, 300nM
    H48A(-05+25)    GUU UCU CAG GUA AAG CUC UGG AAA CCU GAA   No skipping
    H48A(+01 +28)   CUU GUU UCU CAG GUA AAG CUC UGG AAA C     faint to 50 nM
    H48A(+07+33)    UUC UCC UUG UUU CUC AGG UAA AGC UCU       faint to 50 nM
    H48A(+40+67)    CAA GCU GCC CAA GGU CUU UUA UUU GAG C     No skipping (sporadic)
    H48A(+75+100)   UUA ACU GCU CUU CAA GGU CUU CAA GC        faint to 1000 nM
    H48A(+96+122)   GAU AAC CAC AGC AGC AGA UGA UUU AAC       No skipping
    H480(+17-10)    AGU UCC CUA CCU GAA CGU CAA AUG GUC       No skipping
    H48D(+16-09)    GUU CCC UAC CUG AAC GUC AAA UGG U         No skipping
    Cocktail 48
    H48A(+01+28)    CUU GUU UCU CAG GUA AAG CUC UGG AAA C
    H48A(+40+67)    CAA GCU GCC CAA GGU CUU UUA UUU GAG C     Strong skipping at 25 nM
10
   Antisense Oligonucleotides Directed at Exon 49

                                             -56
   Antisense oligonucleotides directed at exon 49 were prepared and tested for their
   ability to induce exon skipping in human muscle cells using similar methods as
   described above. See Figure 18.
   Table 39: Antisense molecule sequences tested to determine if they induce exon
 5 49 skipping
    Antisense       Sequence                                   Ability to Induce skipping
    Oligonucleotlde
    name
    Exon 49
    H49A(-07+19)    GAA CUG CUA UUU CAG UUU CCU GGG GA        Skipping   to 1OOnM
    H49A(+22+47)    AUC UCU UCC ACA UCC GGU UGU UUA GC        Skipping   to 25nM
    H49A(+45+70)    ACA AAU GCU GCC CUU UAG ACA AAA UC        Skipping   to 25nM
    H49D(+18-08)    UUC AUU ACC UUC ACU GGC UGA GUG GC        Skipping   to 1OOnM
   Antisense Oligonucleotides Directed at Exon 50
   Antisense oligonucleotides directed at exon 50 were prepared and tested for their
   ability to induce exon skipping in human muscle cells using similar methods as
10 described above. See Figures 19 and 33.
   Table 40: Antisense molecule sequences tested to determine if they induce exon
   50 skipping
    Antisense        Sequence                                  Ability to Induce skipping
    Oligonucleotide
    name
    Exon 50
    H50A(-07+20)    CUC AGA UCU UCU AAC UUC CUC UUU AAC       Faint skipping 25 nM
    H50A(-02+27)    CUC AGA GCU CAG AUC UUC UAA CUU CCU CU    faint skipping 100 nM
    H50A(+10+36)    CGC CUU CCA CUC AGA GCU CAG AUC UUC       skipping faintly to 25
    H50A(+35+61)    UCA GCU CUU GAA GUA AAC GGU UUA CCG       strong skipping to 25 nM
    H50A(+42+68)    UUU GCC CUC AGC UCU UGA AGU AAA CGG       reasonable skipping to 25 nM
    H50A(+48+74)    GGC UGC UUU GCC CUC AGC UCU UGA AGU       strong skipping at 25 nM
    H50A(+63+88)    CAG GAG CUA GGU CAG GCU GCU UUG CC        strong skipping to 25 nM
    H50A(+81+105)   UCC AAU AGU GGU CAG UCC AGG AGC U
    H50D(-01-27)    AAA GAG AAU GGG AUC CAG UAU ACU UAC       faint skipping 100 nM
    H50D(-15-41)    AAA UAG CUA GAG CCA AAG AGA AUG GGA       No skipping
    H50A(+42+74)    GGC UGC UUU GCC CUC AGC UCU UGA AGU AAA   Strong skipping to 10 nM faint at 5
    ___________     CGG                                       nM
    H50A(+46+75)    AGG CUG CUU UGC CCU CAG CUC UUG AAG UAA   Strong skipping to 25 nM faint at 10
                                                              nM
    H50A(+48+78)    GUC AGG CUG CUU UGC CCU CAG CUC UUG AAG U Strong skipping to 10 nM faint at 2.5
    H50A(+51+80)    AGG UCA GGC UGC UUU GCC CUC AGC UCU UGA   Strong skipping to 25 nM faint at 2.5
                                                              nM
    Hint49(-72-46)  MAG AUA AUU GAU GMA GAU OUU MAU OOA       No skipping

                                               - 57
   Antisense Oligonucleotides Directed at Exon 51
   Antisense oligonucleotides directed at exon 51 were prepared and tested for their
   ability to induce exon skipping in human muscle cells using similar methods as
   described above. See Figure 20 and Figure 41.
 5 Table 41: Antisense molecule sequences tested to determine if they induce exon
   51 skipping
    Antisense        Sequence                                 Ability to induce skipping
    Oligonucleotide
    name
    Exon 51
    H51A(-29-10)     UUU GGG UUU UUG CAA AAA GG              No skipping
    H51A(-22-01)     CUA AAA UAU UUU GGG UUU UUG C           No skipping
    H51A(-14+10)     UGA GUA GGA GCU AAA AUA UUU UGG         No skipping
    H51(+26+52)      GUU UCC UUA GUA ACC ACA GGU UGU GUC     very faint skipping to 25 nM
    H51A(+40+67)     AGU UUG GAG AUG GCA GUU UCC UUA GUA A   skipping to 25nM also skips 50 or
                     UGG CAU UUC UAG
                    H51A(+66+77)                                a well
                                                               o52
    H51A(+66+77)     UGG CAU UUC UAG                         No skipping
    H51A(+66+80)     AGA UGG CAU    UUC
                                      UAG                    No skipping
    H51A(+66+83)     GGA AGA UGG CAU UUC UAG                 No skipping
    H51A(+78+95)     CUC CAA CAU CAA GGA AGA                 No skipping
    H51A(+81+95)     CUC CAA CAU CAA GGA                     No skipping
    H51A(+84+95)     cuc CAA CAU CAA                         No skipping
    H51A(+90+116)    GAA AUC UGC CAG AGC AGG UAC CUC CAA     No skipping
    H51A(+53+79)     GAU GGC AUU UCU AGU UUG GAG AUG GCA     Strong skipping to 25 nM
                     AAG  GAA GAU GGC AUU UCU AGU UUG GAG AU
                      M51A(+57+85)                           Strong skipping to 25 nM faint at 2.5
                    H51A(+7+85)nM
    H51A(+71+100)    GGU ACC UCC AAC AUC AAG GAA GAU GGC AUU Strong skipping to 5 nM
    H51A(+76+104)    AGC AGG UAC CUC CAA CAU CAA GGA AGA UG  Strong skipping to 25 nM
   Antisense Oligonucleotides Directed at Exon 52
   Antisense oligonucleotides directed at exon 52 were prepared and tested for their
10 ability to induce exon skipping in human muscle cells using similar methods as
   described above. See Figure 42.
   Table 42: Antisense molecule sequences tested to determine if they induce exon
   52 skipping
    Antisense         Sequence                                Abilityto Induce skipping
    Ollgonucleotlde
    name
    Exon 52
    H52A(-12+13)     CCU GCA UUG UUG CCU GUA AGA ACA A        No skipping
    H52A(-10+10)     GCA UUG UUG CCU GUA AGA AC               No skipping
    H52A(+07+33)     GGG ACG CCU CUG UUC CAA AUC CUG CAU      skippping 50 nM
    H52A(+17+46)     GUU CUU CCA ACU GGG GAC GCC UCU GUU CCA  skippping 25 nM

                                                -58
    H52A(+17+37)      ACU GGG GAC GCC UCU GUU CCA                 skippping 25 nM
    H52A(+67+94)      CCU CUU GAU UGC UGG UCU UGU UUU UCA A      vey very faint skipping to 25 nM
    Hint5l (-40-14)    UAC CCC UUA GUA UCA GGG UUC UUC AGC       No skipping (SNP C or T)
    H52A(+09+38)      AAC UGG GGA CGC CUC UGU UCC AAA UCC UGC    Strong skipping to 2.5 nM
    H52A(+09+41)       UCC AAC UGG GGA CGC CUC UGU UCC AAA UCC
                      UGC                                        Strong skipping to 5nM faint at 5 nM
    H52A(+15+44)       UCU UCC AAC UGG GGA CGC CUC UGU UCC AAA   Strong skipping to 10nM faint at 5
                    ________________nM
  Antisense Oligonucleotides Directed at Exon 53
  Antisense oligonucleotides directed at exon 53 were prepared and tested for their
  ability to induce exon skipping in human muscle cells using similar methods as
5 described above. See Figure 43.
  Table 43: Antisense molecule sequences tested to determine if they induce exon
  53 skipping
   Antisense           Sequence                                   Ability to induce skipping
   Oligonucleotide
    name
    Exon 53
    H53A(-49-26)      AUA GUA GUA AAU GCU AGU CUG GAG            No skipping
    H53A(-38-13)      GAA AAA UAA AUA UAU AGU AGU AAA UG         No skipping
    H53A(-32-06)      AUA AAA GGA AAA AUA AAU AUA UAG UAG        No skipping
    H53A(-15+15)       UCU GAA UUC UUU CAA CUA GAA UAA AAG GAA   No skipping
    H53A(+39+65)      CAA CUG UUG CCU CCG GUU CUG AAG GUG         skippping 50 nM
    H53A(+39+67)       UUC AAC UGU UGC CUC CGG UUC UGA AGG UG     skippping 100 nM
    H39A(+39+69)SNP   CGU UCA ACU GUU GCC UCC GGU UCU GAA GGU G  skipping to 25 nM
    H53A(+40+70)       UCA UUC AAC UGU UGC CUC CGG UUC UGA AGG U  skippping 50 nM
    H53A(+41+69)      CAU UCA ACU GUU GCC UCC GGU UCU GAA GG      skippping 50 nM
    H53A(+43+69)       CAU UCA ACU GUU GCC UCC GGU UCU GAA        skippping 50 nM
    H53A(+69+98)       CAG CCA UUG UGU UGA AUC CUU UAA CAU UUC    Skipping at 50 nM
    HintS2(-47-23)     UAU AUA GUA GUA AAU GCU AGU CUG G         No skipping
    H53A(+27+56)       CCU CCG GUU CUG AAG GUG UUC UUG UAC UUC   strong skipping to 25 nM faint at 5
                                                                 nM
    H53A(+27+59)       UUG CCU CCG GUU CUG AAG GUG UUC UUG UAC   strong skipping to 10 nM faint at 5
                       UUC                                       nM
    H53A(+30+59)       UUG CCU CCG GUU CUG AAG GUG UUC UUG UAC
    H53A(+30+64)      AAC UGU UGC CUC CGG UUC UGA AGG UGU UCU    strong skipping to 25 nM faint at 10
                       UGU AC                                    nM
    H53A(+30+69)       CAU UCA ACU GUU GCC UCC GGU UCU GAA GGU   strong skipping to 25 nM faint at 5
                       GUU CUU GUA C                             nM
    H53A(+33+63)      ACU GUU GCC UCC GGU UCU GAA GGU GUU CUU G  strong skipping to 25 nM faint at 5
                                                                 nM
    H53A(+33+67)       UUC AAC UGU UGC CUC CGG UUC UGA AGG UGU   strong skipping to 50 nM faint at 5
                       UCU UG                                    nM
    H53A(+33+65)       CAA CUG UUG CCU CCG GUU CUG AAG GUG UUC   strong skipping to 25 nM faint at 2.5
                       UUG                                       nM
    H53A(+35+67)       UUC AAC UGU UGC CUC CGG UUC UGA AGG UGU
                       UCU                                       strong skipping to 25 nM
    H53A(+37+67)       UUC AAC UGU UGC CUC CGG UUC UGA AGG UGU U strong skipping to 25 nM
   -H53A(+36+70)       UCA UUC AAC UGU UGC CUC CGG UUC UGA AGG
                       UGU UC                                    reasonable sipping to 5 nM
    H53A(+39+71)       UUC AUU CAA CUG UUG CCU CCG GUU CUG AAG   strong skipping to 25 nM

                                               -59
                    GUG
    H53A(+42+71)    UUC AUU CAA CUG UUG CCU CCG GUU CUG AAG     strong skipping to 100 nM faint at 5
                                                                nM
   Antisense Oligonucleotides Directed at Exon 54
   Antisense oligonucleotides directed at exon 54 were prepared and tested for their
   ability to induce exon skipping in human muscle cells using similar methods as
 5 described above. See Figure 21.
   Table 44: Antisense molecule sequences tested to determine if they induce exon
   54 skipping
    Antisense       Sequence                                     Ability to Induce skipping
    Oligonucleotide
    name
    Exon 64
    H54A(+13+34)    UUG UCU  GCC ACU GGC GGA GGU C              Skipping at 300nM brings out 55+54
    H54A(+60+90)    AUC UGC  AGA AUA AUC CCG GAG AAG UUU CAG    Skipping at 25nM
    H54A (+67+89)   UCU GCA  GAA UAA UCC CGG AGA AG             Weak skipping to 40nM - both 54+55
    H54A(+67+97)    UGG UCU   CAU CUG CAG AAU AAU CCC GGA GAA G Skipping at 1OnM
    H54A(+77+106)   GGA CUU   UUC UGG UAU CAU CUG CAG AAU AAU   Skipping 50 nM
    Cocktail for
    Exons 54+55
    H54A(+67+97)    UGG UCU CAU CUG CAG AAU AAU CCC GGA GAA G   Specific for 54&55 Skipping at 1OnM
    H55A(-10+14)    CUC GCU CAC UCA CCC UGC AAA GGA             No additional bands
   Antisense Oligonucleotides Directed at Exon 55
10 Antisense oligonucleotides directed at exon 55 were prepared and tested for their
   ability to induce exon skipping in human muscle cells using similar methods as
   described above. See Figure 22.
   Table 45: Antisense molecule sequences tested to determine if they induce exon
   55 skipping
    Antisense        Sequence                                    Ability to Induce skipping
    Oligonucleotide
    name
    Exon 55
    H55A(-10+14)    CUC  GCU CAC UCA CCC UGC AAA GGA            No Skipping
    H55A(-10 +20)   CAG  CCU CUC GCU CAC UCA CCC UGC AAA GGA    Skipping at 1OnM
    H55A(+39 +61)   CAG  GGG GAA CUG UUG CAG UAA UC             No Skipping
    H55A(+41+71)    UCU  UUU ACU CCC UUG GAG UCU UCU AGG AGC C  No Skipping
    H55A(+73+93)    UCU  GUA AGC CAG GCA AGA AAC                No Skipping

                                              -60
     H55A(+107+137)  CCU UAC GGG UAG CAU CCU GAU GGA CAU UGG C No Skipping
     H55A(+112 +136) CUU ACG GGU AGC AUC CUG UAG GAC A         very weak skipping at 100 nM
     H55A(+132 +161) CCU UGG AGU CUU CUA GGA GCC UUU CCU UAC   Skipping at 200nM
     H55A(+141 +160) CUU GGA GUC UUC UAG GAG CC                Skipping at 1O0nM
     H55A(+143 +171) CUC UUU UAC UCC CUU GGA GUC UUC UAG GAG   No skipping
     H55D(+11 -09)   CCU GAC UUA CUU GCC AUU GU                No skipping
    Antisense Oligonucleotides Directed at Exon 56
    Antisense oligonucleotides directed at exon 56 were prepared and tested for their
    ability to induce exon skipping in human muscle cells using similar methods as
 5. described above. See Figure 23.
    Table 46: Antisense molecule sequences tested to determine if they induce exon
    56 skipping
     Antisense       Sequence                                   Ability to induce skipping
     Oligonucleotide
     name
     Exon 56
     H56A(-06+23)    GCU UCA AUU UCA CCU UGG AGG UCC UAC AG    Skipping at 25nM
     H56A(-06+15)    UUC ACC UUG GAG GUC CUA CAG               No Skipping
     H56A(+23 +44)   GUU GUG AUA AAC AUC UGU GUG A             No skipping
     H56A(+56 +81)   CCA GGG AUC UCA GGA UUU UUU GGC UG        No skipping
     H56A(+67+91)    CGG AAC CUU CCA GGG AUC UCA GGA.U         Skipping at 200nM
     H56A(+92+121)   CCA AAC GUC UUU GUA ACA GGA CUG CAU       skipping at 25 nM
     H56A(+102+126)  GUU AUC CAA ACG UCU UUG UAA CAG G         skipping at 100 nM
     H56A(+102+131)  UUC AUG UUA UCC AAA CGU CUU UGU AAC AGG   skipping at 25 nM
     H56A(+112+141)  CCA CUU GAA GUU CAU GUU AUC CAA ACG UCU   skipping at 25 nM
     H56A(+1 17+146) UCA CUC CAC UUG AAG UUC AUG UUA UCC AAA   skipping weakly at 25 nM
     H56A(+121+143)  CUC CAC UUG AAG UUC AUG UUA UC            No Skipping
     H56D(+11-10)    CUU UUC CUA CCA AAU GUU GAG               Skipping at 600nM
    Antisense Oligonucleotides Directed at Exon 57
10  Antisense oligonucleotides directed at exon 57 were prepared and tested for their
    ability to induce exon skipping in human muscle cells using similar methods as
    described above. See Figure 24.
    Table 47: Antisense molecule sequences tested to determine if they induce exon
    57 skipping
     Antisense        Sequence                                  Ability to induce skipping
     Oligonucleotide
     name
     Exon S7

                                             -61
                    CUG GCU UCC AAA UGG GAC CUG AAA AAG AAC
    H57A(-15+18)    AGC                                       No Skipping
    H57A (-12 +18)  CUG GCU UCC AAA UGG GAC CUG AAA AAG MAC   Skipping at 5OnM
    H57A(-10+20)    AAC UGG CUU CCA AAU GGG ACC UGA AAA AGA   Skipping at 300nM
    H57A(-06 +24)   UCA GAA CUG GCU UCC AAA UGG GAC CUG AAA   Skipping at 300nM
    H57A(+21+44)    GGU GCA GAC GCU UCC ACU GGU CAG           No Skipping
    H57A(+47 +77)   GCU GUA GCC ACA CCA GAA GUU CCU GCA GAG A No Skipping
    H57A(+79+103)   CUG CCG GCU UAA UUC AUC AUC UUU C         No Skipping
    H57A(+105+131)  CUG CUG GAA AGU CGC CUC CAA UAG GUG       No Skipping
   Antisense Oligonucleotides Directed at Exon 59
   Antisense oligonucleotides directed at exon 59 were prepared and tested for their
   ability to induce exon skipping in human muscle cells using similar methods as
 5 described above. See Figure 25.
   Table 48: Antisense molecule sequences tested to determine if they induce exon
   59 skipping
    Antisense       Sequence                                   Ability to induce skipping
    Oligonucleotide
    name
    Exon 59
    H59A (-06 +16)  UCC UCA GGA GGC AGC UCU AAA U             No skipping
    H59A(+31 +61)   UCC UC GCC UGC UUU CGU AGA AGC CGA GUG A  No skipping
    H59A(+66+91)    AGG UUC AAU UUU UCC CAC UCA GUA UU        No Skipping
    H59A(+96 +120)  CUA UUU UUC UCU GCC AGU CAG CGG A         Skipping at 1OOnM
    H59A(+96+125)   CUC AUC UAU UUU UCU CUG CCA GUC AGC GGA   No skipping
    H59A(+101 +132) CA GGG UCU CAU CUA UUU UUC UCU GCC AGU CA No skipping
    H59A(+141 +165) CAU CCG UGG CCU CUU GAA GUU CCU G         Skipping exon 58& 59 at 200nM
    H59A(+151 +175) AGG UCC AGC UCA UCC GUG GCC UCU U         Skipping at 300nM
    H59A(+161 +185) GCG CAG CUU GAG GUC CAG CUC AUC C         weak skipping at 200 nM
    H59A(+161+190)  GCU UGG CGC AGC UUG AGG UCC AGC UCA UCC   Skipping at 100 nM
    H59A(+171+197)  CAC CUC AGC UUG GCG CAG CUU GAG GUC       No skipping
    H59A(+181+205)  CCC UUG AUC ACC UCA GCU UGG CGC A         No Skipping
    H59A(+200+220)  ACG GGC UGC CAG GAU CCC UUG               No Skipping
    H59A(+221+245)  GAG AGA GUC AAU GAG GAG AUC GCC C         No Skipping
                    CUC AUC UAU UUU UCU CUG CCA GUC AGC GGA
    H59A(.92+125)   GUG C
   Antisense Oligonucleotides Directed at Exon 60
10 Antisense oligonucleotides directed at exon 60 were prepared and tested for their
   ability to induce exon skipping in human muscle cells using similar methods as
   described above. See Figure 26.

                                              -62
  Table 49: Antisense molecule sequences tested to determine if they induce exon
  60 skipping
   Antisense          Sequence                                  Ability to Induce skipping
   Oligonucleotide
   name
   Exon 60
   H60A(-10+20)      GCA AUU UCU CCU CGA AGU GCC UGU GUG CAA   no skipping
   H60A(-8+19)       CAA UUU CUC CUC GAA GUG CCU GUG UGC       no skipping
   H60A(+29+58)      CAA GGU CAU UGA CGU GGC UCA CGU UCU CUU   skipping to 50 nM
   H60A(+33+62)      CGA GCA AGG UCA UUG ACG UGG CUC ACG UUC   strong skipping to 50 nM
   H60A(+37+66)      CUG GCG AGC AAG GUC CUU GAC GUG GCU CAC   good skipping at 1OOnM
   H60A(+37+66)      CUG GCG AGC AAG GUC AUU GAC GUG GCU CAC   SNP
   H60A(+39+66)      CUG GCG AGC AAG GUC CUU GAC GUG GCU C     good skipping at 100nM
   H60A(+43+73)      UGG UAA GCU GGC GAG CAA GGU CCU UGA CGU G weak skipping at 1OOnM
   H60A(+51+75)      AGU GGU AAG CUG GCG UGC AAG GUC A         weak skipping at 1OOnM
   H60A(+72+102)     UUA UAC GGU GAG AGC UGA AUG CCC AAA GUG   no skipping
   H60A(+75+105)     GAG GUU AUA CGG UGA GAG CUG AAU GCC CAA A no skipping
   H60A(+80+109)     UGC UGA GGU UAU ACG GUG AGA GCU GAA       good skipping at 1OOnM
   H60A(+87+116)     UCC AGA GUG CUG AGG UUA UAC GGU GAG AGC   weak skipping at 100nM
   H60D(+25-5)       CUU UCC UGC AGA AGC UUC CAU CUG GUG UUC   weak skipping at 600nM
   Exon 60 cocktails
   H60A(-8+19)       CAA UUU CUC CUC GAA GUG CCU GUG UGC
   H60A(+37+66)      CUG GCG AGOAAG GUC CUU GAC GUG GCU CAC    weak skipping at 1OnM
   H60A(+87+116)     UCC AGA GUG CUG AGG UUA UAC GGU GAG AGC
   H60A(+37+66)      CUG GCG AGC AAG GUC CUU GAO GUG GCU CAC   skipping at 1OnM
   H60A(-10+20)      GCA AUU UCU CCU CGA AGU GCC UGU GUG CAA
   H60A(+43+73)      UGG UAA GCU GGC GAG CAA GGU CCU UGA CGU G skipping at 1OnM
   H60A(+39+66)      CUG GCG AGC AAG GUC CUU GAC GUG GCU C
   H60A(-10+20)      GCA AUU UCU CCU CGA AGU GCC UGU GUG CAA   skipping at 1OnM
  Antisense Oligonucleotides Directed at Exon 61
5 Antisense oligonucleotides directed at exon 61 were prepared and tested for their
  ability to induce exon skipping in human muscle cells using similar methods as
  described above.
  Table 50: Antisense molecule sequences tested to determine if they induce exon
  61 skipping
   Antisense          Sequence                                  Ability to Induce skipping
   Oligonucleotide
   name
   Exon 61
   H61A(-7+19)       CUC GGU CCU CGA CGG CCA CCU GGG AG        no skipping
   H61A(+05+34)      CAU GCA GCU GCC UGA CUC GGU CCU CGC CGG   skipping to 50 nM
   H61A(+1O+40)      GGG CUU CAU GCA GCU GCC UGA CUC GGU CCU C Skipping at 1OOnM
   H61A(+16+40)      GGG CUU CAU GCA GCU GCC UGA CUC G         no skipping
   H61A(+16+45)      CCU GUG GGC UUC AUG CAG CUG CCU GAC UCG   skipping to 50 nM
   H61A(+42+67)      GCU GAG AUG CUG GAC CAA AGU CCC UG        no skipping
   H61D(+10-16)      GCU GAA AAU GAC UUA CUG GAA AGA AA        no skipping

                                             -63
   Antisense Oliqonucleotides Directed at Exon 62
   Antisense oligonucleotides directed at exon 62 were prepared and tested for their
   ability to induce exon skipping in human muscle cells using similar methods as
 5 described above.
   Table 51: Antisense molecule sequences tested to determine if they induce exon
   62 skipping
    Antisense        Sequence                                 Ability to induce skipping
    Oligonucleotide
    name
    Exon 62
    H62A(-15+15)    GAC CCU GGA CAG ACG CUG AAA AGA AGG GAG   No skipping
    H62A(-1 0+20)   CCA GGG ACC CUG GAC AGA CGC UGA AAA GAA   No skipping
    H62A(-05+15)    GAC CCU GGA CAG ACG CUG AA                Faint to 25nM
    H62A(-3+25)     CUC UCC CAG GGA CCC UGG ACA GAC GCU G     No skipping
    H62A(+01+30)    UGG CUC UCU CCC AGG GAC CCU GGA CAG ACG   almost 100% skipping to 300 nM
    H62A(+8+34)     GAG AUG GCU CUC UCC CAG GGA CCC UGG       Skipping at 300nM
    H62A(+13+43)    UUG UUU GGU GAG AUG GCU CUC UCC CAG GGA C Faint to 25nM
    H62A(23+52)     UAG GGC ACU UUG UUU GGC GAG AUG GCU CUC   Skipping at 1O0nM
    H62D(+17-03)    UAC UUG AUA UAG UAG GGC AC                Faint to 1OOnM
    H62D(+25-5)     CUU ACU UGA UAU AGU AGG GCA CUU UGU UUG   No skipping
   Antisense Oligonucleotides Directed at Exon 63
10 Antisense oligonucleotides directed at exon 63 were prepared and tested for their
   ability to induce exon skipping in human muscle cells using similar methods as
   described above. See Figure 27.
   Table 52: Antisense molecule sequences tested to determine if they induce exon
   63 skipping
    Antisense        Sequence                                 Ability to induce skipping
    Oligonucleotide
    name
    Exon 63
    H63A(-14+1 1).  GAG UCU CGU GGC UAA AAC ACA AAA C         No visible skipping
    H63A(+11+35)    UGG GAU GGU CCC AGC AAG UUG UUU G         Possible skipping at 600nM
    H63A(+20+49)    GAG CUC UGU CAU UUU GGG AUG GUC CCA GCA   Skipping to 100 nM
    H63A(+33+57)    GAC UGG UAG AGC UCU GUC AUU UUG G         No visible skipping
    H63A(+40+62)    CUA AAG ACU GGU AGA GCU CUG UC            No Skipping
    H63D(+8-17)     CAU GGC CAU GUC CUU ACC UAA AGA C         No visible skipping
15

                                             -64
   Antisense Oligonucleotides Directed at Exon 64
   Antisense oligonucleotides directed at exon 64 were prepared and tested for their
   ability to induce exon skipping in human muscle cells using similar methods as
   described above. See Figure 28.
 5 Table 53: Antisense molecule sequences tested to determine if they induce exon
   64 skipping
    Antisense        Sequence                               Ability to Induce skipping
    Oligonucleotide
    name
    Exon 64
    H64A(-3+27)     CUG AGA AUC UGA CAU UAU UCA GGU CAG CUG No skipping
    H64A(+34+62)    CUG CAG UCU UCG GAG UUU CAU GGC AGU CC  Skipping at 50 nM
    H64A(+43+72)    AAA GGG CCU UCU GCA GUC UUC GGA GUU UCA Skipping at 50 nM
    H64A(+47+74)    GCA AAG GGC CUU CUG CAG UCU UCG GAG     Skipping at 200nM
    H64D(+15-10)    CAA UAC UUA CAG CAA AGG GCC UUC U       No skipping
   Antisense Oligonucleotides Directed at Exon 65
   Antisense oligonucleotides directed at exon 65 were prepared and tested for their
10 ability to induce exon skipping in human muscle cells using similar methods as
   described above.
   Table 54: Antisense molecule sequences tested to determine if they induce exon
   65 skipping
    Antisense       Sequence                                Ability to Induce skipping
    Ollgonucleotlde
    name
    Exon 65
    H65A(+123+148)  UUG ACC MA UUG UUG UGC UCU UGC UC       No skipping
15 Antisense Oligonucleotides Directed at Exon 66
   Antisense oligonucleotides directed at exon 66 were prepared and tested for their
   ability to induce exon skipping in human muscle cells using similar methods as
   described above. See Figure 29.
   Table 55: Antisense molecule sequences tested to determine if they induce exon
20 66 skipping

                                               -65
    Antisense          Sequence                                   Ability to induce skipping
    Oligonucleotide
    name
    Exon 66
    H66A(-8+19)       GAU CCU CCC UGU UCG UCC CCU AUU AUG        Skipping at 1OOnM
    H66A(-02+28)      CAG GAC ACG GAU CCU CCC UGU UCG UCC CCU    No skipping
    H66D(+13-17)      UAA UAU ACA CGA CUU ACA UCU GUA CUU GUC    No skipping
    Exon 66 cocktails
    H66A(-02+28)      CAG GAC ACG GAU CCU CCC UGU UCG UCC CCU
    H66D(+13-17)      UAA UAU ACA CGA CUU ACA UCU GUA CUU GUC    skipping at 25nM
   Antisense Oliqonucleotides Directed at Exon 67
   Antisense oligonucleotides directed at exon 67 were prepared and tested for their
   ability to induce exon skipping in human muscle cells using similar methods as
 5 described above. See Figure 30.
   Table 56: Antisense molecule sequences tested to determine if they induce exon
   67 skipping
    Antisense         Sequence                                    Ability to induce skipping
    Oligonucleotide
    name
    Exon 67
    H67A(+17+47)      GCG CUG GUC ACA AAA UCC UGU UGA ACU UGC    strong skipping at 25 nM
    H67A(+120+147)    AGC UCC GGA CAC UUG GCU CAA UGU UAC U      No skipping
    H67A(+125+149)    GCA GCU CCG GAC ACU UGG CUC AAU G          Skipping at 600nM
    H67D(+22-08)      UAA CUU ACA AAU UGG AAG CAG CUC CGG ACA    No skipping
   Antisense Oliqonucleotides Directed at Exon 68
10 Antisense oligonucleotides directed      at exon 68   were prepared and tested for their
   ability to induce exon skipping in human muscle cells using similar methods as
   described above. See Figure 31.
   Table 57: Antisense molecule sequences tested to determine if they induce exon
   68 skipping
    Antisense          Sequence                                   Ability to induce skipping
    Oligonucleotide
    name
    Exon 68
    H68A(-4+21)       GAU CUC UGG CUU AUU AUU AGC CUG C          Skipping at 1OOnM
    H68A(+22+48)      CAU CCA GUC UAG GAA GAG GGC CGC UUC        Skipping at 200nM
    H68A(+48+72)      CAC CAU GGA CUG GGG UUC CAG UCU C          Skipping at 200nM
    H68A(+74+103)     CAG CAG CCA CUC UGU GCA GGA CGG GCA GCC    No skipping

                                               -66
    H68D(+23-03)      UAC CUG AAU CCA AUG AUU GGA CAC UC        No skipping
    Exon 68 cocktails
    H68A(+48+72)      CAC CAU GGA CUG GGG UUC CAG UCU C
    H68D(+23-03)      UAC CUG AAU CCA AUG AUU GGA CAC UC        skipping at 10 nM
   Antisense Oliqonucleotides Directed at Exon 69
   Antisense oligonucleotides directed at exon 69 were prepared and tested for their
   ability to induce exon skipping in human muscle cells using similar methods as
 5 described above. See Figure 32 which shows a cocktail of H69A(+32+60) and
   H70A(-06+1 8) to remove both exons 69 and 70.
   Table 58: Antisense molecule sequences tested to determine if they induce exon
   69 skipping
    Antisense         Sequence                                   Ability to Induce skipping
    Oligonucleotide
    name
    Exon 69
    H69A(-12+19)      GUG CUU UAG ACU CCU GUA CCU GAU AAA GAG C No skipping
    H69A(+09 +39)     UGG CAG AUG UCA UAA UUA AAG UGC UUU AGAC  Skipping 68-71 at 200nM
    H69A(+29 +57)     CCA GAA AAA AAG CAG CUU UGG CAG AUG UC    Skipping 68-71 at 200nM also 68+69
                                                                & 69+70
    H69A(+51+74)      GGC CUU UUG CAA CUC GAC CAG AAA            Skipping 68-71
    H69A(+51 +80)     UUU UAU GGC CUU UUG CAA CUC GAC CAG AAA   -90% Skipping of 68-71 at 200nM
    H69D(+08-16)      CUG GCG UCA AAC UUA CCG GAG UGC           no skipping
10 Antisense Oligonucleotides Directed at Exon 70
   Antisense oligonucleotides directed at exon 70 were prepared and tested for their
   ability to induce exon skipping in human muscle cells using similar methods as
   described above.
   Table 59: Antisense molecule sequences tested to determine if they induce exon
15 70 skipping
    Antisense          Sequence                                  Ability to Induce skipping
    Oligonucleotide
    name
    Exon 70
    H70A(-09+15)      UUC UCC UGA UGU AGU CUA AAA GGG           no skipping
    H70A(-07 +23)     CGA ACA UCU UCU CCU GAU GUA GUC UAA AAG   No skipping
    H70A(+16 +40      GUA CCU UGG CAA AGU CUC GAA CAU C         No skipping
    H70A(+25 +48)     GUU UUU UAG UAC CUU GGC AAA GUC            No Skipping
    H70A(+32+60)      GGU UCG AAA UUU GUU UUU UAG UAC CUU GG    No skipping

                                             - 67
    H70A(+64 -93)   GCC CAU UCG GGG AUG CUU CGC AAA AUA CCU No skipping
   Antisense Oligonucleotides Directed at Exon 71
   Antisense oligonucleotides directed at exon 71 were prepared and tested for their
   ability to induce exon skipping in human muscle cells using similar methods as
 5 described above.
   Table 60: Antisense molecule sequences tested to determine if they induce exon
   71 skipping
    Antisense        Sequence                                Ability to induce skipping
    Oligonucleotide
    name
    Exon71
    H71A(-08+16)    GAU CAG AGU AAC GGG ACU GCA AAA
    H71A(+07+30)    ACU GGC CAG AAG UUG AUC AGA GUA         weak skipping at 1OOnM
    H71A(+16+39)    GCA GAA UCU ACU GGC CAG AAG UUG         skipping at 1OOnM
    H71D(+19-05)    CUC ACG CAG AAU CUA CUG GCC AGA
   Antisense Oligonucleotides Directed at Exon 72
10 Antisense oligonucleotides directed at exon 72 were prepared and tested for their
   ability to induce exon skipping in human muscle cells using similar methods as
   described above.
   Table 61: Antisense molecule sequences tested to determine if they induce exon
   72 skipping
    Antisense        Sequence                                Ability to induce skipping
    Oligonucleotide
    name
    Exon 72
    H72A(-8+22)     AAG CUG AGG GGA CGA GGC AGG CCU AUA AGG faint skipping at 600 nM
    H72A(+02+28)    GUG UGA AAG CUG AGG GGA CGA GGC AGG     no skipping.
    H72D(+14-10)    AGU CUC AUA CCU GCU AGC AUA AUG         no skipping
15
   Antisense Oligonucleotides Directed at Exon 73

                                              -68
   Antisense oligonucleotides directed at exon 73 were prepared and tested for their
   ability to induce exon skipping in human muscle cells using similar methods as
   described above.
   Table 62: Antisense molecule sequences tested to determine if they induce exon
 5 73 skipping
    Antisense       Sequence                               Ability to induce skipping
    Oligonucleotide
    name
    Exon 73
    H73A(+24+49)    AUG CUA UCA UUU AGA UAA GAU CCA U     weak skipping
    H73A(-16+10)    UUC UGC  UAG CCU GAU AAA AAA CGU AA   Faint to 25 nM
    H73A(+02+26)    CAU UGC UGU UUU CCA UUU CUG GUA G     Strong to 25 nM
    H73D(+23-02)    ACA UGC UCU CAU UAG GAG AGA UGC U     Skipping to 25 nM
    HM73A(+19+44)   UAU CAU UUA GAU AAG AUC CAU UGC UG     Faint skipping to 25 nM
   Antisense Oligonucleotides Directed at Exon 74
   Antisense oligonucleotides directed at exon 74 were prepared and tested for their
   ability to induce exon skipping in human muscle cells using similar methods as
10 described above.
   Table 66: Antisense molecule sequences tested to determine if they induce exon
   74 skipping
    Antisense       Sequence                               Ability to Induce skipping
    oligonucleotide
    name
    HM74A(+20+46)   GUU CAA ACU UUG GCA GUA AUG CUG GAU   skipping 25 nM
    HM74A(+50+77)   GAC UAC GAG GCU GGC UCA GGG GGG AGU C  100 % skipping at 25 nM
    HM74A(+96+122)  GCU CCC CUC UUU CCU CAC UCU CUA AGG   skipping 25 nM
   Antisense Oligonucleotides Directed at Exon 76
15 Antisense oligonucleotides directed at exon 76 were prepared and tested for their
   ability to induce exon skipping in human muscle cells using similar methods as
   described above.
   Table 63: Antisense molecule sequences tested to determine if they induce exon
   76 skipping

                                              -69
   Antisense         Sequence                              Ability to induce skipping
   Oligonucleotide
   name
   Exon 76
   H76A(-02+25)      CAU UCA CUU UGG CCU CUG CCU GGG GCU   no detectable skipping
   H76A(+80+106)   - GAC UGC CAA CCA CUC GGA GCA GCA UAG   no detectable skipping
  Modifications of the above-described modes -of         carrying out the various
  embodiments of this invention will be apparent to those skilled in the art based on
  the above teachings related to the disclosed invention. The above embodiments
5 of the invention are merely exemplary and should not be construed to be in any
  way limiting.

                                          - 70
   The Claim Defining the Invention is as Follows:
   1. An antisense molecule capable of binding to a selected target site to induce
      exon skipping in the dystrophin gene, as set forth in a sequence selected from
      the following: SEQ ID NOs: 1, 3 to 6, 9 to 18, 20 to 24, 26 to 28, 30 to 32, 34
 5    to 36, 40, 42, 44 to 46, and 48 to 59.
   2. An antisense molecule according to claim 1 capable of inducing exon skipping
      in exons 5, 11, 12, 17, 21, 22, 24, 43-47, 49-64, 66 and 67 of the dystrophin
      gene.
   3. A combination of two or more antisense molecules according to claim 1 or 2
10    capable of binding to a selected target to induce exon skipping in the
      dystrophin gene.
   4. An antisense molecule according to claim 1 in combination with an antisense
      molecule selected from the following: SEQ ID NOs: 2, 4, 7, 8, 19, 25, 29, 33,
      37 to 39, 41, 43 and 47 wherein the combination is capable of binding to a
15    selected target to induce exon skipping in the dystrophin gene.
   5. A combination of two or more antisense molecules selected from the following
      combinations: SEQ ID NO: 31 and 32; SEQ ID NO: 33 and 34; SEQ ID NO:
      35 and 36; SEQ ID NO: 39, 40 and 41; SEQ ID NO: 42 and 43; SEQ ID NO:
      44 and 45; SEQ ID NO: 46 and 47; SEQ ID NO: 48 and 49; SEQ ID NO: 50
20    and 51; wherein the combination is capable of binding to a selected target to
      induce exon skipping in the dystrophin gene.
   6. The antisense molecule according to any one of claims 1 to 5, capable of
      binding to a selected target site, wherein the target site is an mRNA splicing
      site selected from a splicer donor site, splice acceptor sites or exonic splicing
25    enhancer elements.
   7. A method of treating muscular dystrophy in a patient comprising administering
      to the patient a composition comprising an antisense molecule according to
      anyone of claims 1 to 5.

                                             -71'
   8. A pharmaceutical or therapeutic composition for the treatment of muscular
       dystrophy in a patient comprising          (a) at least an antisense molecule
       according to any one of claims 1 to 5, and (b) one or more pharmaceutically
       acceptable carriers and/or diluents.
 5 9. The composition according to claim 8, comprising about 20 nM to 600 nM.of
       the antisense molecule.
   10. The use of an antisense molecule according to any one of claims 1 to 5 for the
       manufacture of a medicament for modulation of muscular dystrophy.
   11. An antisense molecule according to any one of claims I to 5 for use in
10     antisense molecule based therapy.
   12. An antisense molecule according to any one of claims 1 to 5 as herein before
       described with reference to the examples.
   13. A kit comprising at least one antisense molecule according to any one of
       claims I to 5, a suitable carrier and instructions for its use.
15

<removed-apn> <removed-date>
<removed-apn> <removed-date>
<removed-apn> <removed-date>
<removed-apn> <removed-date>
<removed-apn> <removed-date>
<removed-apn> <removed-date>
<removed-apn> <removed-date>
<removed-apn> <removed-date>
<removed-apn> <removed-date>
<removed-apn> <removed-date>
<removed-apn> <removed-date>
<removed-apn> <removed-date>
<removed-apn> <removed-date>
<removed-apn> <removed-date>
<removed-apn> <removed-date>
<removed-apn> <removed-date>
<removed-apn> <removed-date>
<removed-apn> <removed-date>
<removed-apn> <removed-date>
<removed-apn> <removed-date>
<removed-apn> <removed-date>
<removed-apn> <removed-date>
<removed-apn> <removed-date>
<removed-apn> <removed-date>
<removed-apn> <removed-date>
<removed-apn> <removed-date>
<removed-date>
                                                    -1-
                                           SEQUENCE LISTING
              <110>   THE UNIVERSITY OF WESTERN AUSTRALIA
                      WILTON, Stephen
                      FLETCHER, Sue
                      ADAMS, Abbie
                      MELONI, Penny
<removed-apn>
              <120>   ANTISENSE MOLECULES AND METHODS FOR TREATING PATHOLOGIES
              <130>   AVN-015USCN
              <140>   US
              <141>   Herewith
              <150>   US 13/509,331
              <151>   2012-07-09
              <150>   PCT/AU2010/001520
              <151>   2010-11-12
              <150>   AU 2009905549
              <151>   2009-11-12
              <160>   464
              <170>   PatentIn version 3.5
              <210>   1
              <211>   31
              <212>   RNA
              <213>   Homo sapiens
              <220>
              <221>   misc_feature
              <222>   (1)..(31)
              <223>   Exon: H5A(+35+65)
              <400> 1
              aaaccaagag ucaguuuaug auuuccaucu a                                 31
              <210>   2
              <211>   24
              <212>   RNA
              <213>   Homo sapiens
              <220>
              <221>   misc_feature
              <222>   (1)..(24)
              <223>   Exon: H12A(+52+75)
              <400> 2
              ucuucuguuu uuguuagcca guca                                         24

<removed-date>
                                                 -2-
              <210>   3
              <211>   30
              <212>   RNA
              <213>   Homo sapiens
              <220>
              <221>   misc_feature
<removed-apn>
              <222>   (1)..(30)
              <223>   Exon: H17A(-07+23)
              <400> 3
              guggugguga cagccuguga aaucugugag         30
              <210>   4
              <211>   26
              <212>   RNA
              <213>   Homo sapiens
              <220>
              <221>   misc_feature
              <222>   (1)..(26)
              <223>   Exon: H17A(+61+86)
              <400> 4
              uguucccuug uggucaccgu aguuac             26
              <210>   5
              <211>   29
              <212>   RNA
              <213>   Homo sapiens
              <220>
              <221>   misc_feature
              <222>   (1)..(29)
              <223>   Exon: H21A(+86+114)
              <400> 5
              cacaaagucu gcauccagga acauggguc          29
              <210>   6
              <211>   30
              <212>   RNA
              <213>   Homo sapiens
              <220>
              <221>   misc_feature
              <222>   (1)..(30)
              <223>   Exon: H21A(+90+119)
              <400> 6
              aaggccacaa agucugcauc caggaacaug         30

              H:\fmt\Interwoven\NRPortbl\DCC\FMT\9992541_1.docx-6/05/2016
<removed-date>
                                                                            -3-
              <210>            7
              <211>            22
              <212>            RNA
              <213>            Homo sapiens
<removed-apn>
              <220>
              <221>            misc_feature
              <222>            (1)..(22)
              <223>            Exon: H22A(+125+146)
              <400> 7
              cugcaauucc ccgagucucu gc                                            22
              <210>            8
              <211>            23
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(23)
              <223>            Exon: H24A(+51 +73)
              <400> 8
              caagggcagg ccauuccucc uuc                                           23
              <210>            9
              <211>            26
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(26)
              <223>            Exon: H43A(+92 +117)
              <400> 9
              gagagcuucc uguagcuuca cccuuu                                        26
              <210>            10
              <211>            24
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(24)
              <223>            Exon: H44A(+65+90)

              H:\fmt\Interwoven\NRPortbl\DCC\FMT\9992541_1.docx-6/05/2016
<removed-date>
                                                                            -4-
              <400> 10
              uguucagcuu cuguuagcca cuga                                          24
              <210>            11
              <211>            34
              <212>            RNA
              <213>            Homo sapiens
<removed-apn>
              <220>
              <221>            misc_feature
              <222>            (1)..(34)
              <223>            Exon: H45A (-09+25)
              <400> 11
              gcugcccaau gccauccugg aguuccugua agau                               34
              <210>            12
              <211>            29
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(29)
              <223>            Exon: H46A(+81+109)
              <400> 12
              uccagguuca agugggauac uagcaaugu                                     29
              <210>            13
              <211>            29
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(29)
              <223>            Exon: H47A(+01+29)
              <400> 13
              uggcgcaggg gcaacucuuc caccaguaa                                     29
              <210>            14
              <211>            26
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(26)

              H:\fmt\Interwoven\NRPortbl\DCC\FMT\9992541_1.docx-6/05/2016
<removed-date>
                                                                            -5-
              <223>            Exon: H49A(+45+ 70)
              <400> 14
              acaaaugcug cccuuuagac aaaauc                                        26
              <210>            15
              <211>            27
<removed-apn>
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(27)
              <223>            Exon: H50A(+48+74)
              <400> 15
              ggcugcuuug cccucagcuc uugaagu                                       27
              <210>            16
              <211>            31
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(31)
              <223>            Exon: H54A(+67+97)
              <400> 16
              uggucucauc ugcagaauaa ucccggagaa g                                  31
              <210>            17
              <211>            30
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(30)
              <223>            Exon: H55A(-10 +20)
              <400> 17
              cagccucucg cucacucacc cugcaaagga                                    30
              <210>            18
              <211>            27
              <212>            RNA
              <213>            Homo sapiens
              <220>

              H:\fmt\Interwoven\NRPortbl\DCC\FMT\9992541_1.docx-6/05/2016
<removed-date>
                                                                            -6-
              <221>            misc_feature
              <222>            (1)..(27)
              <223>            Exon: H56A(+92+121)
              <400> 18
              ccaaacgucu uuguaacagg acugcau                                       27
<removed-apn>
              <210>            19
              <211>            30
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(30)
              <223>            Exon: H56A(+112+141)
              <400> 19
              ccacuugaag uucauguuau ccaaacgucu                                    30
              <210>            20
              <211>            30
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(30)
              <223>            Exon: H57A(-10+20)
              <400> 20
              aacuggcuuc caaaugggac cugaaaaaga                                    30
              <210>            21
              <211>            31
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(31)
              <223>            Exon: H58A(+34+64)
              <400> 21
              uucguacagu cucaagagua cucaugauua c                                  31
              <210>            22
              <211>            24
              <212>            RNA
              <213>            Homo sapiens

              H:\fmt\Interwoven\NRPortbl\DCC\FMT\9992541_1.docx-6/05/2016
<removed-date>
                                                                            -7-
              <220>
              <221>            misc_feature
              <222>            (1)..(24)
              <223>            Exon: H58D(+17-07)
              <400> 22
              caauuaccuc ugggcuccug guag                                          24
<removed-apn>
              <210>            23
              <211>            25
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(25)
              <223>            Exon: H59A(+96 +120)
              <400> 23
              cuauuuuucu cugccaguca gcgga                                         25
              <210>            24
              <211>            30
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(30)
              <223>            Exon: H60A(+33+62)
              <400> 24
              cgagcaaggu cauugacgug gcucacguuc                                    30
              <210>            25
              <211>            31
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(31)
              <223>            Exon: H61A(+10+40)
              <400> 25
              gggcuucaug cagcugccug acucgguccu c                                  31
              <210>            26
              <211>            30
              <212>            RNA

              H:\fmt\Interwoven\NRPortbl\DCC\FMT\9992541_1.docx-6/05/2016
<removed-date>
                                                                            -8-
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(30)
              <223>            Exon: H62A(23+52)
<removed-apn>
              <400> 26
              uagggcacuu uguuuggcga gauggcucuc                                    30
              <210>            27
              <211>            30
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(30)
              <223>            Exon: H63A(+20+49)
              <400> 27
              gagcucuguc auuuugggau ggucccagca                                    30
              <210>            28
              <211>            29
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(29)
              <223>            Exon: H64A(+34+62)
              <400> 28
              cugcagucuu cggaguuuca uggcagucc                                     29
              <210>            29
              <211>            27
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(27)
              <223>            Exon: H66A(-8+19)
              <400> 29
              gauccucccu guucgucccc uauuaug                                       27
              <210>            30

              H:\fmt\Interwoven\NRPortbl\DCC\FMT\9992541_1.docx-6/05/2016
<removed-date>
                                                                            -9-
              <211>            30
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(30)
<removed-apn>
              <223>            Exon: H67A(+17+47)
              <400> 30
              gcgcugguca caaaauccug uugaacuugc                                    30
              <210>            31
              <211>            31
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(31)
              <223>            Exon: H3A(+30+60)
              <400> 31
              uaggaggcgc cucccauccu guaggucacu g                                  31
              <210>            32
              <211>            25
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(25)
              <223>            Exon: H3A(+61 +85)
              <400> 32
              gcccugucag gccuucgagg agguc                                         25
              <210>            33
              <211>            30
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(30)
              <223>            Exon: H4A(+11+40)
              <400> 33
              uguucagggc augaacucuu guggauccuu                                    30

              H:\fmt\Interwoven\NRPortbl\DCC\FMT\9992541_1.docx-6/05/2016
<removed-date>
                                                                            - 10 -
              <210>            34
              <211>            25
              <212>            RNA
              <213>            Homo sapiens
              <220>
<removed-apn>
              <221>            misc_feature
              <222>            (1)..(25)
              <223>            Exon: H4D(+14-11 )
              <400> 34
              guacuacuua cauuauuguu cugca                                            25
              <210>            35
              <211>            30
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(30)
              <223>            Exon: H8A(-06+24)
              <400> 35
              uaucuggaua ggugguauca acaucuguaa                                       30
              <210>            36
              <211>            25
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(25)
              <223>            Exon: H8A{+134+158)
              <400> 36
              auguaacuga aaauguucuu cuuua                                            25
              <210>            37
              <211>            21
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(21)
              <223>            Exon: H10A{-05+16)
              <400>            37

              H:\fmt\Interwoven\NRPortbl\DCC\FMT\9992541_1.docx-6/05/2016
<removed-date>
                                                                            - 11 -
              caggagcuuc gaaauggugg a                                                21
              <210>            38
              <211>            22
              <212>            RNA
              <213>            Homo sapiens
<removed-apn>
              <220>
              <221>            misc_feature
              <222>            (1)..(22)
              <223>            Exon: H10A(+98+119)
              <400> 38
              uccucagcag aaagaagcca cg                                               22
              <210>            39
              <211>            26
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(26)
              <223>            Exon: H26A(-07+19)
              <400> 39
              ccuccuuucu ggcauagacc uuccac                                           26
              <210>            40
              <211>            27
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(27)
              <223>            Exon: H26A{+24+50)
              <400> 40
              cuuacaguuu ucuccaaacc ucccuuc                                          27
              <210>            41
              <211>            25
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(25)
              <223>            Exon: H26A{ +68+92)

              H:\fmt\Interwoven\NRPortbl\DCC\FMT\9992541_1.docx-6/05/2016
<removed-date>
                                                                            - 12 -
              <400> 41
              ugugucaugc auucgugcau gucug                                            25
              <210>            42
              <211>            25
              <212>            RNA
<removed-apn>
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(25)
              <223>            Exon: H36A( -16+09)
              <400> 42
              cugguauucc uuaauuguac agaga                                            25
              <210>            43
              <211>            30
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(30)
              <223>            Exon: H36A(+22+51)
              <400> 43
              ugugaugugg uccacauucu ggucaaaagu                                       30
              <210>            44
              <211>            28
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(28)
              <223>            Exon: H48A(+01 +28)
              <400> 44
              cuuguuucuc agguaaagcu cuggaaac                                         28
              <210>            45
              <211>            28
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature

              H:\fmt\Interwoven\NRPortbl\DCC\FMT\9992541_1.docx-6/05/2016
<removed-date>
                                                                            - 13 -
              <222>            (1)..(28)
              <223>            Exon: H48A(+40+67)
              <400> 45
              caagcugccg aaggucuuuu auuugagc                                         28
              <210>            46
<removed-apn>
              <211>            30
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(30)
              <223>            Exon: H60A(+87+116)
              <400> 46
              uccagagugc ugagguuaua cggugagagc                                       30
              <210>            47
              <211>            30
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(30)
              <223>            Exon: H60A(+37+66)
              <400> 47
              cuggcgagca agguccuuga cguggcucac                                       30
              <210>            48
              <211>            30
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(30)
              <223>            Exon: H66A(-02+28)
              <400> 48
              caggacacgg auccucccug uugguccccu                                       30
              <210>            49
              <211>            30
              <212>            RNA
              <213>            Homo sapiens

              H:\fmt\Interwoven\NRPortbl\DCC\FMT\9992541_1.docx-6/05/2016
<removed-date>
                                                                            - 14 -
              <220>
              <221>            misc_feature
              <222>            (1)..(30)
              <223>            Exon: H66D(+13-17)
              <400> 49
              uaauauacac gacuuacauc uguacuuguc                                       30
<removed-apn>
              <210>            50
              <211>            25
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(25)
              <223>            Exon: H68A(+48+ 72)
              <400> 50
              cagcauggac ugggguucca gucuc                                            25
              <210>            51
              <211>            26
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(26)
              <223>            Exon: H68D(+23-03)
              <400> 51
              uaccugaauc caaugauugg acacuc                                           26
              <210>            52
              <211>            30
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(30)
              <223>            Exon: H11A(+50+79)
              <400> 52
              cuguuccaau cagcuuacuu cccaauugua                                       30
              <210>            53
              <211>            28
              <212>            RNA
              <213>            Homo sapiens

              H:\fmt\Interwoven\NRPortbl\DCC\FMT\9992541_1.docx-6/05/2016
<removed-date>
                                                                            - 15 -
              <220>
              <221>            misc_feature
              <222>            (1)..(28)
              <223>            Exon: H12A(+30+57)
              <400> 53
<removed-apn>
              cagucauuca agucuuucag uuugugau                                         28
              <210>            54
              <211>            27
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(27)
              <223>            Exon: H44A(+59+85)
              <400> 54
              cuguucagcu ucuguuagcc acugauu                                          27
              <210>            55
              <211>            28
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(28)
              <223>            Exon: H45A(-03+25)
              <400> 55
              gcugcccaau gccauccugg aguuccug                                         28
              <210>            56
              <211>            30
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(30)
              <223>            Exon: H46A(+93+122)
              <400> 56
              guugcugcuc uuuuccaggu ucaaguggga                                       30
              <210>            57
              <211>            30

              H:\fmt\Interwoven\NRPortbl\DCC\FMT\9992541_1.docx-6/05/2016
<removed-date>
                                                                            - 16 -
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(30)
              <223>            Exon: H51A(+71 +100)
<removed-apn>
              <400> 57
              gguaccucca acaucaagga agauggcauu                                       30
              <210>            58
              <211>            33
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(33)
              <223>            Exon: H52A(+09+38)
              <400> 58
              uccaacuggg gacgccucug uuccaaaucc ugc                                   33
              <210>            59
              <211>            33
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(33)
              <223>            Exon: H53A(+33+65)
              <400> 59
              uucaacuguu gccuccgguu cugaaggugu ucu                                   33
              <210>            60
              <211>            25
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(25)
              <223>            Exon: H73A(+02+26)
              <400> 60
              cauugcuguu uuccauuucu gguag                                            25

              H:\fmt\Interwoven\NRPortbl\DCC\FMT\9992541_1.docx-6/05/2016
<removed-date>
                                                                            - 17 -
              <210>            61
              <211>            31
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
<removed-apn>
              <222>            (1)..(31)
              <223>            Exon: H45A(-06+25)
              <400> 61
              gcugcccaau gccauccugg aguuccugua a                                     31
              <210>            62
              <211>            31
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(31)
              <223>            Exon: H45A(-12+19)
              <400> 62
              caaugccauc cuggaguucc uguaagauac c                                     31
              <210>            63
              <211>            22
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(22)
              <223>            Exon: H45A(-3+19)
              <400> 63
              caaugccauc cuggaguucc ug                                               22
              <210>            64
              <211>            28
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(28)
              <223>            Exon: H45A(-9+19)
              <400> 64
              caaugccauc cuggaguucc uguaagau                                         28

              H:\fmt\Interwoven\NRPortbl\DCC\FMT\9992541_1.docx-6/05/2016
<removed-date>
                                                                            - 18 -
              <210>            65
              <211>            25
              <212>            RNA
              <213>            Homo sapiens
<removed-apn>
              <220>
              <221>            misc_feature
              <222>            (1)..(25)
              <223>            Exon: H45A(-9+16)
              <400> 65
              ugccauccug gaguuccugu aagau                                            25
              <210>            66
              <211>            28
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(28)
              <223>            Exon: H45A(-7+21)
              <400> 66
              ugccauccug gaguuccugu aagauacc                                         28
              <210>            67
              <211>            30
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(30)
              <223>            Exon: H53A(+27+56)
              <400> 67
              ccuccgguuc ugaagguguu cuuguacuuc                                       30
              <210>            68
              <211>            26
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(26)
              <223>            Exon: H44A(-6+20)

              H:\fmt\Interwoven\NRPortbl\DCC\FMT\9992541_1.docx-6/05/2016
<removed-date>
                                                                            - 19 -
              <400> 68
              caacagaucu gucaaaucgc cugcag                                           26
              <210>            69
              <211>            30
              <212>            RNA
              <213>            Homo sapiens
<removed-apn>
              <220>
              <221>            misc_feature
              <222>            (1)..(30)
              <223>            Exon: H51A(+71+100)
              <400> 69
              gguaccucca acaucaagga agauggcauu                                       30
              <210>            70
              <211>            27
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(27)
              <223>            Exon: H8A(+57+83)
              <400> 70
              gcucacuugu ugaggcaaaa cuuggaa                                          27
              <210>            71
              <211>            25
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(25)
              <223>            Exon: H8A(+42+66)
              <400> 71
              aaacuuggaa gagugaugug augua                                            25
              <210>            72
              <211>            23
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(23)

              H:\fmt\Interwoven\NRPortbl\DCC\FMT\9992541_1.docx-6/05/2016
<removed-date>
                                                                            - 20 -
              <223>            Exon: H7A(+49+71)
              <400> 72
              ugaaugcaug uuccagucgu ugu                                              23
              <210>            73
              <211>            27
<removed-apn>
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(27)
              <223>            Exon: H7A(+41+67)
              <400> 73
              ugcauguucc agucguugug uggcuga                                          27
              <210>            74
              <211>            29
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(29)
              <223>            Exon: H43A(+92+120)
              <400> 74
              ggagagagcu uccuguagcu ucacccuuu                                        29
              <210>            75
              <211>            24
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(24)
              <223>            Exon: H2A(-14+10)
              <400> 75
              ucucuuucau cuaaaaugca aaau                                             24
              <210>            76
              <211>            24
              <212>            RNA
              <213>            Homo sapiens
              <220>

              H:\fmt\Interwoven\NRPortbl\DCC\FMT\9992541_1.docx-6/05/2016
<removed-date>
                                                                            - 21 -
              <221>            misc_feature
              <222>            (1)..(24)
              <223>            Exon: H2A(-1+23)
              <400> 76
              cuuuugaaca ucuucucuuu cauc                                             24
<removed-apn>
              <210>            77
              <211>            32
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(32)
              <223>            Exon: H2A(+7+38)
              <400> 77
              uuuugugaau guuuucuuuu gaacaucuuc uc                                    32
              <210>            78
              <211>            24
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(24)
              <223>            Exon: H2A(+16+39)
              <400> 78
              auuuugugaa uguuuucuuu ugaa                                             24
              <210>            79
              <211>            31
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(31)
              <223>            Exon: H2A(+30+60)
              <400> 79
              uagaaaauug ugcauuuacc cauuuuguga a                                     31
              <210>            80
              <211>            30
              <212>            RNA
              <213>            Homo sapiens

              H:\fmt\Interwoven\NRPortbl\DCC\FMT\9992541_1.docx-6/05/2016
<removed-date>
                                                                            - 22 -
              <220>
              <221>            misc_feature
              <222>            (1)..(30)
              <223>            Exon: H2D(+19-11)
              <400> 80
              accauucuua ccuuagaaaa uugugcauuu                                       30
<removed-apn>
              <210>            81
              <211>            24
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(24)
              <223>            Exon: H2D(+03-21)
              <400> 81
              aaaguaacaa accauucuua ccuu                                             24
              <210>            82
              <211>            25
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(25)
              <223>            Exon: H3A(+14+38)
              <400> 82
              aggucacuga agagguucuc aauau                                            25
              <210>            83
              <211>            21
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(21)
              <223>            Exon: H3A(+20+40)
              <400> 83
              guaggucacu gaagagguuc u                                                21
              <210>            84
              <211>            35
              <212>            RNA

              H:\fmt\Interwoven\NRPortbl\DCC\FMT\9992541_1.docx-6/05/2016
<removed-date>
                                                                            - 23 -
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(35)
              <223>            Exon: H3A(+25+60)
<removed-apn>
              <400> 84
              aggaggcguc ucccauccug uaggucacug aagag                                 35
              <210>            85
              <211>            21
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(21)
              <223>            Exon: H3A(+45+65)
              <400> 85
              aggucuagga ggcgccuccc a                                                21
              <210>            86
              <211>            26
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(26)
              <223>            Exon: H3A(+48+73)
              <400> 86
              cuucgaggag gucuaggagg cgccuc                                           26
              <210>            87
              <211>            25
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(25)
              <223>            Exon: H30D(+17-08)
              <400> 87
              ucacauacag uuuuugcccu gucag                                            25
              <210>            88

              H:\fmt\Interwoven\NRPortbl\DCC\FMT\9992541_1.docx-6/05/2016
<removed-date>
                                                                            - 24 -
              <211>            21
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(21)
<removed-apn>
              <223>            Exon: H3D(+19-02)
              <400> 88
              uacaguuuuu gcccugucag g                                                21
              <210>            89
              <211>            24
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(24)
              <223>            Exon: H3D(+14-10)
              <400> 89
              aagucacaua caguuuuugc ccug                                             24
              <210>            90
              <211>            19
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(19)
              <223>            Exon: H3D(+12-07)
              <400> 90
              ucacauacag uuuuugccc                                                   19
              <210>            91
              <211>            25
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(25)
              <223>            Exon: H4A(-08+17)
              <400> 91
              gauccuuuuu cuuuuggcug agaac                                            25

              H:\fmt\Interwoven\NRPortbl\DCC\FMT\9992541_1.docx-6/05/2016
<removed-date>
                                                                            - 25 -
              <210>            92
              <211>            25
              <212>            RNA
              <213>            Homo sapiens
              <220>
<removed-apn>
              <221>            misc_feature
              <222>            (1)..(25)
              <223>            Exon: H4A(+36+60)
              <400> 92
              ccgcagugcc uuguugacau uguuc                                            25
              <210>            93
              <211>            25
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(25)
              <223>            Exon: H4D(+14-11)
              <400> 93
              guacuacuua cauuauuguu cugca                                            25
              <210>            94
              <211>            31
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(31)
              <223>            Exon: H5D(+26-05)
              <400> 94
              cuuaccugcc aguggaggau uauauuccaa a                                     31
              <210>            95
              <211>            26
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(26)
              <223>            Exon: H6A{-09+17)
              <400>            95

              H:\fmt\Interwoven\NRPortbl\DCC\FMT\9992541_1.docx-6/05/2016
<removed-date>
                                                                            - 26 -
              uucauuacau uuuugaccua caugug                                           26
              <210>            96
              <211>            26
              <212>            RNA
              <213>            Homo sapiens
<removed-apn>
              <220>
              <221>            misc_feature
              <222>            (1)..(26)
              <223>            Exon: H6A(+32+57)
              <400> 96
              cuuuucacug uugguuuguu gcaauc                                           26
              <210>            97
              <211>            29
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(29)
              <223>            Exon: KH9 6A(+66+94)
              <400> 97
              aauuacgagu ugauugucgg acccagcuc                                        29
              <210>            98
              <211>            28
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(28)
              <223>            Exon: H6A(+69+96)
              <400> 98
              auaauuacga guugauuguc ggacccag                                         28
              <210>            99
              <211>            26
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(26)
              <223>            Exon: H6A(+98+123)

              H:\fmt\Interwoven\NRPortbl\DCC\FMT\9992541_1.docx-6/05/2016
<removed-date>
                                                                            - 27 -
              <400> 99
              ggugaaguug auuacauuaa ccugug                                           26
              <210>            100
              <211>            24
              <212>            RNA
<removed-apn>
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(24)
              <223>            Exon: H6D(+18-06)
              <400> 100
              ucuuaccuau gacuauggau gaga                                             24
              <210>            101
              <211>            22
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(22)
              <223>            Exon: H6D(+07-15)
              <400> 101
              caguaaucuu cuuaccuaug ac                                               22
              <210>            102
              <211>            23
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(23)
              <223>            Exon: H6D(+07-16)
              <400> 102
              ucaguaaucu ucuuaccuau gac                                              23
              <210>            103
              <211>            24
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature

              H:\fmt\Interwoven\NRPortbl\DCC\FMT\9992541_1.docx-6/05/2016
<removed-date>
                                                                            - 28 -
              <222>            (1)..(24)
              <223>            Exon: H6D(+04-20)
              <400> 103
              ugucucagua aucuucuuac cuau                                             24
              <210>            104
<removed-apn>
              <211>            22
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(22)
              <223>            Exon: H7A(-07+15)
              <400> 104
              ucaaauaggu cuggccuaaa ac                                               22
              <210>            105
              <211>            22
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(22)
              <223>            Exon: H7A(-03+18)
              <400> 105
              ccagucaaau aggucuggcc ua                                               22
              <210>            106
              <211>            23
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(23)
              <223>            Exon: H7A(+41+63)
              <400> 106
              uguuccaguc guuguguggc uga                                              23
              <210>            107
              <211>            28
              <212>            RNA
              <213>            Homo sapiens

              H:\fmt\Interwoven\NRPortbl\DCC\FMT\9992541_1.docx-6/05/2016
<removed-date>
                                                                            - 29 -
              <220>
              <221>            misc_feature
              <222>            (1)..(28)
              <223>            Exon: H7A(+47+74)
              <400> 107
              uguugaaugc auguuccagu cguugugu                                         28
<removed-apn>
              <210>            108
              <211>            30
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(30)
              <223>            Exon: H8A(-10+20)
              <400> 108
              uggauaggug guaucaacau cuguaagcac                                       30
              <210>            109
              <211>            22
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(22)
              <223>            Exon: H8A(-07+15)
              <400> 109
              aggugguauc aacaucugua ag                                               22
              <210>            110
              <211>            22
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(22)
              <223>            Exon: H8A(-04+18)
              <400> 110
              gauagguggu aucaacaucu gu                                               22
              <210>            111
              <211>            25
              <212>            RNA
              <213>            Homo sapiens

              H:\fmt\Interwoven\NRPortbl\DCC\FMT\9992541_1.docx-6/05/2016
<removed-date>
                                                                            - 30 -
              <220>
              <221>            misc_feature
              <222>            (1)..(25)
              <223>            Exon: H8A(+96+120)
              <400> 111
<removed-apn>
              gccuuggcaa cauuuccacu uccug                                            25
              <210>            112
              <211>            25
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(25)
              <223>            Exon: H8D(+13-12)
              <400> 112
              uacacacuuu accuguugag aauag                                            25
              <210>            113
              <211>            31
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(31)
              <223>            Exon: H9A(+154+184)
              <400> 113
              agcagccugu guguaggcau agcucuugaa u                                     31
              <210>            114
              <211>            30
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(30)
              <223>            Exon: H9D(+26-04)
              <400> 114
              agaccuguga aggaaauggg cuccguguag                                       30
              <210>            115
              <211>            25

              H:\fmt\Interwoven\NRPortbl\DCC\FMT\9992541_1.docx-6/05/2016
<removed-date>
                                                                            - 31 -
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(25)
              <223>            Exon: H10A(-09+16)
<removed-apn>
              <400> 115
              caggagcuuc caaaugcugc acaau                                            25
              <210>            116
              <211>            20
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(20)
              <223>            Exon: H10A(+08+27)
              <400> 116
              ugacuugucu ucaggagcuu                                                  20
              <210>            117
              <211>            22
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(22)
              <223>            Exon: H10A (+21 +42)
              <400> 117
              caaugaacug ccaaaugacu ug                                               22
              <210>            118
              <211>            25
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(25)
              <223>            Exon: H10A(+27+51)
              <400> 118
              acucuccauc aaugaacugc caaau                                            25

              H:\fmt\Interwoven\NRPortbl\DCC\FMT\9992541_1.docx-6/05/2016
<removed-date>
                                                                            - 32 -
              <210>            119
              <211>            25
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
<removed-apn>
              <222>            (1)..(25)
              <223>            Exon: H10A(+55+79)
              <400> 119
              cuguuugaua acgguccagg uuuac                                            25
              <210>            120
              <211>            24
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(24)
              <223>            Exon: H10A(+80+103)
              <400> 120
              gccacgauaa uacuucuucu aaag                                             24
              <210>            121
              <211>            25
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(25)
              <223>            Exon: H10D(+16-09)
              <400> 121
              uuaguuuacc ucaugaguau gaaac                                            25
              <210>            122
              <211>            20
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(20)
              <223>            Exon: H10A(+130+149)
              <400> 122
              uuagaaaucu cuccuugugc                                                  20

              H:\fmt\Interwoven\NRPortbl\DCC\FMT\9992541_1.docx-6/05/2016
<removed-date>
                                                                            - 33 -
              <210>            123
              <211>            20
              <212>            RNA
              <213>            Homo sapiens
<removed-apn>
              <220>
              <221>            misc_feature
              <222>            (1)..(20)
              <223>            Exon: H11A(-07+13)
              <400> 123
              ccaucaugua ccccugacaa                                                  20
              <210>            124
              <211>            24
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(24)
              <223>            Exon: H11A+(+134+157)
              <400> 124
              cccugaggca uucccaucuu gaau                                             24
              <210>            125
              <211>            26
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(26)
              <223>            Exon: H11A(+20+45)
              <400> 125
              auuaccaacc cggcccugau gggcug                                           26
              <210>            126
              <211>            30
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(30)
              <223>            Exon: H11A(+46+75)

              H:\fmt\Interwoven\NRPortbl\DCC\FMT\9992541_1.docx-6/05/2016
<removed-date>
                                                                            - 34 -
              <400> 126
              uccaaucagc uuacuuccca auuguagaau                                       30
              <210>            127
              <211>            26
              <212>            RNA
              <213>            Homo sapiens
<removed-apn>
              <220>
              <221>            misc_feature
              <222>            (1)..(26)
              <223>            Exon: H11A(+50+75)
              <400> 127
              uccaaucagc uuacuuccca auugua                                           26
              <210>            128
              <211>            26
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(26)
              <223>            Exon: H11A(+80+105)
              <400> 128
              aguuucuuca ucuucugaua auuuuc                                           26
              <210>            129
              <211>            30
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(30)
              <223>            Exon: H11A(+106+135)
              <400> 129
              auuuaggaga uucaucugcu cuuguacuuc                                       30
              <210>            130
              <211>            26
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(26)

              H:\fmt\Interwoven\NRPortbl\DCC\FMT\9992541_1.docx-6/05/2016
<removed-date>
                                                                            - 35 -
              <223>            Exon: H11A(+110+135)
              <400> 130
              auuuaggaga uucaucugcu cuugua                                           26
              <210>            131
              <211>            30
<removed-apn>
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(30)
              <223>            Exon: H11A(+110+139)
              <400> 131
              uugaauuuag gagauucauc ugcucuugua                                       30
              <210>            132
              <211>            22
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(22)
              <223>            Exon: H12D(+06-16)
              <400> 132
              cauaagauac accuaccuua ug                                               22
              <210>            133
              <211>            28
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(28)
              <223>            Exon: H12A(+60+87)
              <400> 133
              uuccuuguuc uuucuucugu uuuuguua                                         28
              <210>            134
              <211>            28
              <212>            RNA
              <213>            Homo sapiens
              <220>

              H:\fmt\Interwoven\NRPortbl\DCC\FMT\9992541_1.docx-6/05/2016
<removed-date>
                                                                            - 36 -
              <221>            misc_feature
              <222>            (1)..(28)
              <223>            Exon: H12A(+90+117)
              <400> 134
              agaucagguc caagaggcuc uuccucca                                         28
<removed-apn>
              <210>            135
              <211>            28
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(28)
              <223>            Exon: H12A(+120+147)
              <400> 135
              uguuguugua cuuggcguuu uaggucuu                                         28
              <210>            136
              <211>            24
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(24)
              <223>            Exon: H13A(-12+12)
              <400> 136
              uucuugaagc accugaaaga uaaa                                             24
              <210>            137
              <211>            29
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(29)
              <223>            Exon: H14A(+45 +73)
              <400> 137
              gaaggauguc uuguaaaaga acccagcgg                                        29
              <210>            138
              <211>            26
              <212>            RNA
              <213>            Homo sapiens

              H:\fmt\Interwoven\NRPortbl\DCC\FMT\9992541_1.docx-6/05/2016
<removed-date>
                                                                            - 37 -
              <220>
              <221>            misc_feature
              <222>            (1)..(26)
              <223>            Exon: H16A(-07+19)
              <400> 138
              cuagauccgc uuuuaaaacc uguuaa                                           26
<removed-apn>
              <210>            139
              <211>            23
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(23)
              <223>            Exon: H16A(+09+31)
              <400> 139
              gcuuuuucuu uucuagaucc gcu                                              23
              <210>            140
              <211>            25
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(25)
              <223>            Exon: H16D(+18-07)
              <400> 140
              cacuaaccug ugcuguacuc uuuuc                                            25
              <210>            141
              <211>            31
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(31)
              <223>            Exon: H17A(+48+78)
              <400> 141
              uguggucacc guaguuacug uuuccauuca a                                     31
              <210>            142
              <211>            31
              <212>            RNA

              H:\fmt\Interwoven\NRPortbl\DCC\FMT\9992541_1.docx-6/05/2016
<removed-date>
                                                                            - 38 -
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(31)
              <223>            Exon: H17A(+55+85)
<removed-apn>
              <400> 142
              guucccuugu ggucaccgua guuacuguuu c                                     31
              <210>            143
              <211>            20
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(20)
              <223>            Exon: H18A(-09+11)
              <400> 143
              caacauccuu ccuaagacug                                                  20
              <210>            144
              <211>            20
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(20)
              <223>            Exon: H18A(+24+43)
              <400> 144
              gcgaguaauc cagcugugaa                                                  20
              <210>            145
              <211>            30
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(30)
              <223>            Exon: H18A(+41 +70)
              <400> 145
              uucaggacuc ugcaacagag cuucugagcg                                       30
              <210>            146

              H:\fmt\Interwoven\NRPortbl\DCC\FMT\9992541_1.docx-6/05/2016
<removed-date>
                                                                            - 39 -
              <211>            26
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(26)
<removed-apn>
              <223>            Exon: H18A(+83+108)
              <400> 146
              uugucuguga aguugccuuc cuuccg                                           26
              <210>            147
              <211>            20
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(20)
              <223>            Exon: H18D(+04-16)
              <400> 147
              uuaaugcaua accuacauug                                                  20
              <210>            148
              <211>            30
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(30)
              <223>            Exon: H19A(+19+48)
              <400> 148
              ggcaucuugc aguuuucuga acuucucagc                                       30
              <210>            149
              <211>            28
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(28)
              <223>            Exon: H19A(+27+54)
              <400> 149
              ucugcuggca ucuugcaguu uucugaac                                         28

              H:\fmt\Interwoven\NRPortbl\DCC\FMT\9992541_1.docx-6/05/2016
<removed-date>
                                                                            - 40 -
              <210>            150
              <211>            20
              <212>            RNA
              <213>            Homo sapiens
              <220>
<removed-apn>
              <221>            misc_feature
              <222>            (1)..(20)
              <223>            Exon: H19D(+3-17)
              <400> 150
              ucaacucgug uaauuaccgu                                                  20
              <210>            151
              <211>            25
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(25)
              <223>            Exon: H20A(+23+47)
              <400> 151
              guucaguugu ucugaggcuu guuug                                            25
              <210>            152
              <211>            25
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(25)
              <223>            Exon: H20A(+140+164)
              <400> 152
              aguaguuguc aucugcucca auugu                                            25
              <210>            153
              <211>            30
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(30)
              <223>            Exon: H23(+69+98)-SNP
              <400>            153

              H:\fmt\Interwoven\NRPortbl\DCC\FMT\9992541_1.docx-6/05/2016
<removed-date>
                                                                            - 41 -
              cggcuaauuu cagagggcgc uuucuuugac                                       30
              <210>            154
              <211>            24
              <212>            RNA
              <213>            Homo sapiens
<removed-apn>
              <220>
              <221>            misc_feature
              <222>            (1)..(24)
              <223>            Exon: H25A(+10+33)
              <400> 154
              ugggcugaau ugucugaaua ucac                                             24
              <210>            155
              <211>            20
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(20)
              <223>            Exon: H25D(+06-14)
              <400> 155
              gagauugucu auaccuguug                                                  20
              <210>            156
              <211>            29
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(29)
              <223>            Exon: H25A(+10+38)
              <400> 156
              agacugggcu gaauugucug aauaucacu                                        29
              <210>            157
              <211>            26
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(26)
              <223>            Exon: H25A(+95+119)-DupA

              H:\fmt\Interwoven\NRPortbl\DCC\FMT\9992541_1.docx-6/05/2016
<removed-date>
                                                                            - 42 -
              <400> 157
              uugaguucug uucucaaguc ucgaag                                           26
              <210>            158
              <211>            27
              <212>            RNA
<removed-apn>
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(27)
              <223>            Exon: H25D(+13-14)
              <400> 158
              gagauugucu auaccuguug gcacaug                                          27
              <210>            159
              <211>            25
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(25)
              <223>            Exon: H26A(-16+09)
              <400> 159
              ggcauagacc uuccacaaaa caaac                                            25
              <210>            160
              <211>            30
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(30)
              <223>            Exon: H26A(-7+23)
              <400> 160
              aaggccuccu uucuggcaua gaccuuccac                                       30
              <210>            161
              <211>            30
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature

              H:\fmt\Interwoven\NRPortbl\DCC\FMT\9992541_1.docx-6/05/2016
<removed-date>
                                                                            - 43 -
              <222>            (1)..(30)
              <223>            Exon: H26A(-03+27)
              <400> 161
              cuucaaggcc uccuuucugg cauagaccuu                                       30
              <210>            162
<removed-apn>
              <211>            30
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(30)
              <223>            Exon: H26A(+5+35)
              <400> 162
              aaccucccuu caaggccucc uuucuggcau                                       30
              <210>            163
              <211>            25
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(25)
              <223>            Exon: H26D(+06-19)
              <400> 163
              uuucuuuuuu uuuuuuuacc uucau                                            25
              <210>            164
              <211>            25
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(25)
              <223>            Exon: H26D(+21-04)
              <400> 164
              uuaccuucau cucuucaacu gcuuu                                            25
              <210>            165
              <211>            20
              <212>            RNA
              <213>            Homo sapiens

              H:\fmt\Interwoven\NRPortbl\DCC\FMT\9992541_1.docx-6/05/2016
<removed-date>
                                                                            - 44 -
              <220>
              <221>            misc_feature
              <222>            (1)..(20)
              <223>            Exon: H26D(+10-10)
              <400> 165
              uuuuuuuuac cuucaucucu                                                  20
<removed-apn>
              <210>            166
              <211>            30
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(30)
              <223>            Exon: H31D(+12-18)
              <400> 166
              uucugaaauu ucauauaccu gugcaacauc                                       30
              <210>            167
              <211>            30
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(30)
              <223>            Exon: H31D(+08-22)
              <400> 167
              uaguuucuga aauaacauau accugugcaa                                       30
              <210>            168
              <211>            30
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(30)
              <223>            Exon: H31D(+06-24)
              <400> 168
              cuuaguuucu gaaauaacau auaccugugc                                       30
              <210>            169
              <211>            24
              <212>            RNA
              <213>            Homo sapiens

              H:\fmt\Interwoven\NRPortbl\DCC\FMT\9992541_1.docx-6/05/2016
<removed-date>
                                                                            - 45 -
              <220>
              <221>            misc_feature
              <222>            (1)..(24)
              <223>            Exon: H31D(+02-22)
              <400> 169
<removed-apn>
              uaguuucuga aauaacauau accu                                             24
              <210>            170
              <211>            26
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(26)
              <223>            Exon: H31D(+01-25)
              <400> 170
              ccuuaguuuc ugaaauaaca uauacc                                           26
              <210>            171
              <211>            30
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(30)
              <223>            Exon: H32A(+49+78)
              <400> 171
              acuuucuugu agacgcugcu caaaauuggc                                       30
              <210>            172
              <211>            24
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(24)
              <223>            Exon: H34A(+36+59)
              <400> 172
              uuucgcaucu uacgggacaa uuuc                                             24
              <210>            173
              <211>            30

              H:\fmt\Interwoven\NRPortbl\DCC\FMT\9992541_1.docx-6/05/2016
<removed-date>
                                                                            - 46 -
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(30)
              <223>            Exon: H34A(+41+70)
<removed-apn>
              <400> 173
              cauucauuuc cuuucgcauc uuacgggaca                                       30
              <210>            174
              <211>            30
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(30)
              <223>            Exon: H34A(+43+72)
              <400> 174
              gacauucauu uccuuucgca ucuuacggga                                       30
              <210>            175
              <211>            30
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(30)
              <223>            Exon: H34A(+51+83)
              <400> 175
              ucugucaaga cauucauuuc cuuucgcauc                                       30
              <210>            176
              <211>            30
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(30)
              <223>            Exon: H34A(+91+120)
              <400> 176
              ugaucucuuu gucaauucca uaucuguagc                                       30

              H:\fmt\Interwoven\NRPortbl\DCC\FMT\9992541_1.docx-6/05/2016
<removed-date>
                                                                            - 47 -
              <210>            177
              <211>            30
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
<removed-apn>
              <222>            (1)..(30)
              <223>            Exon: H34A(+92+121)
              <400> 177
              cugaucucuu ugucaauucc auaucugugg                                       30
              <210>            178
              <211>            26
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(26)
              <223>            Exon: H34A(+95+120)
              <400> 178
              ugaucucuuu gucaauucca uaucug                                           26
              <210>            179
              <211>            30
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(30)
              <223>            Exon: H34A(+95+124)
              <400> 179
              cugcugaucu cuuugucaau uccauaucug                                       30
              <210>            180
              <211>            30
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(30)
              <223>            Exon: H35A(+14+43)
              <400> 180
              ucuucaggug caccuucugu uucucaaucu                                       30

              H:\fmt\Interwoven\NRPortbl\DCC\FMT\9992541_1.docx-6/05/2016
<removed-date>
                                                                            - 48 -
              <210>            181
              <211>            30
              <212>            RNA
              <213>            Homo sapiens
<removed-apn>
              <220>
              <221>            misc_feature
              <222>            (1)..(30)
              <223>            Exon: H35A(+24+53)
              <400> 181
              ucugugauac ucuucaggug caccuucugu                                       30
              <210>            182
              <211>            20
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(20)
              <223>            Exon: H36A(-01+19)
              <400> 182
              ccauguguuu cugguauucc                                                  20
              <210>            183
              <211>            30
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(30)
              <223>            Exon: H36A(+10+39)
              <400> 183
              cacauucugg ucaaaaguuu ccauguguuu                                       30
              <210>            184
              <211>            25
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(25)
              <223>            Exon: H36A(+27+51)

              H:\fmt\Interwoven\NRPortbl\DCC\FMT\9992541_1.docx-6/05/2016
<removed-date>
                                                                            - 49 -
              <400> 184
              ugugaugugg uccacauucu gguca                                            25
              <210>            185
              <211>            30
              <212>            RNA
              <213>            Homo sapiens
<removed-apn>
              <220>
              <221>            misc_feature
              <222>            (1)..(30)
              <223>            Exon: H36A(+27+56)
              <400> 185
              cacuuuguga ugugguccac auucugguca                                       30
              <210>            186
              <211>            30
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(30)
              <223>            Exon: H36A(+32+61)
              <400> 186
              ugauccacuu ugugaugugg uccacauucu                                       30
              <210>            187
              <211>            20
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(20)
              <223>            Exon: H36A(+59+78)
              <400> 187
              aaguguguca gccugaauga                                                  20
              <210>            188
              <211>            30
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(30)

              H:\fmt\Interwoven\NRPortbl\DCC\FMT\9992541_1.docx-6/05/2016
<removed-date>
                                                                            - 50 -
              <223>            Exon: H36A(+65+94)
              <400> 188
              ucucugauuc auccaaaagu gugucagccu                                       30
              <210>            189
              <211>            30
<removed-apn>
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(30)
              <223>            Exon: H36A(+80+109)
              <400> 189
              gcugggguuu cuuuuucucu gauucaucca                                       30
              <210>            190
              <211>            25
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(25)
              <223>            Exon: H36D(+15-10)
              <400> 190
              uauuugcuac cuuaagcacg ucuuc                                            25
              <210>            191
              <211>            21
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(21)
              <223>            Exon: H38A(-21-01)
              <400> 191
              cuaaaaaaaa agauagugcu a                                                21
              <210>            192
              <211>            26
              <212>            RNA
              <213>            Homo sapiens
              <220>

              H:\fmt\Interwoven\NRPortbl\DCC\FMT\9992541_1.docx-6/05/2016
<removed-date>
                                                                            - 51 -
              <221>            misc_feature
              <222>            (1)..(26)
              <223>            Exon: H38A(-12+14)
              <400> 192
              aaaggaaugg aggccuaaaa aaaaag                                           26
<removed-apn>
              <210>            193
              <211>            25
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(25)
              <223>            Exon: H38D(+14-11)
              <400> 193
              aaccaauuua ccauaucuuu auuga                                            25
              <210>            194
              <211>            29
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(29)
              <223>            Exon: H39A(-07+23)
              <400> 194
              acaguaccau cauugucuuc auucugauc                                        29
              <210>            195
              <211>            29
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(29)
              <223>            Exon: H39A(-07+23)
              <400> 195
              acaguacccu cauugucuuc auucugauc                                        29
              <210>            196
              <211>            30
              <212>            RNA
              <213>            Homo sapiens

              H:\fmt\Interwoven\NRPortbl\DCC\FMT\9992541_1.docx-6/05/2016
<removed-date>
                                                                            - 52 -
              <220>
              <221>            misc_feature
              <222>            (1)..(30)
              <223>            Exon: H39A(+58+87)
              <400> 196
              cucucgcuuu cucucaucug ugauucuuug                                       30
<removed-apn>
              <210>            197
              <211>            30
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(30)
              <223>            Exon: H39A(+60+89)
              <400> 197
              uccucucgcu uucucucauc ugugauucuu                                       30
              <210>            198
              <211>            25
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(25)
              <223>            Exon: H39A(+102+126)
              <400> 198
              uauguuuugu cuguaacagc ugcug                                            25
              <210>            199
              <211>            20
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(20)
              <223>            Exon: H41A(-15+5)
              <400> 199
              auuuccuauu gagcaaaacc                                                  20
              <210>            200
              <211>            25
              <212>            RNA

              H:\fmt\Interwoven\NRPortbl\DCC\FMT\9992541_1.docx-6/05/2016
<removed-date>
                                                                            - 53 -
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(25)
              <223>            Exon: H41A(+66+90)
<removed-apn>
              <400> 200
              cauugcggcc ccauccucag acaag                                            25
              <210>            201
              <211>            29
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(29)
              <223>            Exon: H41A(+92+120)
              <400> 201
              gcugagcugg aucugaguug gcuccacug                                        29
              <210>            202
              <211>            29
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(29)
              <223>            Exon: H41A(+143+171)
              <400> 202
              guugagucuu cgaaacugag caaauuugc                                        29
              <210>            203
              <211>            20
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(20)
              <223>            Exon: H41D(+5-15)
              <400> 203
              ccaguaacaa cucacaauuu                                                  20
              <210>            204

              H:\fmt\Interwoven\NRPortbl\DCC\FMT\9992541_1.docx-6/05/2016
<removed-date>
                                                                            - 54 -
              <211>            21
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(21)
<removed-apn>
              <223>            Exon: H42D(+18-02)
              <400> 204
              accuucagag acuccucuug c                                                21
              <210>            205
              <211>            28
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(28)
              <223>            Exon: H43A(+83+110)
              <400> 205
              uccuguagcu ucacccuuuc cacaggcg                                         28
              <210>            206
              <211>            29
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(29)
              <223>            Exon: H43A(+101 +130)
              <400> 206
              aaucagcugg gagagagcuu ccuguagcu                                        29
              <210>            207
              <211>            20
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(20)
              <223>            Exon: H43D(+08-12)
              <400> 207
              uguguuaccu acccuugucg                                                  20

              H:\fmt\Interwoven\NRPortbl\DCC\FMT\9992541_1.docx-6/05/2016
<removed-date>
                                                                            - 55 -
              <210>            208
              <211>            27
              <212>            RNA
              <213>            Homo sapiens
              <220>
<removed-apn>
              <221>            misc_feature
              <222>            (1)..(27)
              <223>            Exon: H43A(-09+18)
              <400> 208
              uagacuaucu uuuauauucu guaauau                                          27
              <210>            209
              <211>            29
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(29)
              <223>            Exon: H43A(+89+117)
              <400> 209
              gagagcuucc uguagcuuca cccuuucca                                        29
              <210>            210
              <211>            31
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(31)
              <223>            Exon: H43A(+81+111)
              <400> 210
              uuccuguagc uucacccuuu ccacaggcgu u                                     31
              <210>            211
              <211>            23
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(23)
              <223>            Exon: H43A(+92+114)
              <400>            211

              H:\fmt\Interwoven\NRPortbl\DCC\FMT\9992541_1.docx-6/05/2016
<removed-date>
                                                                            - 56 -
              agcuuccugu agcuucaccc uuu                                              23
              <210>            212
              <211>            23
              <212>            RNA
              <213>            Homo sapiens
<removed-apn>
              <220>
              <221>            misc_feature
              <222>            (1)..(23)
              <223>            Exon: H43A(+95+117)
              <400> 212
              gagagcuucc uguagcuuca ccc                                              23
              <210>            213
              <211>            26
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(26)
              <223>            Exon: H44A(-13+13)
              <400> 213
              ucugucaaau cgccugcagg uaaaag                                           26
              <210>            214
              <211>            30
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(30)
              <223>            Exon: H44A(-06+24)
              <400> 214
              uucucaacag aucugucaaa ucgccugcag                                       30
              <210>            215
              <211>            25
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(25)
              <223>            Exon: H44A(+44+68)

              H:\fmt\Interwoven\NRPortbl\DCC\FMT\9992541_1.docx-6/05/2016
<removed-date>
                                                                            - 57 -
              <400> 215
              gccacugauu aaauaucuuu auauc                                            25
              <210>            216
              <211>            30
              <212>            RNA
<removed-apn>
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(30)
              <223>            Exon: H44A(+46+75)
              <400> 216
              ucuguuagcc acugauuaaa uaucuuuaua                                       30
              <210>            217
              <211>            24
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(24)
              <223>            Exon: H44A(+61+84)
              <400> 217
              uguucagcuu cuguuagcca cuga                                             24
              <210>            218
              <211>            31
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(31)
              <223>            Exon: H44A(+61+91)
              <400> 218
              gagaaacugu ucagcuucug uuagccacug a                                     31
              <210>            219
              <211>            31
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature

              H:\fmt\Interwoven\NRPortbl\DCC\FMT\9992541_1.docx-6/05/2016
<removed-date>
                                                                            - 58 -
              <222>            (1)..(31)
              <223>            Exon: H44A(+68+98)
              <400> 219
              ucuuucugag aaacuguuca gcuucuguua g                                     31
              <210>            220
<removed-apn>
              <211>            26
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(26)
              <223>            Exon: H44A(-09+17)
              <400> 220
              cagaucuguc aaaucgccug caggua                                           26
              <210>            221
              <211>            33
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(33)
              <223>            Exon: H44A(+56+88)
              <400> 221
              aaacuguuca gcuucuguua gccacugauu aaa                                   33
              <210>            222
              <211>            31
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(31)
              <223>            Exon: H44A(+59+89)
              <400> 222
              gaaacuguuc agcuucuguu agccacugau u                                     31
              <210>            223
              <211>            28
              <212>            RNA
              <213>            Homo sapiens

              H:\fmt\Interwoven\NRPortbl\DCC\FMT\9992541_1.docx-6/05/2016
<removed-date>
                                                                            - 59 -
              <220>
              <221>            misc_feature
              <222>            (1)..(28)
              <223>            Exon: H44A(+61+88)
              <400> 223
              aaacuguuca gcuucuguua gccacuga                                         28
<removed-apn>
              <210>            224
              <211>            28
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(28)
              <223>            Exon: H44A(+65+92)
              <400> 224
              ugagaaacug uucagcuucu guuagcca                                         28
              <210>            225
              <211>            32
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(32)
              <223>            Exon: H44A(+64+95)
              <400> 225
              uucugagaaa cuguucagcu ucuguuagcc ac                                    32
              <210>            226
              <211>            26
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(26)
              <223>            Exon: H44A(+70+95)
              <400> 226
              uucugagaaa cuguucagcu ucuguu                                           26
              <210>            227
              <211>            32
              <212>            RNA
              <213>            Homo sapiens

              H:\fmt\Interwoven\NRPortbl\DCC\FMT\9992541_1.docx-6/05/2016
<removed-date>
                                                                            - 60 -
              <220>
              <221>            misc_feature
              <222>            (1)..(32)
              <223>            Exon: H45A(-14+25)
              <400> 227
<removed-apn>
              gcugcccaau gccauccugg aguuccugua ag                                    32
              <210>            228
              <211>            30
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(30)
              <223>            Exon: H45A(-10 +20)
              <400> 228
              ccaaugccau ccuggaguuc cuguaagaua                                       30
              <210>            229
              <211>            39
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(39)
              <223>            Exon: H45A(-09+30)
              <400> 229
              uugccgcugc ccaaugccau ccuggaguuc cuguaagau                             39
              <210>            230
              <211>            27
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(27)
              <223>            Exon: H45A(-08 +19)
              <400> 230
              caaugccauc cuggaguucc uguaaga                                          27
              <210>            231
              <211>            32

              H:\fmt\Interwoven\NRPortbl\DCC\FMT\9992541_1.docx-6/05/2016
<removed-date>
                                                                            - 61 -
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(32)
              <223>            Exon: HM45A(-07+25)
<removed-apn>
              <400> 231
              gcugcccaau gccauccugg aguuccugua ag                                    32
              <210>            232
              <211>            26
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(26)
              <223>            Exon: H45A(+09 +34)
              <400> 232
              caguuugccg cugcccaaug ccaucc                                           26
              <210>            233
              <211>            24
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(24)
              <223>            Exon: H45A(+41 +64)
              <400> 233
              cuuccccagu ugcauucaau guuc                                             24
              <210>            234
              <211>            23
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(23)
              <223>            Exon: H45A(+76 +98)
              <400> 234
              cuggcaucug uuuuugagga uug                                              23

              H:\fmt\Interwoven\NRPortbl\DCC\FMT\9992541_1.docx-6/05/2016
<removed-date>
                                                                            - 62 -
              <210>            235
              <211>            20
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
<removed-apn>
              <222>            (1)..(20)
              <223>            Exon: H45D(+02-18)
              <400> 235
              uuagaucugu cgcccuaccu                                                  20
              <210>            236
              <211>            39
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(39)
              <223>            Exon: H45A(-14+25)
              <400> 236
              gcugcccaau gccauccugg aguuccugua agauaccaa                             39
              <210>            237
              <211>            34
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(34)
              <223>            Exon: H45A(-12+22)
              <400> 237
              gcccaaugcc auccuggagu uccuguaaga uacc                                  34
              <210>            238
              <211>            25
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(25)
              <223>            Exon: H45A(-12+13)
              <400> 238
              cauccuggag uuccuguaag auacc                                            25

              H:\fmt\Interwoven\NRPortbl\DCC\FMT\9992541_1.docx-6/05/2016
<removed-date>
                                                                            - 63 -
              <210>            239
              <211>            31
              <212>            RNA
              <213>            Homo sapiens
<removed-apn>
              <220>
              <221>            misc_feature
              <222>            (1)..(31)
              <223>            Exon: H45A(-09+22)
              <400> 239
              gcccaaugcc auccuggagu uccuguaaga u                                     31
              <210>            240
              <211>            39
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(39)
              <223>            Exon: H45A(-09+30)
              <400> 240
              uugccgcugc ccaaugccau ccuggaguuc cuguaagau                             39
              <210>            241
              <211>            32
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(32)
              <223>            Exon: HM45A(-07+25)
              <400> 241
              gcugcccaau gccauccugg aguuccugua ag                                    32
              <210>            242
              <211>            28
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(28)
              <223>            Exon: H45A(-06+22)

              H:\fmt\Interwoven\NRPortbl\DCC\FMT\9992541_1.docx-6/05/2016
<removed-date>
                                                                            - 64 -
              <400> 242
              gcccaaugcc auccuggagu uccuguaa                                         28
              <210>            243
              <211>            34
              <212>            RNA
              <213>            Homo sapiens
<removed-apn>
              <220>
              <221>            misc_feature
              <222>            (1)..(34)
              <223>            Exon: H45A(-06+28)
              <400> 243
              gccgcugccc aaugccaucc uggaguuccu guaa                                  34
              <210>            244
              <211>            25
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(25)
              <223>            Exon: H45A(-03+22)
              <400> 244
              gcccaaugcc auccuggagu uccug                                            25
              <210>            245
              <211>            31
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(31)
              <223>            Exon: H45A(-03+28)
              <400> 245
              gccgcugccc aaugccaucc uggaguuccu g                                     31
              <210>            246
              <211>            29
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(29)

              H:\fmt\Interwoven\NRPortbl\DCC\FMT\9992541_1.docx-6/05/2016
<removed-date>
                                                                            - 65 -
              <223>            Exon: H45D(+10-19)
              <400> 246
              auuagaucug ucgcccuacc ucuuuuuuc                                        29
              <210>            247
              <211>            27
<removed-apn>
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(27)
              <223>            Exon: H45D(+16-11)
              <400> 247
              ugucgcccua ccucuuuuuu cugucug                                          27
              <210>            248
              <211>            24
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(24)
              <223>            Exon: H46A(-05+19)
              <400> 248
              auucuuuugu ucuucuagcc ugga                                             24
              <210>            249
              <211>            27
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(27)
              <223>            Exon: H46A(+16+42)
              <400> 249
              ucucuuugaa auucugacaa gauauuc                                          27
              <210>            250
              <211>            20
              <212>            RNA
              <213>            Homo sapiens
              <220>

              H:\fmt\Interwoven\NRPortbl\DCC\FMT\9992541_1.docx-6/05/2016
<removed-date>
                                                                            - 66 -
              <221>            misc_feature
              <222>            (1)..(20)
              <223>            Exon: H46A(+27+44)
              <400> 250
              uuaaaucucu uugaaauucu                                                  20
<removed-apn>
              <210>            251
              <211>            26
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(26)
              <223>            Exon: H46A(+35+60)
              <400> 251
              aaaacaaauu cauuuaaauc ucuuug                                           26
              <210>            252
              <211>            22
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(22)
              <223>            Exon: H46A(+56+77)
              <400> 252
              cugcuuccuc caaccauaaa ac                                               22
              <210>            253
              <211>            25
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(25)
              <223>            Exon: H46A(+63+87)
              <400> 253
              gcaauguuau cugcuuccuc caacc                                            25
              <210>            254
              <211>            21
              <212>            RNA
              <213>            Homo sapiens

              H:\fmt\Interwoven\NRPortbl\DCC\FMT\9992541_1.docx-6/05/2016
<removed-date>
                                                                            - 67 -
              <220>
              <221>            misc_feature
              <222>            (1)..(21)
              <223>            Exon: H46A(+83+103)
              <400> 254
              uucaaguggg auacuagcaa u                                                21
<removed-apn>
              <210>            255
              <211>            20
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(20)
              <223>            Exon: H46A(+90+109)
              <400> 255
              uccagguuca agugggauac                                                  20
              <210>            256
              <211>            28
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(28)
              <223>            Exon: H46A(+91+118)
              <400> 256
              cugcucuuuu ccagguucaa gugggaua                                         28
              <210>            257
              <211>            28
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(28)
              <223>            Exon: H46A(+95+122)
              <400> 257
              guugcugcuc uuuuccaggu ucaagugg                                         28
              <210>            258
              <211>            28
              <212>            RNA

              H:\fmt\Interwoven\NRPortbl\DCC\FMT\9992541_1.docx-6/05/2016
<removed-date>
                                                                            - 68 -
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(28)
              <223>            Exon: H46A(+101+128)
<removed-apn>
              <400> 258
              cuuuuaguug cugcucuuuu ccagguuc                                         28
              <210>            259
              <211>            24
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(24)
              <223>            Exon: H46A(+113+136)
              <400> 259
              aagcuuuucu uuuaguugcu gcuc                                             24
              <210>            260
              <211>            20
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(20)
              <223>            Exon: H46A(+115+134)
              <400> 260
              gcuuuucuuu uaguugcugc                                                  20
              <210>            261
              <211>            30
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(30)
              <223>            Exon: H46A(+116+145)
              <400> 261
              gacuugcuca agcuuuucuu uuaguugcug                                       30
              <210>            262

              H:\fmt\Interwoven\NRPortbl\DCC\FMT\9992541_1.docx-6/05/2016
<removed-date>
                                                                            - 69 -
              <211>            20
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(20)
<removed-apn>
              <223>            Exon: H46D(+02-18)
              <400> 262
              uucagaaaau aaaauuaccu                                                  20
              <210>            263
              <211>            30
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(30)
              <223>            Exon: H46A(+95+124)
              <400> 263
              uaguugcugc ucuuuuccag guucaagugg                                       30
              <210>            264
              <211>            31
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(31)
              <223>            Exon: H46A(+107 +137)
              <400> 264
              caagcuuuuc uuuuaguugc ugcucuuuuc c                                     31
              <210>            265
              <211>            26
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(26)
              <223>            Exon: H47A(-07+19)
              <400> 265
              gcaacucuuc caccaguaac ugaaac                                           26

              H:\fmt\Interwoven\NRPortbl\DCC\FMT\9992541_1.docx-6/05/2016
<removed-date>
                                                                            - 70 -
              <210>            266
              <211>            27
              <212>            RNA
              <213>            Homo sapiens
              <220>
<removed-apn>
              <221>            misc_feature
              <222>            (1)..(27)
              <223>            Exon: H47A(+44+70)
              <400> 266
              gcacgggucc uccaguuuca uuuaauu                                          27
              <210>            267
              <211>            25
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(25)
              <223>            Exon: H47A(+68+92)
              <400> 267
              gggcuuaugg gagcacuuac aagca                                            25
              <210>            268
              <211>            31
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(31)
              <223>            Exon: H47A(+73+103)
              <400> 268
              cuugcucuuc ugggcuuaug ggagcacuua c                                     31
              <210>            269
              <211>            28
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(28)
              <223>            Exon: H47A(+76+103)
              <400>            269

              H:\fmt\Interwoven\NRPortbl\DCC\FMT\9992541_1.docx-6/05/2016
<removed-date>
                                                                            - 71 -
              cuugcucuuc ugggcuuaug ggagcacu                                         28
              <210>            270
              <211>            27
              <212>            RNA
              <213>            Homo sapiens
<removed-apn>
              <220>
              <221>            misc_feature
              <222>            (1)..(27)
              <223>            Exon: H47D(+17-10)
              <400> 270
              aaugucuaac cuuuauccac uggagau                                          27
              <210>            271
              <211>            30
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(30)
              <223>            Exon: H48A(-09+21)
              <400> 271
              cucagguaaa gcucuggaaa ccugaaagga                                       30
              <210>            272
              <211>            27
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(27)
              <223>            Exon: H48A(-08+19)
              <400> 272
              cagguaaagc ucuggaaacc ugaaagg                                          27
              <210>            273
              <211>            30
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(30)
              <223>            Exon: H48A(-07+23)

              H:\fmt\Interwoven\NRPortbl\DCC\FMT\9992541_1.docx-6/05/2016
<removed-date>
                                                                            - 72 -
              <400> 273
              uucucaggua aagcucugga aaccugaaag                                       30
              <210>            274
              <211>            30
              <212>            RNA
<removed-apn>
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(30)
              <223>            Exon: H48A(-05+25)
              <400> 274
              guuucucagg uaaagcucug gaaaccugaa                                       30
              <210>            275
              <211>            27
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(27)
              <223>            Exon: H48A(+07+33)
              <400> 275
              uucuccuugu uucucaggua aagcucu                                          27
              <210>            276
              <211>            26
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(26)
              <223>            Exon: H48A(+75+100)
              <400> 276
              uuaacugcuc uucaaggucu ucaagc                                           26
              <210>            277
              <211>            27
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature

              H:\fmt\Interwoven\NRPortbl\DCC\FMT\9992541_1.docx-6/05/2016
<removed-date>
                                                                            - 73 -
              <222>            (1)..(27)
              <223>            Exon: H48A(+96+122)
              <400> 277
              gauaaccaca gcagcagaug auuuaac                                          27
              <210>            278
<removed-apn>
              <211>            27
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(27)
              <223>            Exon: H48D(+17-10)
              <400> 278
              aguucccuac cugaacguca aaugguc                                          27
              <210>            279
              <211>            25
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(25)
              <223>            Exon: H48D(+16-09)
              <400> 279
              guucccuacc ugaacgucaa auggu                                            25
              <210>            280
              <211>            26
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(26)
              <223>            Exon: H49A(-07+19)
              <400> 280
              gaacugcuau uucaguuucc ugggga                                           26
              <210>            281
              <211>            26
              <212>            RNA
              <213>            Homo sapiens

              H:\fmt\Interwoven\NRPortbl\DCC\FMT\9992541_1.docx-6/05/2016
<removed-date>
                                                                            - 74 -
              <220>
              <221>            misc_feature
              <222>            (1)..(26)
              <223>            Exon: H49A(+22+47)
              <400> 281
              aucucuucca cauccgguug uuuagc                                           26
<removed-apn>
              <210>            282
              <211>            26
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(26)
              <223>            Exon: H49D(+18-08)
              <400> 282
              uucauuaccu ucacuggcug aguggc                                           26
              <210>            283
              <211>            27
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(27)
              <223>            Exon: H50A(-07+20)
              <400> 283
              cucagaucuu cuaacuuccu cuuuaac                                          27
              <210>            284
              <211>            29
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(29)
              <223>            Exon: H50A(-02+27)
              <400> 284
              cucagagcuc agaucuucua acuuccucu                                        29
              <210>            285
              <211>            27
              <212>            RNA
              <213>            Homo sapiens

              H:\fmt\Interwoven\NRPortbl\DCC\FMT\9992541_1.docx-6/05/2016
<removed-date>
                                                                            - 75 -
              <220>
              <221>            misc_feature
              <222>            (1)..(27)
              <223>            Exon: H50A(+10+36)
              <400> 285
<removed-apn>
              cgccuuccac ucagagcuca gaucuuc                                          27
              <210>            286
              <211>            27
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(27)
              <223>            Exon: H50A(+35+61)
              <400> 286
              ucagcucuug aaguaaacgg uuuaccg                                          27
              <210>            287
              <211>            27
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(27)
              <223>            Exon: H50A(+42+68)
              <400> 287
              uuugcccuca gcucuugaag uaaacgg                                          27
              <210>            288
              <211>            26
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(26)
              <223>            Exon: H50A(+63+88)
              <400> 288
              caggagcuag gucaggcugc uuugcc                                           26
              <210>            289
              <211>            25

              H:\fmt\Interwoven\NRPortbl\DCC\FMT\9992541_1.docx-6/05/2016
<removed-date>
                                                                            - 76 -
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(25)
              <223>            Exon: H50A(+81+105)
<removed-apn>
              <400> 289
              uccaauagug gucaguccag gagcu                                            25
              <210>            290
              <211>            27
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(27)
              <223>            Exon: H50D(-01-27)
              <400> 290
              aaagagaaug ggauccagua uacuuac                                          27
              <210>            291
              <211>            27
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(27)
              <223>            Exon: H50D(-15-41)
              <400> 291
              aaauagcuag agccaaagag aauggga                                          27
              <210>            292
              <211>            33
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(33)
              <223>            Exon: H50A(+42+74)
              <400> 292
              ggcugcuuug cccucagcuc uugaaguaaa cgg                                   33

              H:\fmt\Interwoven\NRPortbl\DCC\FMT\9992541_1.docx-6/05/2016
<removed-date>
                                                                            - 77 -
              <210>            293
              <211>            30
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
<removed-apn>
              <222>            (1)..(30)
              <223>            Exon: H50A(+46+75)
              <400> 293
              aggcugcuuu gcccucagcu cuugaaguaa                                       30
              <210>            294
              <211>            31
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(31)
              <223>            Exon: H50A(+48+78)
              <400> 294
              gucaggcugc uuugcccuca gcucuugaag u                                     31
              <210>            295
              <211>            30
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(30)
              <223>            Exon: H50A(+51+80)
              <400> 295
              aggucaggcu gcuuugcccu cagcucuuga                                       30
              <210>            296
              <211>            27
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(27)
              <223>            Exon: Hint49(-72-46)
              <400> 296
              aagauaauuc augaacaucu uaaucca                                          27

              H:\fmt\Interwoven\NRPortbl\DCC\FMT\9992541_1.docx-6/05/2016
<removed-date>
                                                                            - 78 -
              <210>            297
              <211>            20
              <212>            RNA
              <213>            Homo sapiens
<removed-apn>
              <220>
              <221>            misc_feature
              <222>            (1)..(20)
              <223>            Exon: H51A(-29-10)
              <400> 297
              uuuggguuuu ugcaaaaagg                                                  20
              <210>            298
              <211>            22
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(22)
              <223>            Exon: H51A(-22-01)
              <400> 298
              cuaaaauauu uuggguuuuu gc                                               22
              <210>            299
              <211>            24
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(24)
              <223>            Exon: H51A(-14+10)
              <400> 299
              ugaguaggag cuaaaauauu uugg                                             24
              <210>            300
              <211>            27
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(27)
              <223>            Exon: H51(+26+52)

              H:\fmt\Interwoven\NRPortbl\DCC\FMT\9992541_1.docx-6/05/2016
<removed-date>
                                                                            - 79 -
              <400> 300
              guuuccuuag uaaccacagg uuguguc                                          27
              <210>            301
              <211>            28
              <212>            RNA
              <213>            Homo sapiens
<removed-apn>
              <220>
              <221>            misc_feature
              <222>            (1)..(28)
              <223>            Exon: H51A(+40+67)
              <400> 301
              aguuuggaga uggcaguuuc cuuaguaa                                         28
              <210>            302
              <211>            12
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(12)
              <223>            Exon: H51A(+66+77)
              <400> 302
              uggcauuucu ag                                                          12
              <210>            303
              <211>            15
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(15)
              <223>            Exon: H51A(+66+80)
              <400> 303
              agauggcauu ucuag                                                       15
              <210>            304
              <211>            18
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(18)

              H:\fmt\Interwoven\NRPortbl\DCC\FMT\9992541_1.docx-6/05/2016
<removed-date>
                                                                            - 80 -
              <223>            Exon: H51A(+66+83)
              <400> 304
              ggaagauggc auuucuag                                                    18
              <210>            305
              <211>            18
<removed-apn>
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(18)
              <223>            Exon: H51A(+78+95)
              <400> 305
              cuccaacauc aaggaaga                                                    18
              <210>            306
              <211>            15
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(15)
              <223>            Exon: H51A(+81+95)
              <400> 306
              cuccaacauc aagga                                                       15
              <210>            307
              <211>            12
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(12)
              <223>            Exon: H51A(+84+95)
              <400> 307
              cuccaacauc aa                                                          12
              <210>            308
              <211>            27
              <212>            RNA
              <213>            Homo sapiens
              <220>

              H:\fmt\Interwoven\NRPortbl\DCC\FMT\9992541_1.docx-6/05/2016
<removed-date>
                                                                            - 81 -
              <221>            misc_feature
              <222>            (1)..(27)
              <223>            Exon: H51A(+90+116)
              <400> 308
              gaaaucugcc agagcaggua ccuccaa                                          27
<removed-apn>
              <210>            309
              <211>            27
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(27)
              <223>            Exon: H51A(+53+79)
              <400> 309
              gauggcauuu cuaguuugga gauggca                                          27
              <210>            310
              <211>            29
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(29)
              <223>            Exon: H51A(+57+85)
              <400> 310
              aaggaagaug gcauuucuag uuuggagau                                        29
              <210>            311
              <211>            29
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(29)
              <223>            Exon: H51A(+76+104)
              <400> 311
              agcagguacc uccaacauca aggaagaug                                        29
              <210>            312
              <211>            25
              <212>            RNA
              <213>            Homo sapiens

              H:\fmt\Interwoven\NRPortbl\DCC\FMT\9992541_1.docx-6/05/2016
<removed-date>
                                                                            - 82 -
              <220>
              <221>            misc_feature
              <222>            (1)..(25)
              <223>            Exon: H52A(-12+13)
              <400> 312
              ccugcauugu ugccuguaag aacaa                                            25
<removed-apn>
              <210>            313
              <211>            20
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(20)
              <223>            Exon: H52A(-10+10)
              <400> 313
              gcauuguugc cuguaagaac                                                  20
              <210>            314
              <211>            27
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(27)
              <223>            Exon: H52A(+07+33)
              <400> 314
              gggacgccuc uguuccaaau ccugcau                                          27
              <210>            315
              <211>            30
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(30)
              <223>            Exon: H52A(+17+46)
              <400> 315
              guucuuccaa cuggggacgc cucuguucca                                       30
              <210>            316
              <211>            21
              <212>            RNA

              H:\fmt\Interwoven\NRPortbl\DCC\FMT\9992541_1.docx-6/05/2016
<removed-date>
                                                                            - 83 -
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(21)
              <223>            Exon: H52A(+17+37)
<removed-apn>
              <400> 316
              acuggggacg ccucuguucc a                                                21
              <210>            317
              <211>            28
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(28)
              <223>            Exon: H52A(+67+94)
              <400> 317
              ccucuugauu gcuggucuug uuuuucaa                                         28
              <210>            318
              <211>            27
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(27)
              <223>            Exon: Hint51(-40-14)
              <400> 318
              uaccccuuag uaucaggguu cuucagc                                          27
              <210>            319
              <211>            33
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(33)
              <223>            Exon: H52A(+09+41)
              <400> 319
              uccaacuggg gacgccucug uuccaaaucc ugc                                   33
              <210>            320

              H:\fmt\Interwoven\NRPortbl\DCC\FMT\9992541_1.docx-6/05/2016
<removed-date>
                                                                            - 84 -
              <211>            30
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(30)
<removed-apn>
              <223>            Exon: H52A(+15+44)
              <400> 320
              ucuuccaacu ggggacgccu cuguuccaaa                                       30
              <210>            321
              <211>            24
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(24)
              <223>            Exon: H53A(-49-26)
              <400> 321
              auaguaguaa augcuagucu ggag                                             24
              <210>            322
              <211>            26
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(26)
              <223>            Exon: H53A(-38-13)
              <400> 322
              gaaaaauaaa uauauaguag uaaaug                                           26
              <210>            323
              <211>            27
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(27)
              <223>            Exon: H53A(-32-06)
              <400> 323
              auaaaaggaa aaauaaauau auaguag                                          27

              H:\fmt\Interwoven\NRPortbl\DCC\FMT\9992541_1.docx-6/05/2016
<removed-date>
                                                                            - 85 -
              <210>            324
              <211>            30
              <212>            RNA
              <213>            Homo sapiens
              <220>
<removed-apn>
              <221>            misc_feature
              <222>            (1)..(30)
              <223>            Exon: H53A(-15+15)
              <400> 324
              ucugaauucu uucaacuaga auaaaaggaa                                       30
              <210>            325
              <211>            27
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(27)
              <223>            Exon: H53A(+39+65)
              <400> 325
              caacuguugc cuccgguucu gaaggug                                          27
              <210>            326
              <211>            29
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(29)
              <223>            Exon: H53A(+39+67)
              <400> 326
              uucaacuguu gccuccgguu cugaaggug                                        29
              <210>            327
              <211>            31
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(31)
              <223>            Exon: H39A(+39+69)SNP
              <400>            327

              H:\fmt\Interwoven\NRPortbl\DCC\FMT\9992541_1.docx-6/05/2016
<removed-date>
                                                                            - 86 -
              cguucaacug uugccuccgg uucugaaggu g                                     31
              <210>            328
              <211>            31
              <212>            RNA
              <213>            Homo sapiens
<removed-apn>
              <220>
              <221>            misc_feature
              <222>            (1)..(31)
              <223>            Exon: H53A(+40+70)
              <400> 328
              ucauucaacu guugccuccg guucugaagg u                                     31
              <210>            329
              <211>            29
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(29)
              <223>            Exon: H53A(+41+69)
              <400> 329
              cauucaacug uugccuccgg uucugaagg                                        29
              <210>            330
              <211>            27
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(27)
              <223>            Exon: H53A(+43+69)
              <400> 330
              cauucaacug uugccuccgg uucugaa                                          27
              <210>            331
              <211>            30
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(30)
              <223>            Exon: H53A(+69+98)

              H:\fmt\Interwoven\NRPortbl\DCC\FMT\9992541_1.docx-6/05/2016
<removed-date>
                                                                            - 87 -
              <400> 331
              cagccauugu guugaauccu uuaacauuuc                                       30
              <210>            332
              <211>            25
              <212>            RNA
<removed-apn>
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(25)
              <223>            Exon: Hint52(-47-23)
              <400> 332
              uauauaguag uaaaugcuag ucugg                                            25
              <210>            333
              <211>            33
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(33)
              <223>            Exon: H53A(+27+59)
              <400> 333
              uugccuccgg uucugaaggu guucuuguac uuc                                   33
              <210>            334
              <211>            30
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(30)
              <223>            Exon: H53A(+30+59)
              <400> 334
              uugccuccgg uucugaaggu guucuuguac                                       30
              <210>            335
              <211>            35
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature

              H:\fmt\Interwoven\NRPortbl\DCC\FMT\9992541_1.docx-6/05/2016
<removed-date>
                                                                            - 88 -
              <222>            (1)..(35)
              <223>            Exon: H53A(+30+64)
              <400> 335
              aacuguugcc uccgguucug aagguguucu uguac                                 35
              <210>            336
<removed-apn>
              <211>            40
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(40)
              <223>            Exon: H53A(+30+69)
              <400> 336
              cauucaacug uugccuccgg uucugaaggu guucuuguac                            40
              <210>            337
              <211>            31
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(31)
              <223>            Exon: H53A(+33+63)
              <400> 337
              acuguugccu ccgguucuga agguguucuu g                                     31
              <210>            338
              <211>            35
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(35)
              <223>            Exon: H53A(+33+67)
              <400> 338
              uucaacuguu gccuccgguu cugaaggugu ucuug                                 35
              <210>            339
              <211>            33
              <212>            RNA
              <213>            Homo sapiens

              H:\fmt\Interwoven\NRPortbl\DCC\FMT\9992541_1.docx-6/05/2016
<removed-date>
                                                                            - 89 -
              <220>
              <221>            misc_feature
              <222>            (1)..(33)
              <223>            Exon: H53A(+35+67)
              <400> 339
              uucaacuguu gccuccgguu cugaaggugu ucu                                   33
<removed-apn>
              <210>            340
              <211>            31
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(31)
              <223>            Exon: H53A(+37+67)
              <400> 340
              uucaacuguu gccuccgguu cugaaggugu u                                     31
              <210>            341
              <211>            35
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(35)
              <223>            Exon: H53A(+36+70)
              <400> 341
              ucauucaacu guugccuccg guucugaagg uguuc                                 35
              <210>            342
              <211>            33
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(33)
              <223>            Exon: H53A(+39+71)
              <400> 342
              uucauucaac uguugccucc gguucugaag gug                                   33
              <210>            343
              <211>            30
              <212>            RNA
              <213>            Homo sapiens

              H:\fmt\Interwoven\NRPortbl\DCC\FMT\9992541_1.docx-6/05/2016
<removed-date>
                                                                            - 90 -
              <220>
              <221>            misc_feature
              <222>            (1)..(30)
              <223>            Exon: H53A(+42+71)
              <400> 343
<removed-apn>
              uucauucaac uguugccucc gguucugaag                                       30
              <210>            344
              <211>            22
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(22)
              <223>            Exon: H54A(+13+34)
              <400> 344
              uugucugcca cuggcggagg uc                                               22
              <210>            345
              <211>            30
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(30)
              <223>            Exon: H54A(+60+90)
              <400> 345
              aucugcagaa uaaucccgga gaaguuucag                                       30
              <210>            346
              <211>            23
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(23)
              <223>            Exon: H54A (+67+89)
              <400> 346
              ucugcagaau aaucccggag aag                                              23
              <210>            347
              <211>            30

              H:\fmt\Interwoven\NRPortbl\DCC\FMT\9992541_1.docx-6/05/2016
<removed-date>
                                                                            - 91 -
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(30)
              <223>            Exon: H54A(+77+106)
<removed-apn>
              <400> 347
              ggacuuuucu gguaucaucu gcagaauaau                                       30
              <210>            348
              <211>            24
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(24)
              <223>            Exon: H55A(-10+14)
              <400> 348
              cucgcucacu cacccugcaa agga                                             24
              <210>            349
              <211>            23
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(23)
              <223>            Exon: H55A(+39 +61)
              <400> 349
              cagggggaac uguugcagua auc                                              23
              <210>            350
              <211>            31
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(31)
              <223>            Exon: H55A(+41+71)
              <400> 350
              ucuuuuacuc ccuuggaguc uucuaggagc c                                     31

              H:\fmt\Interwoven\NRPortbl\DCC\FMT\9992541_1.docx-6/05/2016
<removed-date>
                                                                            - 92 -
              <210>            351
              <211>            21
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
<removed-apn>
              <222>            (1)..(21)
              <223>            Exon: H55A(+73+93)
              <400> 351
              ucuguaagcc aggcaagaaa c                                                21
              <210>            352
              <211>            31
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(31)
              <223>            Exon: H55A(+107+137)
              <400> 352
              ccuuacgggu agcauccuga uggacauugg c                                     31
              <210>            353
              <211>            25
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(25)
              <223>            Exon: H55A(+112 +136)
              <400> 353
              cuuacgggua gcauccugua ggaca                                            25
              <210>            354
              <211>            30
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(30)
              <223>            Exon: H55A(+132 +161)
              <400> 354
              ccuuggaguc uucuaggagc cuuuccuuac                                       30

              H:\fmt\Interwoven\NRPortbl\DCC\FMT\9992541_1.docx-6/05/2016
<removed-date>
                                                                            - 93 -
              <210>            355
              <211>            20
              <212>            RNA
              <213>            Homo sapiens
<removed-apn>
              <220>
              <221>            misc_feature
              <222>            (1)..(20)
              <223>            Exon: H55A(+141 +160)
              <400> 355
              cuuggagucu ucuaggagcc                                                  20
              <210>            356
              <211>            30
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(30)
              <223>            Exon: H55A(+143 +171)
              <400> 356
              cucuuuuacu cccuuggagu cuucuaggag                                       30
              <210>            357
              <211>            20
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(20)
              <223>            Exon: H55D(+11 -09)
              <400> 357
              ccugacuuac uugccauugu                                                  20
              <210>            358
              <211>            29
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(29)
              <223>            Exon: H56A(-06+23)

              H:\fmt\Interwoven\NRPortbl\DCC\FMT\9992541_1.docx-6/05/2016
<removed-date>
                                                                            - 94 -
              <400> 358
              gcuucaauuu caccuuggag guccuacag                                        29
              <210>            359
              <211>            21
              <212>            RNA
              <213>            Homo sapiens
<removed-apn>
              <220>
              <221>            misc_feature
              <222>            (1)..(21)
              <223>            Exon: H56A(-06+15)
              <400> 359
              uucaccuugg agguccuaca g                                                21
              <210>            360
              <211>            22
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(22)
              <223>            Exon: H56A(+23 +44)
              <400> 360
              guugugauaa acaucugugu ga                                               22
              <210>            361
              <211>            26
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(26)
              <223>            Exon: H56A(+56 +81)
              <400> 361
              ccagggaucu caggauuuuu uggcug                                           26
              <210>            362
              <211>            25
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(25)

              H:\fmt\Interwoven\NRPortbl\DCC\FMT\9992541_1.docx-6/05/2016
<removed-date>
                                                                            - 95 -
              <223>            Exon: H56A(+67+91)
              <400> 362
              cggaaccuuc cagggaucuc aggau                                            25
              <210>            363
              <211>            25
<removed-apn>
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(25)
              <223>            Exon: H56A(+102+126)
              <400> 363
              guuauccaaa cgucuuugua acagg                                            25
              <210>            364
              <211>            30
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(30)
              <223>            Exon: H56A(+102+131)
              <400> 364
              uucauguuau ccaaacgucu uuguaacagg                                       30
              <210>            365
              <211>            30
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(30)
              <223>            Exon: H56A(+117+146)
              <400> 365
              ucacuccacu ugaaguucau guuauccaaa                                       30
              <210>            366
              <211>            23
              <212>            RNA
              <213>            Homo sapiens
              <220>

              H:\fmt\Interwoven\NRPortbl\DCC\FMT\9992541_1.docx-6/05/2016
<removed-date>
                                                                            - 96 -
              <221>            misc_feature
              <222>            (1)..(23)
              <223>            Exon: H56A(+121+143)
              <400> 366
              cuccacuuga aguucauguu auc                                              23
<removed-apn>
              <210>            367
              <211>            21
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(21)
              <223>            Exon: H56D(+11-10)
              <400> 367
              cuuuuccuac caaauguuga g                                                21
              <210>            368
              <211>            33
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(33)
              <223>            Exon: H57A(-15+18)
              <400> 368
              cuggcuucca aaugggaccu gaaaaagaac agc                                   33
              <210>            369
              <211>            30
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(30)
              <223>            Exon: H57A (-12 +18)
              <400> 369
              cuggcuucca aaugggaccu gaaaaagaac                                       30
              <210>            370
              <211>            30
              <212>            RNA
              <213>            Homo sapiens

              H:\fmt\Interwoven\NRPortbl\DCC\FMT\9992541_1.docx-6/05/2016
<removed-date>
                                                                            - 97 -
              <220>
              <221>            misc_feature
              <222>            (1)..(30)
              <223>            Exon: H57A(-06 +24)
              <400> 370
              ucagaacugg cuuccaaaug ggaccugaaa                                       30
<removed-apn>
              <210>            371
              <211>            24
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(24)
              <223>            Exon: H57A(+21+44)
              <400> 371
              ggugcagacg cuuccacugg ucag                                             24
              <210>            372
              <211>            31
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(31)
              <223>            Exon: H57A(+47 +77)
              <400> 372
              gcuguagcca caccagaagu uccugcagag a                                     31
              <210>            373
              <211>            25
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(25)
              <223>            Exon: H57A(+79+103)
              <400> 373
              cugccggcuu aauucaucau cuuuc                                            25
              <210>            374
              <211>            27
              <212>            RNA

              H:\fmt\Interwoven\NRPortbl\DCC\FMT\9992541_1.docx-6/05/2016
<removed-date>
                                                                            - 98 -
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(27)
              <223>            Exon: H57A(+105+131)
<removed-apn>
              <400> 374
              cugcuggaaa gucgccucca auaggug                                          27
              <210>            375
              <211>            22
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(22)
              <223>            Exon: H59A (-06 +16)
              <400> 375
              uccucaggag gcagcucuaa au                                               22
              <210>            376
              <211>            30
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(30)
              <223>            Exon: H59A(+31 +61)
              <400> 376
              uccucgccug cuuucguaga agccgaguga                                       30
              <210>            377
              <211>            26
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(26)
              <223>            Exon: H59A(+66+91)
              <400> 377
              agguucaauu uuucccacuc aguauu                                           26
              <210>            378

              H:\fmt\Interwoven\NRPortbl\DCC\FMT\9992541_1.docx-6/05/2016
<removed-date>
                                                                            - 99 -
              <211>            30
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(30)
<removed-apn>
              <223>            Exon: H59A(+96+125)
              <400> 378
              cucaucuauu uuucucugcc agucagcgga                                       30
              <210>            379
              <211>            31
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(31)
              <223>            Exon: H59A(+101 +132)
              <400> 379
              cagggucuca ucuauuuuuc ucugccaguc a                                     31
              <210>            380
              <211>            25
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(25)
              <223>            Exon: H59A(+141 +165)
              <400> 380
              cauccguggc cucuugaagu uccug                                            25
              <210>            381
              <211>            25
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(25)
              <223>            Exon: H59A(+151 +175)
              <400> 381
              agguccagcu cauccguggc cucuu                                            25

              H:\fmt\Interwoven\NRPortbl\DCC\FMT\9992541_1.docx-6/05/2016
<removed-date>
                                                                            - 100 -
              <210>            382
              <211>            25
              <212>            RNA
              <213>            Homo sapiens
              <220>
<removed-apn>
              <221>            misc_feature
              <222>            (1)..(25)
              <223>            Exon: H59A(+161 +185)
              <400> 382
              gcgcagcuug agguccagcu caucc                                             25
              <210>            383
              <211>            30
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(30)
              <223>            Exon: H59A(+161+190)
              <400> 383
              gcuuggcgca gcuugagguc cagcucaucc                                        30
              <210>            384
              <211>            27
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(27)
              <223>            Exon: H59A(+171+197)
              <400> 384
              caccucagcu uggcgcagcu ugagguc                                           27
              <210>            385
              <211>            25
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(25)
              <223>            Exon: H59A(+181+205)
              <400>            385

              H:\fmt\Interwoven\NRPortbl\DCC\FMT\9992541_1.docx-6/05/2016
<removed-date>
                                                                            - 101 -
              cccuugauca ccucagcuug gcgca                                             25
              <210>            386
              <211>            21
              <212>            RNA
              <213>            Homo sapiens
<removed-apn>
              <220>
              <221>            misc_feature
              <222>            (1)..(21)
              <223>            Exon: H59A(+200+220)
              <400> 386
              acgggcugcc aggaucccuu g                                                 21
              <210>            387
              <211>            25
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(25)
              <223>            Exon: H59A(+221+245)
              <400> 387
              gagagaguca augaggagau cgccc                                             25
              <210>            388
              <211>            34
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(34)
              <223>            Exon: H59A(+92+125)
              <400> 388
              cucaucuauu uuucucugcc agucagcgga gugc                                   34
              <210>            389
              <211>            30
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(30)
              <223>            Exon: H60A(-10+20)

              H:\fmt\Interwoven\NRPortbl\DCC\FMT\9992541_1.docx-6/05/2016
<removed-date>
                                                                            - 102 -
              <400> 389
              gcaauuucuc cucgaagugc cugugugcaa                                        30
              <210>            390
              <211>            27
              <212>            RNA
<removed-apn>
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(27)
              <223>            Exon: H60A(-8+19)
              <400> 390
              caauuucucc ucgaagugcc ugugugc                                           27
              <210>            391
              <211>            30
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(30)
              <223>            Exon: H60A(+29+58)
              <400> 391
              caaggucauu gacguggcuc acguucucuu                                        30
              <210>            392
              <211>            30
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(30)
              <223>            Exon: H60A(+37+66)
              <400> 392
              cuggcgagca aggucauuga cguggcucac                                        30
              <210>            393
              <211>            28
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature

              H:\fmt\Interwoven\NRPortbl\DCC\FMT\9992541_1.docx-6/05/2016
<removed-date>
                                                                            - 103 -
              <222>            (1)..(28)
              <223>            Exon: H60A(+39+66)
              <400> 393
              cuggcgagca agguccuuga cguggcuc                                          28
              <210>            394
<removed-apn>
              <211>            31
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(31)
              <223>            Exon: H60A(+43+73)
              <400> 394
              ugguaagcug gcgagcaagg uccuugacgu g                                      31
              <210>            395
              <211>            25
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(25)
              <223>            Exon: H60A(+51+75)
              <400> 395
              agugguaagc uggcgugcaa gguca                                             25
              <210>            396
              <211>            30
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(30)
              <223>            Exon: H60A(+72+102)
              <400> 396
              uuauacggug agagcugaau gcccaaagug                                        30
              <210>            397
              <211>            31
              <212>            RNA
              <213>            Homo sapiens

              H:\fmt\Interwoven\NRPortbl\DCC\FMT\9992541_1.docx-6/05/2016
<removed-date>
                                                                            - 104 -
              <220>
              <221>            misc_feature
              <222>            (1)..(31)
              <223>            Exon: H60A(+75+105)
              <400> 397
              gagguuauac ggugagagcu gaaugcccaa a                                      31
<removed-apn>
              <210>            398
              <211>            27
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(27)
              <223>            Exon: H60A(+80+109)
              <400> 398
              ugcugagguu auacggugag agcugaa                                           27
              <210>            399
              <211>            30
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(30)
              <223>            Exon: H60D(+25-5)
              <400> 399
              cuuuccugca gaagcuucca ucugguguuc                                        30
              <210>            400
              <211>            26
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(26)
              <223>            Exon: H61A(-7+19)
              <400> 400
              cucgguccuc gacggccacc ugggag                                            26
              <210>            401
              <211>            30
              <212>            RNA
              <213>            Homo sapiens

              H:\fmt\Interwoven\NRPortbl\DCC\FMT\9992541_1.docx-6/05/2016
<removed-date>
                                                                            - 105 -
              <220>
              <221>            misc_feature
              <222>            (1)..(30)
              <223>            Exon: H61A(+05+34)
              <400> 401
<removed-apn>
              caugcagcug ccugacucgg uccucgccgg                                        30
              <210>            402
              <211>            25
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(25)
              <223>            Exon: H61A(+16+40)
              <400> 402
              gggcuucaug cagcugccug acucg                                             25
              <210>            403
              <211>            30
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(30)
              <223>            Exon: H61A(+16+45)
              <400> 403
              ccugugggcu ucaugcagcu gccugacucg                                        30
              <210>            404
              <211>            26
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(26)
              <223>            Exon: H61A(+42+67)
              <400> 404
              gcugagaugc uggaccaaag ucccug                                            26
              <210>            405
              <211>            26

              H:\fmt\Interwoven\NRPortbl\DCC\FMT\9992541_1.docx-6/05/2016
<removed-date>
                                                                            - 106 -
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(26)
              <223>            Exon: H61D(+10-16)
<removed-apn>
              <400> 405
              gcugaaaaug acuuacugga aagaaa                                            26
              <210>            406
              <211>            30
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(30)
              <223>            Exon: H62A(-15+15)
              <400> 406
              gacccuggac agacgcugaa aagaagggag                                        30
              <210>            407
              <211>            30
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(30)
              <223>            Exon: H62A(-10+20)
              <400> 407
              ccagggaccc uggacagacg cugaaaagaa                                        30
              <210>            408
              <211>            20
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(20)
              <223>            Exon: H62A(-05+15)
              <400> 408
              gacccuggac agacgcugaa                                                   20

              H:\fmt\Interwoven\NRPortbl\DCC\FMT\9992541_1.docx-6/05/2016
<removed-date>
                                                                            - 107 -
              <210>            409
              <211>            28
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
<removed-apn>
              <222>            (1)..(28)
              <223>            Exon: H62A(-3+25)
              <400> 409
              cucucccagg gacccuggac agacgcug                                          28
              <210>            410
              <211>            30
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(30)
              <223>            Exon: H62A(+01+30)
              <400> 410
              uggcucucuc ccagggaccc uggacagacg                                        30
              <210>            411
              <211>            27
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(27)
              <223>            Exon: H62A(+8+34)
              <400> 411
              gagauggcuc ucucccaggg acccugg                                           27
              <210>            412
              <211>            31
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(31)
              <223>            Exon: H62A(+13+43)
              <400> 412
              uuguuuggug agauggcucu cucccaggga c                                      31

              H:\fmt\Interwoven\NRPortbl\DCC\FMT\9992541_1.docx-6/05/2016
<removed-date>
                                                                            - 108 -
              <210>            413
              <211>            20
              <212>            RNA
              <213>            Homo sapiens
<removed-apn>
              <220>
              <221>            misc_feature
              <222>            (1)..(20)
              <223>            Exon: H62D(+17-03)
              <400> 413
              uacuugauau aguagggcac                                                   20
              <210>            414
              <211>            30
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(30)
              <223>            Exon: H62D(+25-5)
              <400> 414
              cuuacuugau auaguagggc acuuuguuug                                        30
              <210>            415
              <211>            25
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(25)
              <223>            Exon: H63A(-14+11)
              <400> 415
              gagucucgug gcuaaaacac aaaac                                             25
              <210>            416
              <211>            25
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(25)
              <223>            Exon: H63A(+11+35)

              H:\fmt\Interwoven\NRPortbl\DCC\FMT\9992541_1.docx-6/05/2016
<removed-date>
                                                                            - 109 -
              <400> 416
              ugggaugguc ccagcaaguu guuug                                             25
              <210>            417
              <211>            25
              <212>            RNA
              <213>            Homo sapiens
<removed-apn>
              <220>
              <221>            misc_feature
              <222>            (1)..(25)
              <223>            Exon: H63A(+33+57)
              <400> 417
              gacugguaga gcucugucau uuugg                                             25
              <210>            418
              <211>            23
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(23)
              <223>            Exon: H63A(+40+62)
              <400> 418
              cuaaagacug guagagcucu guc                                               23
              <210>            419
              <211>            25
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(25)
              <223>            Exon: H63D(+8-17)
              <400> 419
              cauggccaug uccuuaccua aagac                                             25
              <210>            420
              <211>            30
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(30)

              H:\fmt\Interwoven\NRPortbl\DCC\FMT\9992541_1.docx-6/05/2016
<removed-date>
                                                                            - 110 -
              <223>            Exon: H64A(-3+27)
              <400> 420
              cugagaaucu gacauuauuc aggucagcug                                        30
              <210>            421
              <211>            30
<removed-apn>
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(30)
              <223>            Exon: H64A(+43+72)
              <400> 421
              aaagggccuu cugcagucuu cggaguuuca                                        30
              <210>            422
              <211>            27
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(27)
              <223>            Exon: H64A(+47+74)
              <400> 422
              gcaaagggcc uucugcaguc uucggag                                           27
              <210>            423
              <211>            25
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(25)
              <223>            Exon: H64D(+15-10)
              <400> 423
              caauacuuac agcaaagggc cuucu                                             25
              <210>            424
              <211>            26
              <212>            RNA
              <213>            Homo sapiens
              <220>

              H:\fmt\Interwoven\NRPortbl\DCC\FMT\9992541_1.docx-6/05/2016
<removed-date>
                                                                            - 111 -
              <221>            misc_feature
              <222>            (1)..(26)
              <223>            Exon: H65A(+123+148)
              <400> 424
              uugaccaaau uguugugcuc uugcuc                                            26
<removed-apn>
              <210>            425
              <211>            28
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(28)
              <223>            Exon: H67A(+120+147)
              <400> 425
              agcuccggac acuuggcuca auguuacu                                          28
              <210>            426
              <211>            25
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(25)
              <223>            Exon: H67A(+125+149)
              <400> 426
              gcagcuccgg acacuuggcu caaug                                             25
              <210>            427
              <211>            30
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(30)
              <223>            Exon: H67D(+22-08)
              <400> 427
              uaacuuacaa auuggaagca gcuccggaca                                        30
              <210>            428
              <211>            25
              <212>            RNA
              <213>            Homo sapiens

              H:\fmt\Interwoven\NRPortbl\DCC\FMT\9992541_1.docx-6/05/2016
<removed-date>
                                                                            - 112 -
              <220>
              <221>            misc_feature
              <222>            (1)..(25)
              <223>            Exon: H68A(-4+21)
              <400> 428
              gaucucuggc uuauuauuag ccugc                                             25
<removed-apn>
              <210>            429
              <211>            27
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(27)
              <223>            Exon: H68A(+22+48)
              <400> 429
              cauccagucu aggaagaggg ccgcuuc                                           27
              <210>            430
              <211>            30
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(30)
              <223>            Exon: H68A(+74+103)
              <400> 430
              cagcagccac ucugugcagg acgggcagcc                                        30
              <210>            431
              <211>            31
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(31)
              <223>            Exon: H69A(-12+19)
              <400> 431
              gugcuuuaga cuccuguacc ugauaaagag c                                      31
              <210>            432
              <211>            31
              <212>            RNA

              H:\fmt\Interwoven\NRPortbl\DCC\FMT\9992541_1.docx-6/05/2016
<removed-date>
                                                                            - 113 -
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(31)
              <223>            Exon: H69A(+09 +39)
<removed-apn>
              <400> 432
              uggcagaugu cauaauuaaa gugcuuuaga c                                      31
              <210>            433
              <211>            29
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(29)
              <223>            Exon: H69A(+29 +57)
              <400> 433
              ccagaaaaaa agcagcuuug gcagauguc                                         29
              <210>            434
              <211>            24
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(24)
              <223>            Exon: H69A(+51+74)
              <400> 434
              ggccuuuugc aacucgacca gaaa                                              24
              <210>            435
              <211>            30
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(30)
              <223>            Exon: H69A(+51 +80)
              <400> 435
              uuuuauggcc uuuugcaacu cgaccagaaa                                        30
              <210>            436

              H:\fmt\Interwoven\NRPortbl\DCC\FMT\9992541_1.docx-6/05/2016
<removed-date>
                                                                            - 114 -
              <211>            24
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(24)
<removed-apn>
              <223>            Exon: H69D(+08-16)
              <400> 436
              cuggcgucaa acuuaccgga gugc                                              24
              <210>            437
              <211>            24
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(24)
              <223>            Exon: H70A(-09+15)
              <400> 437
              uucuccugau guagucuaaa aggg                                              24
              <210>            438
              <211>            30
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(30)
              <223>            Exon: H70A(-07 +23)
              <400> 438
              cgaacaucuu cuccugaugu agucuaaaag                                        30
              <210>            439
              <211>            25
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(25)
              <223>            Exon: H70A(+16 +40)
              <400> 439
              guaccuuggc aaagucucga acauc                                             25

              H:\fmt\Interwoven\NRPortbl\DCC\FMT\9992541_1.docx-6/05/2016
<removed-date>
                                                                            - 115 -
              <210>            440
              <211>            24
              <212>            RNA
              <213>            Homo sapiens
              <220>
<removed-apn>
              <221>            misc_feature
              <222>            (1)..(24)
              <223>            Exon: H70A(+25 +48)
              <400> 440
              guuuuuuagu accuuggcaa aguc                                              24
              <210>            441
              <211>            29
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(29)
              <223>            Exon: H70A(+32+60)
              <400> 441
              gguucgaaau uuguuuuuua guaccuugg                                         29
              <210>            442
              <211>            30
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(30)
              <223>            Exon: H70A(+64 +93)
              <400> 442
              gcccauucgg ggaugcuucg caaaauaccu                                        30
              <210>            443
              <211>            24
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(24)
              <223>            Exon: H71A(-08+16)
              <400>            443

              H:\fmt\Interwoven\NRPortbl\DCC\FMT\9992541_1.docx-6/05/2016
<removed-date>
                                                                            - 116 -
              gaucagagua acgggacugc aaaa                                              24
              <210>            444
              <211>            24
              <212>            RNA
              <213>            Homo sapiens
<removed-apn>
              <220>
              <221>            misc_feature
              <222>            (1)..(24)
              <223>            Exon: H71A(+07+30)
              <400> 444
              acuggccaga aguugaucag agua                                              24
              <210>            445
              <211>            24
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(24)
              <223>            Exon: H71A(+16+39)
              <400> 445
              gcagaaucua cuggccagaa guug                                              24
              <210>            446
              <211>            24
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(24)
              <223>            Exon: H71D(+19-05)
              <400> 446
              cucacgcaga aucuacuggc caga                                              24
              <210>            447
              <211>            30
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(30)
              <223>            Exon: H72A(-8+22)

              H:\fmt\Interwoven\NRPortbl\DCC\FMT\9992541_1.docx-6/05/2016
<removed-date>
                                                                            - 117 -
              <400> 447
              aagcugaggg gacgaggcag gccuauaagg                                        30
              <210>            448
              <211>            27
              <212>            RNA
<removed-apn>
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(27)
              <223>            Exon: H72A(+02+28)
              <400> 448
              gugugaaagc ugaggggacg aggcagg                                           27
              <210>            449
              <211>            24
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(24)
              <223>            Exon: H72D(+14-10)
              <400> 449
              agucucauac cugcuagcau aaug                                              24
              <210>            450
              <211>            25
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(25)
              <223>            Exon: H73A(+24+49)
              <400> 450
              augcuaucau uuagauaaga uccau                                             25
              <210>            451
              <211>            26
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature

              H:\fmt\Interwoven\NRPortbl\DCC\FMT\9992541_1.docx-6/05/2016
<removed-date>
                                                                            - 118 -
              <222>            (1)..(26)
              <223>            Exon: H73A(-16+10)
              <400> 451
              uucugcuagc cugauaaaaa acguaa                                            26
              <210>            452
<removed-apn>
              <211>            25
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(25)
              <223>            Exon: H73D(+23-02)
              <400> 452
              acaugcucuc auuaggagag augcu                                             25
              <210>            453
              <211>            26
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(26)
              <223>            Exon: HM73A(+19+44)
              <400> 453
              uaucauuuag auaagaucca uugcug                                            26
              <210>            454
              <211>            27
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(27)
              <223>            Exon: HM74A(+20+46)
              <400> 454
              guucaaacuu uggcaguaau gcuggau                                           27
              <210>            455
              <211>            28
              <212>            RNA
              <213>            Homo sapiens

              H:\fmt\Interwoven\NRPortbl\DCC\FMT\9992541_1.docx-6/05/2016
<removed-date>
                                                                            - 119 -
              <220>
              <221>            misc_feature
              <222>            (1)..(28)
              <223>            Exon: HM74A(+50+77)
              <400> 455
              gacuacgagg cuggcucagg ggggaguc                                          28
<removed-apn>
              <210>            456
              <211>            27
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(27)
              <223>            Exon: HM74A(+96+122)
              <400> 456
              gcuccccucu uuccucacuc ucuaagg                                           27
              <210>            457
              <211>            27
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(27)
              <223>            Exon: H76A(-02+25)
              <400> 457
              cauucacuuu ggccucugcc uggggcu                                           27
              <210>            458
              <211>            27
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(27)
              <223>            Exon: H76A(+80+106)
              <400> 458
              gacugccaac cacucggagc agcauag                                           27
              <210>            459
              <211>            30
              <212>            RNA
              <213>            Homo sapiens

              H:\fmt\Interwoven\NRPortbl\DCC\FMT\9992541_1.docx-6/05/2016
<removed-date>
                                                                            - 120 -
              <220>
              <221>            misc_feature
              <222>            (1)..(30)
              <223>            Exon: H17A(-12 +18)
              <400> 459
<removed-apn>
              ggugacagcc ugugaaaucu gugagaagua                                        30
              <210>            460
              <211>            23
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(23)
              <223>            Exon: H17A(-07+16)
              <400> 460
              ugacagccug ugaaaucugu gag                                               23
              <210>            461
              <211>            26
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(26)
              <223>            Exon: H17A(+10 +35)
              <400> 461
              agugauggcu gagugguggu gacagc                                            26
              <210>            462
              <211>            20
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(20)
              <223>            Exon: H17A(+31+50)
              <400> 462
              acaguugucu guguuaguga                                                   20
              <210>            463
              <211>            20

              H:\fmt\Interwoven\NRPortbl\DCC\FMT\9992541_1.docx-6/05/2016
<removed-date>
                                                                            - 121 -
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(20)
              <223>            Exon: H17A(+144+163)
<removed-apn>
              <400> 463
              cagaauccac aguaaucugc                                                   20
              <210>            464
              <211>            25
              <212>            RNA
              <213>            Homo sapiens
              <220>
              <221>            misc_feature
              <222>            (1)..(25)
              <223>            Exon: H3A(+30+54)
              <400> 464
              gcgccuccca uccuguaggu cacug                                             25

